var title_f10_47_10992="Finger flexion extension PI";
var content_f10_47_10992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Finger flexion/extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hold both hands with fingers pointing toward ceiling. Roll tips of all fingers down slowly to make a fist. Hold for 5 seconds. Relax fingers. Repeat 10 times.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_10992=[""].join("\n");
var outline_f10_47_10992=null;
var title_f10_47_10993="Th1 and Th2 cells";
var content_f10_47_10993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Schematic representation showing cytokines released by Th1 and Th2 cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Advanced T cells secrete an extraordinary array of cytokines with a bewildering number of functions. Such cytokines have been divided into two general groups according to their general mode of action, Th1 and Th2. In general, allograft rejection is mediated by T cells that produce Th1 cytokines. In contrast, transplantation tolerance has been associated with T cells that produce Th2 cytokines; however, the casual link between such cytokine production and the induction and maintenance of the tolerant state remains controversial.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_10993=[""].join("\n");
var outline_f10_47_10993=null;
var title_f10_47_10994="Cushing's syndrome treatment";
var content_f10_47_10994=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Cushing's syndrome treatment (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/47/10994/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/10994/contributors\" id=\"au4031\">",
"       Lynnette K Nieman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/47/10994/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/10994/contributors\" id=\"se6385\">",
"       Andre Lacroix, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/47/10994/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/10994/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?10/47/10994?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CUSHING'S SYNDROME OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of Cushing's syndrome depends upon the underlying cause. Treatment can reverse most of the symptoms of Cushing's syndrome, although this must be done carefully to minimize the possibility of permanent hormone deficiency and treatment side effects.",
"    </p>",
"    <p>",
"     This article discusses the treatment of Cushing's syndrome. The causes, symptoms, and diagnosis of Cushing's syndrome are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=see_link\">",
"      \"Patient information: Cushing's syndrome (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information about treatment of Cushing's syndrome is also available. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=see_link\">",
"      \"Overview of the treatment of Cushing's syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      MEDICATION-ASSOCIATED CUSHING'S SYNDROME",
"     </span>",
"    </p>",
"    <p>",
"     When Cushing's syndrome is caused by glucocorticoids that are taken for another medical condition, discontinuing the glucocorticoids will resolves symptoms. However, in most cases, the body has adapted to the presence of the glucocorticoids, and they must be tapered off gradually to allow the pituitary and adrenal glands to resume normal function.",
"    </p>",
"    <p>",
"     Some conditions require prolonged glucocorticoid therapy. In this situation, an alternate plan for managing the signs and symptoms of Cushing's syndrome is necessary.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      TREATMENT OF CUSHING'S DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     When Cushing's syndrome results from an ACTH-producing tumor of the pituitary gland (Cushing's disease), treatment may include surgery, radiation, or medication to lower cortisol levels. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=see_link\">",
"      \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgical removal of a small, well-defined pituitary adenoma is called transsphenoidal adenomectomy. The pituitary is located at the base of the brain. It is possible to access this area through the gums above the upper front teeth or the nose (",
"     <a class=\"graphic graphic_figure graphicRef63094 \" href=\"UTD.htm?18/19/18739\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Using special instruments, the surgeon makes an incision in one of these areas (",
"     <a class=\"graphic graphic_figure graphicRef75464 \" href=\"UTD.htm?43/36/44608\">",
"      figure 2",
"     </a>",
"     ). The incision is extended through the sphenoid sinus, allowing the surgeon to see and remove the adenoma with an endoscope (a thin, lighted tube with a camera). This type of surgery permanently cures Cushing's syndrome in 60 to 70 percent of people.",
"    </p>",
"    <p>",
"     Sometimes a tumor cannot be identified; in these cases, half of the pituitary gland may be removed (hemihypophysectomy) or 85 to 90 percent of the pituitary gland may be removed (subtotal hypophysectomy) to be certain that the tumor has been removed.",
"    </p>",
"    <p>",
"     Surgical removal of half or more of the pituitary gland can reduce pituitary function and interfere with ovulation (in women) and sperm production (in men). Lifelong hormone replacement is often necessary after surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H173528877\">",
"     <span class=\"h2\">",
"      Medical therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;When pituitary surgery is unable to restore normal cortisol production, several drugs can be used to control cortisol production. Cabergoline, a drug used mostly to treat prolactin-secreting pituitary tumors, can normalize ACTH and cortisol production in about 30 percent of patients. Similarly, pasireotide can normalize ACTH and cortisol in 20 to 25 percent of patients with Cushing&rsquo;s disease. This new drug has been approved in Europe and the US. It is already available in Europe and is expected to available in the US soon.",
"    </p>",
"    <p>",
"     Mifepristone is a medication that was approved in the US to decrease the effects of excess cortisol on glucose, but its role on long-term therapy of Cushing&rsquo;s disease is uncertain. Other drugs that block production of cortisol, such as ketoconazole, metyrapone or mitotane, can also be used to reduce high levels of cortisol while waiting for more definitive therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Radiation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiation can be a useful treatment when pituitary tumors cannot be completely removed by surgery. Radiation of pituitary tumors reduces cortisol levels in about half of adults and most children with Cushing's disease. Because this cortisol-lowering effect takes time (3 to 24 months), medications that lower adrenal cortisol production may be given while waiting for the effects of radiation. These medications include ketoconazole and metyrapone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Adrenalectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgical removal of the adrenal glands (adrenalectomy) is a final measure that may be recommended if other treatments are not successful. Adrenalectomy stops excess cortisol production but requires that you begin lifelong daily glucocorticoid and mineralocorticoid replacement therapy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/0/9220?source=see_link&amp;anchor=H16#H16\">",
"      \"Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)\", section on 'Primary insufficiency'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      ECTOPIC ACTH SYNDROME",
"     </span>",
"    </p>",
"    <p>",
"     In some people with ACTH-producing, non-pituitary tumors, surgical removal of the tumor eliminates the symptoms of Cushing's syndrome. These tumors are usually in the lung. When complete surgical removal is not possible, treatment with medications that reduce adrenal cortisol production (ketoconazole and metyrapone) or surgical removal of the adrenal glands (adrenalectomy) may be necessary to lower cortisol levels.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      ADRENAL GLAND TUMORS",
"     </span>",
"    </p>",
"    <p>",
"     Adrenal tumors are usually treated with surgical removal of the affected adrenal gland, leaving the opposite adrenal gland for cortisol production. If the tumor is an adenoma (a benign tumor), surgery always cures the associated Cushing's syndrome.",
"    </p>",
"    <p>",
"     If the tumor is a carcinoma (a cancerous tumor), surgery is the only way to cure the cancer; radiation, chemotherapy, and treatment with mitotane (a medication that is toxic to cortisol-producing cells) are usually required to lower cortisol levels. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link&amp;anchor=H20#H20\">",
"      \"Treatment of adrenocortical carcinoma\", section on 'Mitotane monotherapy'",
"     </a>",
"     .) After these treatments, daily adrenal hormone replacement is usually necessary. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/0/9220?source=see_link&amp;anchor=H16#H16\">",
"      \"Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)\", section on 'Primary insufficiency'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      NODULAR ADRENAL HYPERPLASIA",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of nodular adrenal hyperplasia usually requires surgical removal of both adrenal glands. Before surgery, medications that inhibit adrenal enzymes (ketoconazole or metyrapone) can lower cortisol levels.",
"    </p>",
"    <p>",
"     After surgery, daily adrenal hormone replacement is usually necessary. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/0/9220?source=see_link&amp;anchor=H16#H16\">",
"      \"Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)\", section on 'Primary insufficiency'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      CUSHING'S SYNDROME DURING PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     Cushing's syndrome is rare during pregnancy. The excess cortisol production is usually caused by an adrenal tumor, most often an adenoma (a benign tumor), although some patients have a pituitary tumor (Cushing's disease). (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4725?source=see_link\">",
"      \"Cushing's syndrome in pregnancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Although most of the excess cortisol does not cross the placenta and affect the fetus, untreated Cushing's syndrome poses a risk to pregnant women because it can lead to maternal complications such as high blood pressure and gestational diabetes, and it is associated with miscarriage and premature delivery.",
"    </p>",
"    <p>",
"     When Cushing's syndrome is caused by an adrenal tumor or a benign pituitary tumor (Cushing's disease), surgical removal of the adrenal or pituitary gland can lower the abnormal cortisol levels without affecting the pregnancy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      EFFECTIVENESS OF CUSHING'S SYNDROME TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     If treatment removes the source of excess cortisol, most of the symptoms of Cushing's syndrome disappear within 2 to 12 months. Osteoporosis begins to improve within six months and continues to improve over several years. With successful treatment, children with Cushing's syndrome can regain much of their lost bone density and growth. Some high blood pressure and glucose intolerance may persist. Although symptoms of excess cortisol on the brain (emotional, sleep, memory disturbances) usually improve, some conditions can linger even after cortisol levels have been lowered.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287506741\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H248133283\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=see_link\">",
"      Patient information: Cushing's syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/53/851?source=see_link\">",
"      Patient information: Adrenal cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H248133292\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=see_link\">",
"      Patient information: Cushing's syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/0/9220?source=see_link\">",
"      Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=see_link\">",
"      Causes and pathophysiology of Cushing's syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=see_link\">",
"      Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4725?source=see_link\">",
"      Cushing's syndrome in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=see_link\">",
"      Dexamethasone suppression tests",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=see_link\">",
"      Overview of the treatment of Cushing's syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=see_link\">",
"      Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link\">",
"      Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hormone Health Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/\">",
"      www.hormone.org",
"     </a>",
"     available in English, Spanish, and Portuguese)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://endocrine.niddk.nih.gov/index.htm\">",
"      file://endocrine.niddk.nih.gov/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Adrenal Diseases Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(516) 487-4992",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nadf.us/\">",
"      www.nadf.us",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pituitary Tumor Network Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"https://www.pituitary.org/intro.aspx\">",
"      www.pituitary.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cushing's Support &amp; Research Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(617) 723-3674",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.csrf.net/\">",
"      www.csrf.net/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?10/47/10994/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?10/47/10994?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10994/abstract/1\">",
"      Vella A, Thompson GB, Grant CS, et al. Laparoscopic adrenalectomy for adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 2001; 86:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10994/abstract/2\">",
"      Ilias I, Torpy DJ, Pacak K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90:4955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10994/abstract/3\">",
"      Batista D, Gennari M, Riar J, et al. An assessment of petrosal sinus sampling for localization of pituitary microadenomas in children with Cushing disease. J Clin Endocrinol Metab 2006; 91:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10994/abstract/4\">",
"      Shimon I, Ram Z, Cohen ZR, Hadani M. Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 2002; 51:57.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f10_47_10994=[""].join("\n");
var outline_f10_47_10994=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CUSHING'S SYNDROME OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           MEDICATION-ASSOCIATED CUSHING'S SYNDROME",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           TREATMENT OF CUSHING'S DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           ECTOPIC ACTH SYNDROME",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           ADRENAL GLAND TUMORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           NODULAR ADRENAL HYPERPLASIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           CUSHING'S SYNDROME DURING PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           EFFECTIVENESS OF CUSHING'S SYNDROME TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/19/18739\" title=\"figure 1\">",
"           Brain pituitary anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/36/44608\" title=\"figure 2\">",
"           Pituitary surgery PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f10_47_10995="Upper extremity nerve roots";
var content_f10_47_10995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F58656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F58656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nerve roots and peripheral nerves corresponding to the principal movements of the upper extremity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The letters labeling the movements form a spiral down the extremity. The nerve roots and peripheral nerves corresponding to each movement are listed below. Figure redrawn with permission from Gelb, DJ. The Neurologic Examination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     In: Introduction to Clinical Neurology. Woburn, MA, Butterworth-Heinemann 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_10995=[""].join("\n");
var outline_f10_47_10995=null;
var title_f10_47_10996="Anatomy left pelvic vessels";
var content_f10_47_10996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of left pelvic vessels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ken Hatch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_10996=[""].join("\n");
var outline_f10_47_10996=null;
var title_f10_47_10997="Cervical displacement due to endometriosis";
var content_f10_47_10997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endometriosis can be associated with lateral displacement of the cervix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 492px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHsATQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5e48VxyeNtK8PaV9ku3mhubq9kWcZto4SseNoByxldVwSMBX7ipfFA1LVf+JNo001kJcC81KPhraI8kRZGDKwGAf4Ad5/hVuT+G+jaUvxB8T3+hRJFpmlQW/h6BY5jIvmRZmm65IIaVFPPLrITliSQD0+iiigDlPiVqF3oXh0eILLzXGkTLd3NumSJrYfLOCMjJWNndc8bkXtWh4Y8SWXiFLkWrxie3YFo1kD5ifLQzKRw0ciYZWHHVThlYDVvbWC+s57S8hjntbiNopYpF3LIjDDKR3BBIxXjPgfSrrW/AOnnw3qsEPjHwdcz6Kl40bCC4WB9vkTr1aGSMRNwcq21l5XBAPbKKxvC2ujXLS4822ks9Rs5fs19aOdxgm2K+0NgB1KurBhwQw6HIGzQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVi+ItUu7RYrTRrVbzVZ2VUR2xHAhOGmlPZVGSAOWI2jGSRtUUAVrWFLO3Ado/NbBll2hPNkIA3EDuTivLP2a/CVj4f8CLqFvaLFcajPPKJQxYyQeYRFj/ZKKrDJPDZzziu1+JuozaX4A8Q3Nk0ovksJzb+S+1/MKlVKn13MuMc5xjJxW3o2nQaRpFjptoNttZwR28Q9ERQo/QCgC5RRRQAHkV5B4X0Wb4f/E7WJfNspPD3iO5jjLo+Jbe8MYZWmHCoJXMqjaMFmjAHzAD1+vM/izpIu5orWPyox4jgfSTM0zoYbuNHuLKYYOPlkSQdiS6ckLigDS8U2lz4b8UQ+LdKh3WNwFttetoYGeSaMcRXKheS8RJDcEmMnqUUV2ttPDdW0VxayxzQSoJI5Y2DK6kZDAjggjnNYHw68RnxX4M0rV5UEdzPDi5jVSqpOjGOVVyTwJEcDk8AHvWno2kw6QtzDZYjs5ZTNHbqoCws3Lhcdi2Wx6s3rgAGjRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSMdqk4Jx2FAHE/ENZb+48N6bbMqre63bxzs0e7EUCvdsowR94wKhzkcniu3rz3Uo/O+MPhOxdjP8AYNKv7/dKfmDs8MQccdcO4x0wx9BXeXFykEkCOHLzPsQIhbnBJJx0AA6njoOpAKAmopkDO8MbSp5chUFk3Z2nuM96fTAK4b4321xP8LPEE1jcra3thCNRt5yMmOS3dZgR6H93gfWu3V0cuEZWKHawBztOM4P4EfnVbV7MahpN7ZE7RcQPDkgHG5SM4IIPXuCPagDzL4fatIYItYsYprfw7e34liimYKkcN5bxSllwcFluzIvOMeY+OgB9YrxP9nTTorbR/E+iS28sMNvMkKK9wXle3lQzRM0itgN5cyr8oXGwHAJIHsWnPOYGS6UCWNyhYAgOP4WGc9QRn3yO1IC1RRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooPFFABRRRQAUUUUAFNdd23JIAOcev1p1IzBFLOQqgZJJwAKAOH0/wCyz/GnXZQyNcWehWUJ+XlA89y7DPbhYzjvx6V0Fje3N/ebTE8EUbszg4OAOEXcDjc338c4UjOMg15Xokmo3HxT1JLW3jW81/TbLUbh3QiIWqXdwoLYcHzPs/koFwQWJLADIrt3vbHwXb6b4Y8PW0+qa3OheG1kuC0hUcNcXMrZKxg4BcgnOFRScLSA7K4nhto/MuJY4o8hdzsFGScAZPckgfjUlcRo/gOGXUIda8Zzrr/iBJDLE8ikWtmcgqtvASVTbtXDnLkgktzgdvTAo3GmRTXsN2kk8E8bbj5MpVZM4BDp91+AACwJHYir1cR4z1zWfCWqx63Ov2/wd5ezUIoYc3Gnf9PIxzLEOd643KPmG4AgdJpuq2eu6X9s0W9gubdyypcW8qSoSDjIZcg9v64PFAHn3wzlafx549vobN7SNtWFrJCrA+YETyxMwPKklCQBjKuCQeDXo160dnMt6YiS2yCVkXnaW+UnjJClj3wAzGvPPhPLPqXiL4jy3emSaRLJqyRvb55DLbRKXBAAIbG8HuHB78+mQP5sQJwGHysM5wR1FICWiqOmvJGWs7hgZYQNjFyzSR9AzEgfNxyBn9avUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKwvF7xTWEOkyKkjatKLLymJAeMgtNyOn7pZMdOcDIJFbtc7YGTUfGV/dnzFtNNiFhEGUgPK+2SVh/eAHkqD2IkHrQBwHxU19PA3xO8Na8unXGoTalpl3o8VvANpkn8yGSCPdg/eYsvPTJPPIPeeCPDz6LZz3eqGGfxFqTCfU7qPJDyY4jQtyIowdqL2HJ+ZmJ4/V/DCeKvjxp+rLcTx2/hazXzHjlYB7mYsVhxjaAI/nfB3ESxg5BGPVScDJ6UAFFYMOpXttfabp941lcXlw8r3PlOyfZ4wrMu1dp3fwrlimeWA/hGm9vPLdW8rzmOOIs3lx5+cnIG455GDnGOoBzxQBbryuPTE+GvxDS6sN0XhLxPOtvLZRRjy7LUWwscigD5UlC7T/t7ecEAeqVmeJdDsPEug32jaxAtxYXkRilRgDwejDPRgcEHqCARyKAOQ8FGS1+JPja2ufKWS7uku41ihYgotvAnMuMbh8pKHpvyCQTju4o/KuZiDIRMd53OWCkALgAngYA4AAzk9TXj/AMLLPV5rK51PVtbgvtQ0jxFcw3skbOnmww2y2jCRc4Dny45+d3bGC3Hr1/CJIhKImmmgJlhRX2kuAQBnOOckc8c0gJXhR5UlKjzUBVXxyAcZGfQ4HHsKkpkMgliRwrKGGcMMEfUU+mAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGb4i1I6Vpck8arJdOyw20TEgSTOdqLxzjJGSOgBPaoXnh8M+GLm81S5MkVlDLd3U5UDP3pHIHQck4H0FWLrSoLvV7HULgu8lksnkRk/IruApkx/fC7lB7B3H8RrkPjXOn/CtfFHmQiaK1sWuMbd481SGjBAOcAqGORjGOcZoAj+A7Xd98P4te1Qk6lr1zNqk/OQu9tsaj2ESRgDtjFd/Iy4YGUIUAdjkcD3z24Nc78MLE6b8OPC9m0Bt5ItMtlkiOQVfy13A577s0/xFr8Ok6kloRJNdXFq80NvsJWTbJHHtyFJBZ7iIZ5AGScAHIBr300catJNPBFbwAyXLSMAEQDOSTwBxkk9s1BY6zpWsi4g0nV7O5lRfnNpcJI0ecgHAzjkHqO1eb6oP+Fg+PR4c8m2fw1pRjvdcmiTfHf3Y2mK0J6MqDY7Z3ZwqkLW74n+GHhu80hv7EsrTw1qtsfPs9U0q1SGa2kAxn5AN6kfKyHhhxwcEAHaEy7UlVXBB+eMlckdM8fnxUl7LLDZXEttAbmdI2aOEMFMjAcLk8DJ4yeK4T4L+MZfHXg+31W8EJulkeN5LbcsbFTt5BxhsYOD2KtxnavoNAHmugWcvhrxvpuiXMOmfY9b0eWa6dI233GoROnmsWYkuHSYn5ssRH14Ndf4ab7Ktxo8jZksCAgJYkwMT5RJKjPAK8Z5Q85zWR8R4/sreG9dTYH0vVoA2VJLRXBNq4GAennh+n8GOM1uawRZXEGrZxFbq0dyWlCIsDEFpDuIX5CoYknhd+Mk4KA0YLeOAy+XuAkcyMCxIBPXAPQcZwOMknqTUtAORkdKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQX11DY2c11ctshhQu7YzgAZ6d/pXAfGi1t7r4X3Fpq6OkF7e6fHdpA3zFXvIBIqn125Art7tWur6GAEiGEiaX/aIPyLkMCORk8EHGO9eZ/tJTIvhXw5ayl1S98RWNuXQZKDczZx3+509aAPWlUIoVAFUDAAGABXlPxs0nVPFl7oXhvwrrf9maw8n2i8ljOHt7EEFpcghgfNSMKAQWIIyFVyOz8beK4fDNnAkVs+pa3fMYdN0uBwst5IOoGeFRQdzyHhF5PYGl8M/CVx4Y0q5n1u8TUvE+qS/atU1ALjzZMYVFOM+Wi/Ko4AGSAucAA8/wBM1jw38KPi1qejavMNPstZ0ywezvZ1CxD7OjQeUzDCrwobOFGWbJwVFem+MfGmieE/Dkus6peR/Zwm6CONgXumIBVIhn5y2RjHHOSQMmrvivw3pPizRJ9I8QWaXlhNgvGzFTkEEEMpBByOoNc34b+FXhXQ7sXRs5NUuI1hS2l1Z/tj2iRZ2LC0gJjAJzhfb0FAGN+zr4WHg/wMum372w8QTML7ULdCpkg83/Vo+ACPlXvxneASBmvU/m3f7P8An/61cT8QPBMmtzW+ueHLpNK8X2AzaXuDsnXvBcAffibkdypOV7hrngTxaNftjZ6rbjS/E9ogGoaU7ZeFum5T0eNuCHUkc4zkEUAO+KWnzan8OPElraeb9rNhM9v5TbW81FLR4Pb5lWl8I+KI9e+zSDAg1GzTUbAlSC8JChwQR1VmXPtIvvXRXsLT2c8McnlvJGyK5XdtJGAcd8eleS/D+W7sfhB4fvbLDXHhqWe3vIIAZftMMEkkMyqODuKqJVH95UXoTQB6hpXnQiazuA5EDbYZZJN7TR4BDE9cgkqc5J27j96tCsy4toNTOnajZ3BYwnzoZYJBsmjdeVJGQyMMH6hSOgrToAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmysUjZgjOQOFXqT6U6igCCzg8iIgvK7MzOTI+4gk5wPQDoAO1eM/tQ3Ef2LwNZv9qZpfEVvL5dpCZZmVFYHYvQt84wO5Peuk8ZfFzSvD/jKDwlY2Vzq/iO4jHlW1sy7FlYgJHI+fk4JdiQdqDODkVq+GPB0wu7XXfGlzFrHiiLzDHKoItrEOcmO2jP3QAFXzGzI2OWxwEBp6LoBj1ufxBqvlya3cQC2+Rt0drAGLCKI7VJBPzMxGWb0AVV6B2WNGd2CooyWJwAPWlrxH4k+IpPHHi+68BaTqX9n+HtOhNz4o1SNwgSEDJthIeFyM7j6ZB4VwWBg+MvHcnxL12+0TQZzD4C0pfM1rUUnkge9B3p5MTIrl0bngL8+xhkDBPcatE/gCIDwTfRyRWqIsnhi9uHlMu8koLZ3ctE5WOUKg3IxUgKCCaw/AvhnSdL1KxfR9CvNNTfLeR3BBjlto5ImQzTNMG2BQFSO3DE4+d1POzr/H3htNb0K21GyEGtJb2zLJaXjlotRt2ClgHUZVzsV1ZQVLKpKkhGRAdL4L8VaT4z8O2utaBcefZT5HzLteNhwyOvZgf8RkEEweMvCGn+KUs5Lh57PU7CXzrHUrRglxav32sQQVYcMjAqw6jgEeH6tca18PPFltr/hO5bWdDvZBBd2znE93Koz5Mq7ci8CklXbazhArBpMeb7TqHjawTwAvi7SgdS01o451EOS7xs6hgoAJ8wAt8hx8w2kryQwMvQfF17o2oReHviCYbbU3l8mx1ZF8u01UH7uOSIpuzRE8kZQsCAMr9nC9u7z4eTjVI1h1KHVb1LuIZBjmMzO6sCBggv0GeMc9h6Jq2m6b4g0mWx1S0tr/AE+4A3wzIJEcZyDg+hAIPYgGvHr221z4JXF7eaDpkerfDmWUXNzaREm+05iAJJAzEmVOA3zEntlQpYgHpPh1f7E1m70DyRFYtm801h90ozEywj0KOcgcDbIoUYQ46euS0nXdG8f+H7bV/CmoW121vMJreQggwzAEFHUjchZWZTkZ2uSOoNdLYXSXtpHPFkBuqnqjA4ZT6EEEEeoNAFiiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiquqaha6Vpt1qGozrb2drE000rdERRkk/gKALVcXqPiq41ue50rwGbe9vInaC71Jmza6e23uQCJpRkHyl9PnZMjPP2Oo+JPiakMlvZS6B4Fu0DGeaVodSvEDBgYwh/dRvjBJJZkOVxuBr0TQtG07w/pUGm6JZQWVjAuI4YV2qPf3J6knknk5oAw/AvgLRvB8LyWkb3mrz/Nd6reMZbu5YgAlpGyccD5Rx7ZyT1lZnhvWrfxBpEeoWkVxDE8ksRjuIzHIjxyNG6sp6EMjCqfjfxdo3grQJ9X8QXaW9tHwi9XmfsiL/Ex9PqTgAkAHJfF3xPqqyxeDfBhKeJ9StzcNd5wun2ocK0xABZmY5RQozk56gA8J4Otnt/CcNg9vYL4D0i9mlj1S8k+0SytbSSyyXZ2KF2mcRoE3ZK78bhhqitWuIdJu7bVZ5ofG/jAvc6zf2xOzSbKM/NGrEjb5cYK4JPzB+WKBTPrms6hrcdhp1r4eePRraMXdla3ExttLsbaEZt579wm7OE8wQbgAuwMuRuKGXIdZF5c2OmHTr+30ZJ0a50+7t47m81i5kjV44p3ZtolKgSMoJVIwhkaMEIPVfGv2ObwjPHrtsptpQnnIPNZIyCGyXiG6MKVz5oA2EBu1eNaBdpofh/Tdc1bWm07wyI5ITrmpqyX96kkm8izhUsVEpBeSdszSbiwCqsZX1K7u9K1b4e6fqei6bd6jaI0UumpsngnJ3+WkqttMq5Vid5HKMSx2sTQI871K1uLPxcNN1GXULqfV7R83cSxRNeNGqtEW2r+9lhLKyXFugkQIN0bBAw5jwV4mvfhl8Q73w/4qvdPufBms3bBbzhI4pWjVhcbRuVI5W3KRkIGWQjaI2FT+GfEa6heX+hJM+oafE4W50JpETVNKuU3bprBovklRNpbEOCu0FUXdhqfxc8D+GbrVNQ1XTz5SIfI8QRQKzCFXClNSEaH+B5FcoMh0zjBDkAHuvhe4k8P63/wieoTtMjQtc6VcOFBlgQqrxNtAy8ZZecfMrqeSGx2DyIjIruqs52oCcbjgnA9TgE/ga+Zvh74w1JvD2oeGviNLcxXPh7VUs4fEUOx/7MlVSsLzZAIjJV1EpBVw7LJtBy3riXKeNNIk0XUJ7ay8U2UcN9b3VuoljV8Hyr22yfniLBhgnkb0bg5ZgV/Efwo0251o6/4Svbjwp4jw2bzTkXypyTk+dAfkkGcnsSTkk4FSy+KfEfhZ3fxjoENxpQDPLrOhb5VjAOA01sR5iDaMkoZAMenNdB4L8TJ4htLmG4i+ya3p0gttSsWyGgmxnK5+9Gw+ZH6MpHQ5AueG9ZTWra7byvs9zaXctncQF9xjdG4yfRkKOP8AZdaAJdA1vTPEOmRajod/b39lJ92aBwwzjODjoRnkHkd60a881X4XadF4gHiPwbcN4a8QgkyPbIGtbsEjKXEGQHBAPKlWyd2SQKmj8b3vh7ZD8RdPi0pC3lrrNq/mafK3AG4n54CSTgSDbxjeTigDvaKZHLHJ/q5Ef5Q/ysD8p6H6HB/Kn0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFNkdY42eRlVFBZmY4AHqaxkvJtcinj05pLaxI2C/Aw0mQPmhBGCuDxIcg44DA5oAualqaWf7uKGa8u2B2W1uAWbgnkkhUBwfmYgZ4zkgV5JpVprPxP8AHd8PFMMJ8E6DOY4bSFHSG9vUYBlcvzPHEwdc4RWYD5SNwrd+Met3uk6dZeHvCkd0viDxFceV9otI/MmtYAV865xxkqpCjLLjIww24rv9D0qy0PR7PS9KgW3sbOJYYYlJO1VGByeSfUnknk0gL1FIpDDKkEe1cl8KI3tvBFtZO24WF1eWCElj8kF1LCnLEn7qDrTAd8OVa20fVo5yiiPWdScEE4CtdyyDr7NXg+oXN98QvHuo+NI5Dd6PpF6mleErWVgIri/YqvnADlo0Yeexxkqo6hGA6jxtrlxc6BceC9IkaHUvFWuajafa2aPZbWkUp+1SnJ5AQOu3IJ+bByBmzPpujaXZ6f4a0fU47Ww0bS1isg0heZr2/MkaTFR95/LE527OfPO0dBSbA8xjuo31ae+leXV9CjsEnaKSJh5tpDPJHZwHKEme7mw77lBKyyHkOyj0zTITqGizW/je4mvtJ0yUXGsxQruhvtSd08qwhRS2+OAhYzGpw8mwEcOtcjodjpU+tX95oNpM2nxXVld20kjgNGywRwaaqiSTosc0txl1GQI1ONpFe3eEtG0bT5bDQtFWNLHw6jbLdR92V9w8w7stnBmG4HBLPnkcAzltI8Lf8Jdqkev/ABD0YWtvYzSW2ieHpwkkUUIQAyNGvDyMVbjlVVRgHhq7LXdXaOysLGTVbDwze6iVS2W5mi+0AZG5Y0bKNIAUGBuUFv4uM8zJrtzH4zPgnw/q1808MiT6jfXcKP8AZUdmlWCI7AHlkUkAtuCIjN8xU1u6T8N/DduLG5v7BtT1C3/eLc6m4nkEpbeZCPuCQkDLqoJ2qCSAKBHgPxgivtQ1ZJPEfhmz1uO1l8ga94ZJju0dR5hkaI71ZRGnKNkApJh0DDHeW3ijTdY8OQSahd2cF19nSOzvr1H+x38c29PLuDuOI3JKmF8mMqXUyKoevUPF/gzTfESRz+WlrrFs/nWd+iZaGUcqzLkCRcgZVuD7HBHiNo9/eafZW+kafC+vbnj1Tw/ciNbS9Ebut5bxHBEUrEpJtOAyNFId7hmoAl0ic/Djx7aLqrxDRbhYtE1KSbyyZbYqx0+7lIUDoZLd2+7mEsfvAV1ni/wnrvgaFNV+G9m19ZWkxuTowkxJAhYNPHbMQ37qUL80GD84Ro8MMHwHxCuval4H2M8+oWMLS2FoAPMna0MFvdwxuUJ48pRLjorWxycs1fUXwH8VTeMfhdo2p31ytzqCo1vdOAFJkQ7csAx+Yjax6Z3ZwAQAwMFPEmneIr2y8b+EZro65ZQ/ZdV0Jl/0me0Vg0kZgPPmxGQujJ94kpzvGNs6taaR4mtvEthdRXPhTxIscNzcwkvHDdjCQzFg2Aki4hY44ZIQcc1Y+IXgL/hILi21rw7fjQfF1l/x76pFEGMiY5hmXpJGeOudpGR3B8m0TxlqngHxYdF+J2jpaWWuO1vf30Mf/EuuZiABdKSQqtICwmXao4V8KS4IB9KVDeW0F7ay215BFcW0qlJIpUDo6nqCDwR7VzfhO9utPvX8Ma1cyXN9bRedaXkud17aghQ7HABlQkLJj1R+PMCiDxZ4nu9K8deCtAtY4PL1ya68+WQEsiQQGTCgYGSSOSeMdDngA4LSLKH4OfESW3eNh4J8QlRb3kg+TSZ1LEQO/aJy/wAuSACcY4Zj7cDkZHSs3xJolj4k0G/0fVoRNY3sTQyoQM4PQjPRgcEHsQD2rzL9n+/1LS017wD4m1B73W/DtyBHI2W32ciK0RDEknqeDyoKjtwAev0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBQu9Jtby/iurkSyNFG8QiaZ/JIYYJaPOxjjIyQSASB1NWru4hs7Wa5u5Y4beFGkklkYKqKBksSegAGc1LXj37RXiOI+G4/B1jcXKav4huItOSSEYji3sPllfoocfKR97axOCBgoDV+EzL4r1bW/iBPG3/EwkOn6SXGNmnQt8pAKhgZJN7kHP8A7V6ZWR4R0G08MeHLHR9PQJb2qbQAAAWJLM2AABliTgADngCtemBXtAy+crRoiCQ7AncHByffJNc98PZkPhy7dc7f7X1QAMRkn7fOMdup6Vu20Pl6heSDdiTYeTkZAxx6dq8C8c+MLi2+Cfhyx0y7g0rXvF91/o4SYDyY7iZpHkZz0GJAGfggvkY7IDK/Z18PXOp6TDrWvXs11ea889vBE77gmnxzmW5OOQVlnYIwO37+QTnB0Nfmkvta8RPpyzXOoLbX1ytzZzgBr67mOnacM5AUpAjck4xIzD1rtvhtYS6Dpmqafo00d5BoGmR2FsI2/dy3ZEk8p5JwW8yAHJ4ORXHeD7G40rRDLexXMMx1fw1p9xCwCOhSC0fa2ec+dMSwPPJ55oGZfiLw9brqfi6CwN2dKtNW0rTbW0FwBi6lntmlkRgMq4jSKNWzuUbunSvWtB1a00K+8V3uqvgNNdahPcGVMRwQFYkUJvLYwr8gAbg/QnFeYeIbqLRPAHiPVLSS7vm/4TqS9l87HzfZ5Q7BT02hLc847YxgCup1vwzoEXxjvLCOa0tYvGOgXUVxbKoAmnWRf3gAwC7K7tnrmNj1OaAOo+F+im40uXxhqOnwW3irXw13JJIN7QQv/AKiEkBThIliUjAJYMTyc0+H4o6JZa7PoXi9v+Ea1eFd+NQcJbXK/89IJzhXT0ztbqCoIIDPgb4gvNc8CxwazK8uuaRPJpmos+SxmiPOSWJLYK5OcFg2OMVW+PsVpeeC7XSprWznv9X1G302we6tlnWCaVsGQBujLGJCDkcjHemIveF/Emo+NPEUWo6H51v4KtoSVuJrcxvqkzLxsWRdywoDndhSzjAyoOfPPimut6Z8S77TNAuL6P/hKtMa7tDbyAeVqdknmIw3EhQ8cSRsMAMGGc4495srdbSzgtkeWRIY1jDzSGR2AGMsxJLHjknkmvK/Gkunap8dPCNrN9uM+g6Ze6qTarlcsY0VX46YST05KjvQBwmuvbN4RvPGWhpJNpFvMl55axiSSBSY7tCseQMLLc3UTjj91O+SQoFR/BlX+HnxjuvD8z3NtoHii2a9023n8s7JVY/IxRigYBZF+QkMPL6ZAG1+zRHNrPgDWbHX0aDSr25e2s7CZQpa3eBW288sDHIuOPugEZFZWsaMdY+CfgOWN4l8TabMtppd1FcgCK6jykSgnKks1vGhU8BmHPHKA+lKrajYWep2UtnqVrBd2kw2yQXEYkjcZzgqcg1zfwp8XL458A6Tr+xIprmMrPEjZCSqxVh7DIyM9iK62mB5RrPwi+zW7HwLr2oaH5aSG2sJZXns7eRg/7yFS2+B8yN8yNjBKlWVmVsW1n1vWPi38N7XxPbi11/Q7TUp75kU/Z7kMiQpJC+MNuyGI428jg8V7jXjfxU1/+xfit4aXT5Em1270u7srG22hys000CxyOoORGNsjEnAxEwBzxQB2HhvULnxH411y9S4uE0XRpDpdrEjlY7m4ABuJXGAW2MREoyVBSQ8kjbz/AMULBfDnjPw14+s/9GSGddL1qVNoElpMwVGfJ5CS7OnzYb0XjR0aw1C08QWPhnw/qElr4f0K1V9Quv3ctxe3UhLeW5ZCAxGZpGGGJmQjG7Ndl4i0i21/QdR0i/BNrfW728m3GQGUjI9CM5B7ECgC+jBsjKll4YA5wcZ/rTq4r4S6lqV74UNn4hKv4h0e4fS9RkVWAlkjxtkBYAsHiaN93Gd/QdB2tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVX1C8jsLOS5mWVkTHyxRmR2JOAAo5JJNAEd/eGBooIFWS7nz5cZYDgdXPfaMjJHqB3FeLpo8uufHjR9Lu5I9Tg8MWjapqV1NGB5l9OR5eFU/IVCRlAc4RMc/ePs1nptvBfXN+EY3l0FEkkh3MFUcIP7qjk4HGWY9STXLfDNBNdeMNTdlkmvNduEL/JuCwKluqHb2HlHAPPOe+SgO3podS5QMC4AJXPIB6fyP5U6sj7bDDr+pLPdJHHBZQTur/Ksa7psuWPGPl/Dbz1pgZGteJLDw5b+K9b1JpTa6asQlWJizk+WGCqpIAYmQAAHnIzivlDQYZvFk+v3HiLTLiF/CPhafT9Ph2KUgntIgC8jZHzh23ABTywycLz2HxA8X6z41PiuTw7rfk6FpLzajFLayDaGgVUR5ZNuAGaM+TGp3l280kBEo0j4YW2gfD/AMMxa1o5u9TnEzXcM0ZKQz3ag2oO4LtIe1ghYEqA0zZbBzSA9e+GZivbLXtYijeK6utXubxUjJYbCwg6cK2Rb5yMjuCeSeZ+JOp2Gl+PtU0aO4NhqXiaystQ068l+S3+32krNCrlhtw5jhU98ADuKuaTqbWXh7S9V02J7ia2J0+S1nYJeTuIkDRD5tzSDYsZB+YtCkgyudy/E2PS/HGgy2ups0/hu/SC/wBJ1mLy/JSUHaYHdvuMc/LvKBjI0e9TQM4S71PSLTSdc+26mINL1y//AOEjto7uBjJbxXTtD5rIjfvIGKyI6Z/1c6sNrfKea1/Qdc1fQ5vCcUMdz478N3Vtc6Xcw3BV7jT/ALMo32zAgHDRLIc9C2AS556Cy8NTWHheHw54w8N2+rXdoZRp2pzW7NGlq0qvIXjQiYRjd99BuiZwrqi4MnKeMZtS8NWcj+Fbm91rw/agXGn6jZyK9xobsxH2Z5l37oGU7WjcrkgcAghwR2Hw/wDiC0viQ634fivL3X5YUg8U6FdCOK7vWhQ/6TaICA0iKHUxjbuA+4Cd1enat8SPhprUEVx4g1RbW40G8ju/sd/HNb3FvcAFVPkkBnK7znAYDOTXhVx4i+G/jOCTVNZTTzq7IZDbXcFxZ3RlLBnZruBjC/RwpaJBkrnbyK7C4m8FXWioknxRaG/McatbatLa61BBuK748yRZkUEsNwfAHPTigD1e5+Lnha5tzF4ZvW1/Vpbbz7ax06J5ZJMkAA4GEwSM7sbRycV5l4nnutRluobnUY7jx54xgi0y3tNICvDYWKOTKpl5+U5cPNtfDbwgOw4wLz4yarPK9h4MlHiG+uGENzrdzZRW8u1sr5UMKbWbGQykknOcgjmqWm6jrs+jalrkOp2XhHRpmCXtxYFb/VLgrGm2OS4ULFB90hEDQCPgBAMZAPVvAWjS6H411u91HV7f+w/DWlxWUVjawultpzlBJIilstKRGsbNITljIcgYAHn/AIDmsrfwH8T75p7v+2tLM32K2uohDPpyZknt/kAG2T7RK+4AnlQMAAArH4rsvBXhjWLPQYrdUs7j+0mbVbnddzyPgLOFfCzSsFSQOdka7l2LOUy2dfLHp/gLTfC2sW9wbS/gTxX4o1Oa6LMYDNhIF5G6VjHFEMYGeQvJKgzuf2ffEM9t4q1bQbi2vUtNagj8SafJdqokkWVQJpCELBUaRSVBIPI45499r5cikutE8SeFfGOuWq2F5pEFv9utYbQxw6dpdwXgSM9AHSTc7AANmZ1A2wkV9RKwZQykFSMgg5BFMQteMfEnUtI8P/Gfw/qzaW1/4iOkz21lCjYNxM80SQIGPCffudzY4TcecAV7PXkWs6Gw/aY8OarNHPNDJo1z5G0sUhkjO1mIJIAKzBeMDLDuckA9B8HaCvh7RI7V5Env5na5v7pYwhurlzmSUgdMnoP4VCqOAK3KKo6Xq1jqrXg065S4+x3DWk5TOElXG5M9CRnBx0OR1BAAOU0y1n0j4v6ztilOn69p8N55hJZRc258qQYH3cxvB1xkjjODjtySH5xtx+tcL49Vbfx58O7/AM1oj/aFzZMQzAOstrK2wgHBBeKM8g4IBGOc92w3KQc4IxwcUALRSAYAHJx60tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVKziuXne5vGC54igXpGvqx7ue56AcDuzWZIhJIjMSQhyF9+mTUlADJJY4ygkkRC7bF3EDceuB6ng1x/wm+0N4Wu3ulEbvrGpuI+pTN9PlSe5Dbuaua1N9r8ceH9MVIJEt459TlLx7mjKgQx4P8JJmc5xzsbkc5yvghdNe/DyC6kfzJZ7/UJJGPBLNezHkdjyOKQHdtkA4GT2FfK3jTXLrx94p1HStGhEAhsJbXxHdzF5Bb29tdykoPLw0nGGxHy25V4BbH1VXmfw90gz6L4ts72CSMT69qUYuIpvLmaOSYHKuvzAngdc/IPamBieJPCmi6D4O8H/AA40WJJbfWtTi8+OeUq9zBCftFzIxAySRGFIGMb1AwBiujgv9G1/xNqWnRN5eq3lhAl/Y3LqJ7YRtIQGQMSD85+ZcjlHXerZql4Gx4l+KfjTxLJma20qRNA07IKtGYhvucA4HMjABs8hcdMUvxi8KDxPbxTT6dch7Ta1nqulktf6fLnl/K482LoSqsWODtUnBCGcOJ1PiK70WUx2ck9ykVvHPviiF1tBaxllA3xuWAntrgDrt2bggjroNKGq6HdzQ6hps13d38Il1XR3ZSl5HyJbm0QExM535ngwCWOVJyhl5261/TfF/hoWfxHt49Kv1xaxeKLALPZO427Vn4/dZL5aC4VQOp2nGGab4q8Q+FtMtdG+IVlF4m8KyxosHiSyQXcMsJ4zLHk+aAuMsMOApOH6kEeg6TB4XlsIU8MapC2lWzln06e4cCC4VgyKSx862lDDGzHQsCnpy+u2cniLW9Mk8P8AiHw/eeIIopXivQ3kXV0okACGa327gilskEpk/NAeCujp+maP4r0rTNW8KXen+I7OKRoYpbq8mt7+2IBJSG7A89Dg58uTJII+YLg1u2Wl6/cXEM0Wo+ItNmjCxiHUraxu1jBAJ2yp85xgqSXJPXHegZ4X8QbTxfB4guLPWdP8E6m0ybjJJqFjBfpDhkZTKVgJB+Y8xFeBxwRVS28KaNYatDqNz4R0bQ7mymI+yTeMIUiCkDaZJGkldmBxwixY9Wzx7d4gttSFkZtflvtRJgO2KHw1FPcM3JCqw8xFPGfmBUHGao6DZzWRj1HSvCXjSfVNhHk3U9nZQq+eXZEdYtzK23csbEBf4TzTEeTafY+Hmdr2y0CHxJrSW487+yrCfVIbZt75Ql3njZiMY3E9CQ6jArtodL1xrJNWvvCusG8hiVY9Q1G5s7WSNRkZQtKyWKkEDbDDvG3lyfmrovF+smyMy+I9d0Dw9csnky28ur3eoyyIRhcWsbQgMd3OA2cjrgCvNtY8efDG21Bpdcttb8aXsRFxuureO2txMygAranywQwXlmRyABknNAztvDd/pGuahqVnqSeE9X0+1U3l1LbJ9rtNKjVc+bNdyANcTSmNd3TiNixOMGCTR59TL6540iudO8PRTtrFydShVZsqCtnCwVMbYoiXMW0r5rhSXZnCz2ninXPGFrbHUPAPinSdFsHhuF0+ygjV7mVXRlYtKY8Ro6ghFBLcMSFDKdnxTqsmsazapp9ql21hK89nb6iki/Y7jLZvroPjy4ol3GNGBZy4K7QFYIDzT4wT67q9jf6Ck0emz6jby61rysUkjhKRq1tZs/3kZIrdNxHBeRD92QV7V8BfEU3ij4WaHqNzM804hFvI8hZpC8YCOzsSdzMys+eOGAxkGvH9WS1gsjpVrLcpq+so0fnBGkniglLO9zOCRsmnCvIsX32b7OnyiEA2P2XdcsdM+IXjjwbpcxfR/tEl5pp3ZXbG/lscnlmZTF7fIaBH0zXBeJTOvxe8EPGWWM2upwybWI3KVt2AI7jK+44HfFd7XCeNwY/iL8OplmK7ry8gaIJkurWcrZz1ABReOnIJ6CmBf+JevTaH4dVLGdLbUNQl+x211Jt8u1JR3e4fccbIo45JDnrsx3qP4X+IbXxH4fkudH0yey0KCY22nSzDabuJAAZgmAVUtuAzycZOCcDm/Fnh1vGnxdtrG9EEvh7SdKD3sZG5pZJ5DthzuygPko7EDJChTlXIr0cXsKaommRRSeYsHnMVT93Gmdqgn1OGwB2RunGQDnvHIQ674GMkrR41ttu0feP2G74rrq5bxgyL4g8EeZjnWJAufX7Bd4/rXU96ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorM8R6qmjaTLdFRJMWWG3hLhTNM5CxxgkgZZiBye9AGL4Kc6rq3iDxA5UpPcnTbTa2cQWrvGcj+8ZzcHI6rs9K539nq6gb4eWVtE87yCS5ncOoKx7rmUbQwGCcqxwSWGecZFd9oumJo+gWWmWRVVtbdYI2YFhlVxuPOTk8nnJ9a8h/ZOlf8A4QfU4JXEri/eYSIG2hW+URgn+75ZOASAGAznNID2+vJdB1Eab8Jtd16WZmi+26pqkbRhQw2TzMm4qSu7cinGMZ+Ug859ar5YvfEAtf2QNJXzGt11m9ksd5zIYo3vJmbAwS2ERh6+nNDA634VeGfFUfw40HXvD/ixPtdyk2oT2ktkk0FzJO4ZxIVZGJBUDdncpDAcHbU/ibxR8RfD1hLqlxa+G4phMkKwWsVyzahPsK+UsbxB3Z2A2FXG1RzvA57PQ7mH4e/DrwzpAtXutTFpFbW1hC22W7udgLABvujcWZmPyooJJAFcj438Uv4d8R2Ooa5a6JL4saCX+zbd72aWLTYCmJJcLFltxUgttV34jQHBYgGFBq+qX/ijUL7xU/hew1y1DpJbWuvzaa8MC7TvnKwt56jKsu9ynzEbQdwrp/D+jarZLFN8OfEMWseHDKZU0rU7dRaEMW3LBcxxkxgEHaoBQZHGCKWw8PXGr+GZrnXltdJ0cRm+lXV08yeWfO4Xl6MhchQNtuzMqDbu+6qx6E2q+FdI8X6fZ3Fzrms6zJFGschuJ7hQ7DzIkaNSIkdliZgSqkhCefmIBlrw54a0PV7h7i98K3GlX9neR3LRahaxkpOFVllinjJDAEAbg5+7tIGAK1/FuvReHtDR9ZutQuHmZzbSaVAPNnbeDFbxpk75GVsADghHY7QDjgfih8QpfB9qmqavrsUGvKAbLw5aAzR7irKfNYFGlG4tljhBjCoXUNWbofgrxj4+ePWvih4hvdKiu7cxr4c0n9wUt5GXIlOSVVtvzKctg4LAgqAR6L4lTSNI0tr/AMQeNNV02ynZI1mkvkhDN1UIQo5Iznb1AOcgV5VHbaTrpbUNRuviDqfh3ypNlpJdXMUNxEh2ma5nmaKGMNgsqKynaAzHLbF9CWx8N+GvEMdp4b0r+1PFd5J9nFxMZbqS2jRUEjy3EjErGiMhMYZc70UD5wa5bxBpLal4iSPxfqEuuWmkW0yPCkqNGpKmR7i5dFRITscxIiqHOzcGC7qAMHwbZ/D/AFWCdPD3wvkvY45NlpcXF1CqzOrKTl5ZQxAJjyU8wYfHOcH1fS9K1q3DJ4Yh8I6Bo5BMUVrp0lwzk5BYhWhVedvGD90888clpPjnxC+h6fdad4b0rQNFkjEA1fVdljGZMYUx2pk3CNjgLl84OecYO74j8S6R4M0K0v8Axt4nkuDdAmJkuWVrhRuOYYoFXK4KcnIGVDOThiAJf+BPGNzYzeZ8Q5zel1YNDpFtAnBXPIBkGcEbg+RnocYNCzvZfDujQ2fi7X3TUxI0Gny648E9uLlFl8ppJo1UlG2h18zZISrDOeBW1XxRqniCyM2kfCPUryW6ZMNrcEEQ4YHLK7542/KDgZAORmsvTLjVNJ1eC31n4V6omniF5nttMgspLRdsa52woDkht+0NKX5O0fMUBYDm/FsJ8J6Zq2oeI73Up9WhuCt1rEcbWqxmbasiWglA865mSIfMoKQIq7CojG/zrS9SvtB8baD8RRKosYLyC0vIoVX7PYW7xhI7KNyR5sqW4bcAPkITcd5YD0B/CWg67fadN461LxnpdjDdzyWcGp6YbWGKOVtyW6MpeNHDZORhioVRt2ALh+MNFuviPZ3EmkeRpnhDR7aV9H01dqRw2yK4lvJ2Bwu54yqKxy5JPCpIxYH2FXmfxt1Gy0Q+CNY1ORYLOz8QxGadgSIkaCdSTjnGStV/2cfHI8afDex+13Kyaxp+bS6Ut87bcbJCOvzKV57turS+OlpZXXgm3Oo2r3UEOr6c5jjjMjkG6iRgqAHeSrMu0g5z0JxQBL4De60vwhqnibxJb3MWp6lNNqdzbtGPOjjA2wwBQB8yxJGu3qWLdScmHULLxBp+kLaaFJbx+LvEFwZry/nzKligX5nVSMOsS7IkTgFmVm6uT0mtKb/XdI0yWKQ2w3ahKwT5C0LJ5als8HeyuBg58s88YNTRWbVvG+s6lvf7LpqLpVuhJAMh2yzyAdCDmFPYxN60gKHi+W6f4keA7RSos4ft+o3DEDrHAIV68/8ALy3TPTp3HZ281vfWcc0EkVxazxh0dCGSRGGQQehBBry34iXmoSfEFTplu+NC0GW+mu0bPlmS4ikVCuMnetlKuBkkOc4HX0vTIUtofIg8v7IoBtxGqqqR44VQOw7dOCB2pgXaKCQBknAooAKKKKACiiigAooooAKKKKACiiigAooooAKwkxrGvR3MF3J9j0qSWJokBCzXBUAncDhlQM67cEbyc4KVc1+4uINLmFg8S38w8m183JXzW4UkAEkD7x46A1NplnFpmmwWsbExwoFLvjLHuze5OST6k0gMfxg819DFoOnzeVd6hxM6uVeG1BAmdSOQxU7FI5DOD0U1wX7O8djZP480mxjEQ07xFdQJEo+WODeTGo9h83v+lek6NZE3M+q3an7ZdAKquqhoIR92Pgn/AHjycsT2wBxfw/S4tvi98TrZ5JTZvJp93ChbKBntyrkDsxMYB74VaAPRrpXa2lWKQxSFCFkC7tpxwcd8elfKHxGsor74A+AtA0RbcXE3iOSxsIGZQ0qrLcwrI2DgkkoWYDbufPAIFfVOrJJJpV4kO7zWhcJtYqc7TjBBBB9wQfevkzTNLt9U8P8AwZWTUZ7G2Ed3L9q3eT9nggDyXbl+QMkqq5GMJnPz8MD0KXR5vCmoLrEV5fav4p1SRbaO8+zh73UXGJNkBdjDbxNhySEZI4VAJDdOg8GeD759Ok1TxOJLy9un+1tb/bFdb2dQzRs8oziFSSIYQSiD5zudvku/DHTH1O8vfFOpwSW15cbYVQjC29si/Jaxhh8iDKvIFx+9yrf6sg7HiXX2t7AXNhdRw31/EDbyyKGjs7XcN1ywIBJwykIeWcomPvNSGc38QPE9tp2hS3WpzWOotbgRzuFSWztLhc70WIuDPOXUqqZynybigLM3LWBvV0LQ4bZyut6j9oDkZivb68k2tP5LE/uwiBo3ujnYqbYlyy0uqTweZb3+rwLOuh3clnp9qrGRzfEAt5aY/ezAsqK5DEzPNKQERAOV1Lw9f6nqD2dsbaDU5YBpVzfgiW00W3lRQ1vGADmTaxtkReSXaQkG4XaAdJ4J8LWup67F4jOqW+p/2ezWWn6nNbn7PG6sd0tuCzGWOMsI0Z2bdKZJGZmMdep655WiWuo6trKRLpksZSW0trfzLq8ldgkcZx98tkqFx1kwCu3Jo6WLfw9Z6RbSWE8+oeQ32KJo8mGCNQPMl2KFiADABVHy7tqAlmzwuiXqeOY5te1a2iuNHtdSH9mNKjkaneLG0XnOCSEtkLNtRSRuLDLNw4Bpa8mr+JHm024uZYLjUHaKSyslMcdnajckSXMsbFnwWfKRsBJIsi7ljjdlmi0/w74L0jUNG8WCLUovMieLTLezid7oyeUvnLbwruRHmHlgSFgW4LneFpdSu7Lwklzp9vrSpq6Qq+ravMq7bAMucpGq/PcOi4ihAO1EXjaqrJyvhvT5fG+uRS+HHv8ATNJtrYXhluX8zVdTkcFI7iaVywhUjzfKOCwXzHRV3RlQCTxLr2uyRyeInsYpdfcfZUkurmE6VoUZkAIglkZIp7nPDsCx8xCoAVSp6Lw9q80+pzXHgXwzeX9zcQNJN4p1mIg3BB5QM2wlM7CFjIj6hVAGRb8T+FvBPhTT49T8aa35Fwlv9mtrh5mia2RAu1bKNDuiKbVxsyxydxbOa888X6g2pQW+n6L4ea0sp3iv1bXLnYXAkZXvJ4cl44sKVBd4s/KE3Z20CO51LXb6a6uG1Xx5NaWFyjxi30mCBhCx2gYuCmIyMSdXf5iw3fJz5c3jjwGk9xDeeJfiN4guSrtHDJqrCJ5F3ABRCRtDYODzgEZ71L8PfBVpc2l1/wAId4cj1pY7gwpdeKctbCcArOy2kYKRjAjx5rb+gGecWNYtteaV9A1T4pmcIgZNG8HaaJbiUnJmQrAqCMZP8ZIIJJx3BlM6x8MNPntbnWtJ8e6cbl033V/cOWCgZKfLNvCsAATtJK8DbnNdT8UdT0DxXpV14K8HX2nTxJaRyWdlp2oIIJ9gODKR8qJHgttBLMUUv5aKGby86HrfhlL7VPCmtweH7QP9nZNXu7dtUbYiKzARIWiUBx8obKg5PUE9tp8nhnxhoc3hzUZLXQoEuVs7vU7jxCAt9DC2Q8Mf7oTtgriSSPAGGJdlwQRzf7Mmvp4R+MV54XXUbS903Uw1uLi25gadAWVo2b5ipw6A/wAWVPPFfR3x4juT8KNdnsVQ3FkIb9d5wMQTxzN267UOPevk/wCJcmg2XxO8NyeHGGmafbzRr9q81t0e2Y4lC5YQoo2lEI3YAdgd4LfX/wAQIby8+EXiOG9SB9Rl0O4Eq2+WjMpgbOzPJXd0zz0pgbOp3EOlPqWs3xdLO0sfMeQkbVVN7vgdc4A68dPeqnw9sZ7Dwdpsd75v2yZWu7gS/eE0ztLID9Gdhxx6Vzkkz6v8MvB9i4aaTXEsIZSxyGj2LNPuI9Yo5BnnlhnjNeg3M8drbS3E7hIYkMjsf4VAyT+VAHAeA521j4j/ABC1RJIH0+Ga10aMIrBi9vGzy788cPcFRjsvTuen8JO0miW0E008lxYO1pK0zhpHaMlMuQACWG1+g+8DWP8ACBrhvh5o11qDwG81NZdVZYRgAXMrTgYPOQJVBPr3PWtKwhTTfGepRBiq6tEt6iHkGWILFKR6fL9n478n1pAdCyhgQwBB7GhT2zkjg0tQGLZciWJEBk4lIQbmx90k57c+vWmBPRRRQAUUUUAFFFFABRRRQAUUUUAFMnljghklmdUijUuzMcBQOSTT6KAM2xt2lv5NSkkvEMkYijtpJMRooYnfsHRm4zuyQAB8vIqS7dbuY2KGN0wRdDewZUKnABHQk47jjNWriZIIt75xkKMAnJJAA/Mikto3jhUSsrynl3VdoZu5AycD2yaQEtcLp7w2nxr1q3QRLJqGhWlyw3He5innQnHoBIgP4V3VeXf2r5v7Si2ELK0UPhlxKRJwJDcI20gD7wUocHBAkz3GWB2/jbUpNG8G69qkChpbGwuLlAc8lI2YDgg9vWvEPhZM+oePfBOn24gFra+AYGn3RnrJLHvAB4ywVcnHIZuTxj1z4uLM/wALfFyW0ZllbSbpQg6nMTA4x3xmvCPgDrV5H8R9XfXp7SK7/sCxgt4LSEbBGLeORNqjksI8sVX0cAcKKQH06hSPMQjEcUQGCMBQB29sV5nb6jDqEdx4tVYruNpsWo2bBuVWWELMSVYjzWQKSFE00ozleOq8eCC48Ox6NK1x/wATuZdOURhS5VwWk+8CMCJZCcg8A8V5L461CG/bw3oGhTf2do8qS31/cQsv7nRbbIMvyrwkxJdWGclUI54AMqNH5Mmn3Nm/ma1fQiw0KMtMBFa5bfdPL8zxvPidxISGWBZNrblNaXgttE0uzt/FWxdT1S+kltNBtihtldUY/aLoxEHyVaYzSu7Z8uIxqMHCNNbaVfWvh/xF4x1LyLfVZrCW7ltXuFi+whVV7KxIwoCBQhlztLMEU71LA7+j6fp/hXwafEuumRItK05Q+7Mc7eUQ20EsMGR0VzGTlpHIfJGAAeceL7j+2Uu4/tSW+o68Rpl3q0kzxmOwhh+03U3kZOxAsjARsVYIYw2S7A2/Bhu9c8R6ZrosraygitVh8JaTduXSxs8rH9tlQH7x3AKu7dKzBQR5YccJpc93481jxFaWd8La3CLIb25h+W7vrh1dIXjIb5XlUAn7vk2sRYYQ7vUdc1i2+Gvw+F/Yve6n418QbWW5nWOa6lZj5a3CopZdih1EcWSo3KvVnJAM7xDpsR1lfCOkzNqHiPUo5oru5vC0xsLHn7RLPIGUeZM+F3BVzEqJxtQns/EHiK88N+X4T+H2mS6t4lndFu7q5jLRWjsObm9mTje6qGC8HABxgop57wR4Yj8F6bb2lrZQW/jXWsveC1UXBsYFYZMa5wAhEalznfKQx3qARofFrUF8A+CLvSvCflWt08El1d3M8gcWsDElizOSWmnfKJnJdt5yBHlQRVin0z4XaHaeI/FE134l8Z6gkht7i7jCy+Uo4C5BMEYDAsBli0pGHYhazNSh8OeH9ObxR8VtbGp3V+ZNRj8O31osSi4kjUR5twZG3JGnlAyFggP8LZJyfh/BYaJpV18W/iRPfXVxeTNLpEV4VaaOMjbEQmFDTSKg27V27VDZVcleqmuLVNd0rV9c8PNrnxI1UobTTpAZINHi3b0UuUxGYlaMyNgvvfIwrrQMsx+D9S+JQsr34hxzaN4UhCCx8Oxt9naVsbVefacoSM4iDErkDdkHLvEfxF8JfDlLbTtUihs4IV8y30zS4DHI4YA75IAwWMYYgLI2SRuwf4eS1Xxp4vvrTTrq88QXvhnQjH/perXFiizXAdfl8m35KqzArHt3SN87k7VxR4V+FOoajrMV7ouiy+FbDc1y2ra6sWo6pdszbhiF9yW7DJG7G/5VJJOaBGzp3jvxP4zaJvAmieMFtZfNuFudQ+x2FqFPTD+RJ5nzHOAcncSSQMjktX8TeOBeSWPinxD4X1ewlX7O+ix3Nhc3E8jcBdpVOc8j3UD5icH3CL4XaFMyt4gudY8RlZPNC6xqEk8Qb/riCIsZ5wUwO2AABla58MLPeY9B8M+AVtQq7VvNGy+4NnllYZGAPqc544pgfNHxXa88UaZaMbXSPDeg+HrArY6f/acd09wzkeY0b8GXkIrHJ5XILZJr6p+B+qQa98H/AAy8bhjFp8dnKvdWjQIcg+uAfcEHoRXmPxC+AuiS+FNc1RdNtNPv7Gye4tU0iSRVlkWLcwkVw+RuHyqgBI4zk5HQfsk+I01n4VRae88kl3pMzW7q6gbUJ3R4I6jBIyecqR0wSAdV8HpbXUfBHg6aNJnax0K3iEucRbyojkXH99WgIJxwGwCcmrHxxkvF+Fev2+lwtPfX8SadDEuAWa4kWADJ4/5aVS+A8LW3hHUrQRyLb2mtahb2zNGqK0S3L4KYOSu4uOeQdw6AUnxrmljHgWGIyYuPFNlG2wAngSOMg9gyKT7A45oA7rT2gGlWUlrbyJD5UYijdSHRCBgEHkYGMg+lZfjO1C29nrUUAlvNHm+0oed3lEbJ1AHLExM5C92VO4FWfDlxGyX+nLHLEdOuDbgOy5KFVdCu3ou1wB3+WtJEElsYZwGyuxxnOR05+opAT0Vzfgu+Yx32iXJIvdGmFsd3BkgI3QS9STlCFLcAukgAGMV0lMAooooAKKKKACiiigAooooAKKKKACiiigCugeaQtNGFRG/d85J/2j6d8c9PyFigcDiigArw8rN/wuPwlq0ElsI9R1LW4pSHwZFjjhgVfmGSw+zZwMDC8Hnn13xLqf8AY+hXd8FDyxqFhjP/AC1mYhY4+3LOyqORya8s8T6dPofir4P6YNRRHsFuftVyQFMyx26CRsHrvJ5xz8+exNIDuPi86x/CnxiXOAdIu1+9jkwsB+p/GvCPghNDbfGzxab2FmW0021hEggKtHIogiEYU5O5j8v+1g9M4r139oy5Nr8FfFLg4LW6R9M/ekRT+hNeWfsnaRqU/iTxT4i1e7W4e68sSBnBLTOqzBiuOCFkIB7fMMUwPXvFNi2seLIJZroQWlhDJaWxWUhvtc6/vJAuQN0dvv2k5x5j8cV414G1Cb4n+PLo6TAlv4Y1CZTehxjFhZ7RFZIrLgBmZHlCEjbcKueCD33xv1w6J4e1IG6FrHb6c3m7GO5Zb2XyUfaGG7aounxzkrnjHMPw/wBDHgf4e3epIltFNo/hsDEm2V4Lllkupw4HIB32+RnnYMDAUlDOqjjt/GKf2Rdym7s3ij1K8fykKZkctbxcEqSmwEqwYERpuyHOfPf2lNUeDwJdaFBbzXdqjQWMMZdpZpZFTzZJWz8zLHGE+bJy8o3fd59d+H9ibXQRdMfn1BxdbdysETy0SNQyjDYjjjBbnJBNeGa7cweO/wBo600XTrq4a00WQRXSgCSOVVka4uA+c4XesEOOO/bggit8M9KGgWkem+J2jkEQvLmeGzWKNCwf7P8AM7FCSxRokY5B89wp6FLmheLbDxD4m1bxB4vitoI9Hxc38izvLHYyI8sMEEbrw5jjeV96HLTXKkY2KKZq+rt4Wu/EWq6ZbXl1pVpPcywu0aym4uoDKkFqcYLRQstzcsedqxoSdwJa74M8MN4T+Fvg/Sbl3jn1a/i1jUo5IeSsY+0FZDyUUeVApO3swPLjAB1fhC1i8PabceLPFNrDYx2tpDMttb5ZrZirrHaqAo3eWjqqjJLSTSk/wY8n1i3v/iH46HhrVZmTQ7C+fVfFN+MCKGdYyPJEh4WONVaBDn5isjkHHHoPxS8WXOh+G4R9jD/Yli1KaQQl/JOWFqdsi4DvcJgHkqsRY/e21F8PPDVpbX9z4ddojpmmWdpYahsVnguDAzyuh3YGZLmefcpBwkYGMTAqDOg1eS41TW7fWIdBe78SyxxRabZ3UbpHZW7yBt08gDKj7Ud3H3gNkYGXO/B1KC1/4QK91q4vrm1TxVcJcXN1FADe6ksoIt7G1XOc7Qqjcu3GSQQXK6Uk8dxZeMtStraW51PxBcR6PZQTSP5TNJGI95CfPGNo3uykEwQwvweag+HVvrniPxFf6693p+oWWi3stlpdpITBFGR+7lmRE3+WAqiONTn5Q56sSwB1vw98ES2MljrHiSKEalaWwtNL06JzLBo1sF2iKJm5eVlAEkx5bG0YUc+hVFbNM0QNxGkcvdUfev4EgfyFS0xBRRRQBxWr6VZasDY3fhrW5Le5bZNIl4sSIG5LMROCRyc7QT1GOefLP2NNZupvC2veHb1NjaPdKVRo2R083fkNn/aRuMAjnPt7/f2UF/CsV0rMiusgCuVIZTkHIIPBANfNH7NKWelfHD4k6PDBkpNcLbzSgySLHFclWXzCc874yc5JKgnpQB698J7O30y+8Y2Fu9rJImtTzzm33FVaZjKqEkDlY2jyBkA5GetN+LkhXVfh4iLl28TQnn0EE+f0NXvAPzeKviC+G/5DMa7iMdLK24/X9awPjNcQWvi/4ZSzvLn+3FjSNFLB2ddgJGQBjdnJBI7dTQB2lyZdP8a2kw3taapbm2fjIjmi3Oh9gyGXPbKL6877NtK56E46d+1UNeKxac100Im+yMtxjZuYBTlto/vbdwH1xV/KyxgqQ6MMgg8EUAc74pA0m6t/EivIsdmhivkVdwktmIy5A5zGfnB5+XzBj5sjo0dZEV0YMjDIYHII9aR0WWIpKisrjDKwyCD1B9a5zwpO+mv/AMI3eRCKSzjP2Ft7OLizUhUbc3JdAUVwSTnDdHFAHS0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc74ih/tTWtG0sgtbxSjUrnoRiEgxKe4JlKOOMHyW57HkvH96YPjR8NLdYTIbiPU4mO3cFUxRndjP+zj6H8D1/hIx6gl3rqxMjak48tmkZt1umViIBOArAs4A4/eZ5JJrlPE9r9r+PPgh9m77FpuoXGQhYru8uPJIYbfvEZIYdsZO4ICl+1G0y/BXXPJMgUtCJDHnOzzVz07dM54xXn/7MenR+Hde1+MJJcFpLC3e8TMoJltWlYFxwVEgQA4yNwz149B/ailnj+CuuLDCsiSvbpKzNjy0MyfNjq3O0YHPzZ7Yrzj9laO6uPC/jPTDDcpe2s9tcBZWEbNOAzBS20lRmJBgg7QelAHQ/ETTjr+r+KLa6h+0h5riS3WTZJhLfSysaFDkhftFxLIpwQGQ8ZNa/jrzW/Z51A6Koku9Vht7WIqigzGaSK3HGMYKkKOpwByTzT4bqwvLuxvI/OuYNQtNTubd/NUKVlXzW2ABcnYYxlgcdAfvE17YDVfg38KbKORJYrq50mOQoD92FRIy8cgjySCfY9KBnq2v6pBoOkm4dYwiYRFZtiD3LYO1VUFicYCqSelfP37MVpCviPxf4mv7O5s7iO323U84LAvJNLPIMnkMEEG5cZyMnrz6X8ULDVNf1KPSdNWOaJbQNNELvyZCs0nkyFRkBj9nNzgtwGwRkiuD8I2slrc6HIl/AtxrvjXUbq6EPAZVF0jIATlo38kAZ4BPOTjAI59I57/Sktbi5jimu5bbeLg/fudTa2iA2AgFktVuFwAMqzEj5iT6v8X7OPVb7wXaJPceQ+uAXP2aRs+WsMrOHIz8gIXIPAHHHby7TdPE2r6VdXcyyRo3hzXZbiMEIJWNtaRI+7lflF0+MdHQk/LWx8bddupdZ8Fql5BLa3N1eW++3mTbH5zPapKzqeNqS5yOjKQSDyABPF0Wmz6R4P1258i1OveKbPVY5LqVEEVuikQBkC8oLeNRtJ4eU/Nyc7Xh/V9R0/wCGukzJcQ/bNTWfW5A8BUtLPP5sMWWAUZ3Pk5B/d5U45qh+1LHp39k2V1fXdtcRwXKRLZSRbxHL5Fww3Mp3LvDIdp6+WtV/GdtfHXdAlVpLGzXStLguo7pAswZppdkZ55YoJw6qBs4bJ2igZy2rav8A8I94I+Gdto9tc3NppFjd6vqMaztC8d8IJeGYEMCs32jcvcKQcjg+8+AdF1bwx4L0HTLNdPu0hgBnMjvESzIGZlOGyWkLsc4618//ABUDf8IzpWrJcXDNqvhtbmWN5Nxt4pbxGBaZ23MB9tMeAAGXPAXhfrCO2hE/2iPdubk4kba2cckZweg5xTEOt3kkj3TRGJ/7pYH9RUtFFAHK+O9XvvDkdjriSBtCs3K6tAIGkcQPgCdCuSPKPzMMY8syHqoroLfULO509L+2u7eaxkTzEuI5FaNk67gwOCPejVLmCz0+e4vEke3Rf3ixwvMxXofkUFm/AGvmu48PPf6zqun/AAcm1bTvDtknnX1za3TTWVzPIm4W0du4IZyGjDMCAq/eUkDcAen+J/HOr6n4ps/DPw5OlX93uSbUNQZ2ngsIeciTaAA7YwqhiThshRhq8g+DUy6b+1h4zt5FkeS9l1FFKDITM6ygsSR8pC44yd2B05r3n4OQeHY/h5pMvhG1W30+4iEjggeaZsBZPOIA3SBlKsfVeOAK+e/C7Jp37ad9F5BUT3VyMMTkF7dn3Djv/JvxoA+gPALE+MviInztjV4TvfgnNlb/AC49Bjg9xjrXC/HrWXg8ffC6LTnZpYvECxTNG+NhbyQYz7skv5HnqK7DwVqOn2fjX4jW8suy6TUUu5SUYgQiytud+NpwS3yjkfTBrzv4sl4PDfw11eZHuNSufFUGoIIEO4pK7yLGBySwXyk7529KQH0MQGBDAEHgg1z3ge9ebS7jT7hs3mk3L2EwIwSFwYmPJ5aJon/4FXRVy98f7I8c2d421bTWIfsMhxyLiPc8P0DIZhnjlUHJYUwOlVdsrHJw/OPQ/wCf5VDcWFrcXlpdzwRvc2pYwSkfNHuG1gD6EdR04HoKs0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZmsSmQxadCzrNdbgzIATHGB8zHII9F+re1aMrFIndUaQqCQi4y3sM4GfrUNrEys80ufOlA3LnIQDoo9hk8+59gEwJYYo4IUihjSOKNQqIgwqgcAAdhXjPw/u5/Efx88bakxEthZWdtZwg5VoQGLKpU4OGIaQEAjBHOcivSPG91cx6TFYaexS/1SdbGGQNtMQYEySDBBykSyOMHOVFc98INKtbH/AISq4txueXWJbUOSp2w2yrBFEMAcIqbecnOSSSaALnxjgFx4GZGiWUf2jpxKsu4Y+3QZyPTGc+2a4X9nZRD4v+J9uv2himsv5skpBDS+fcA7T94jYsZ+bnJPavQfiivmaBp0LR+ZFLrWmLIuM/L9thP5ZAz7Zrm/hRGNP+JXxT0pHVkTU7e/4Xbg3EAc8ZPpjPfBPsGA3XtFudC8OMuj3kS31lryjTpJ8yC1F4RbquOBtjF0SqcjCKMHtw/wjvBpnhzwT4e1ScJd6XraSwB1K7oLm0uSmSeGxI8seQcb0wCTgH0+S7tPFmoeINJuY54LGO8OlvLFMA8kiwxzBwT8yFWZguzPzJnI6V5BJJDba9o1rqdvFIreJbjw/qA+beY5p2ubIqof5VxNJtOOAxxygwgPV9P1tj8Q71Z0ghiiujoqOFKO7LZpdg4KtkfNNjDKAF6OWGPH/Al040r4Ojdlft2pXEgHzR7ftUkRKlepBuM53YUDPPfo9Wnm8N+Pvst6bnVbkLp92bpflEzIWsbiVl3Y3tBcHkc7oGzgKMY/wrtDc6f4U0a7uJFNrdat4bYwgK1uZLNJ3+ZeCwaNueuTjnGaBnSeBrOy1W71iPWdPlezn8O6dZX1nK+37Ooku4ZosKAfkaM8gAgrkEZrmfi7ZRWHi3w7c3F3I9st3MgM7QKdkVxbRqI0VVVysk8rbGwRhmzhebvhhbvT/HPjDUdKvmfVbGfTZ7/T45jHG7mSeO8TDcMrOXmRsIAZlJwMg4Pxei1O2vIJLaygm0XTpZb0zSTtJlfttsJImVcEShxG7ZIOJXXqpNAF79oaM3Nzc6vYwXAuJ00VoIo5RHE7lrt99wuPn2qm0cjGc9Aa6bWHvtU8e+GrfxTa2ltq14umNcW0bsVBiOpiQrjLbcvHjPHz8nGTWh4z8P2usweFreGSGSy1eA6U09uhBEkVhfBCqO3YyMQGwQVGW4FVr5pNe0b4NeO7kNd3lvc21vePGIyP9KQRM7YOOJtnA5XceARigRwnxdt7zxV8F/hveWFr5erGycskZ+RreK382RSgG0gm3jYKRgEACvpXwZqlnrnhXS9V00bbW+gW5VC24oXG4qfcEkEdiMcV4P8ACK+iuPhPpbaj56R+Fr+aG8hmkzIlrIGxM3+wjPncMAJFIBkiur+BXiBbPxB4j8AzQpCdLc31htkEnm20xEhbcCVIzKpBGOHHAINAHs1FFFMDhPiZHrl7Y2Wl6DpUFxcX80ivPcSN5FuEQsjShR8yMVVSpBBBIwc1ueENCPhrwnZaZGUubqKHdcTSO2bq5bmSV2OSS7lmJOTzWstpF9ve8aKP7QUEKyAfNs64z9c/pVmgDyzStM1Lwp8U9Qvkha18O680jy28dws0ZulBYz7SqtGzIuSAWB2vuOQmfJ4mtn/bjQ2riQEuJDv3YcaewYdOMEYxz/QfS+u2GnaiLEapbPcfZbyO4t9qOfLmXlH+XoBk8njnBr5S8G6zb6r+2OLm1gaBWur23fKOjOyQzLllc5BwoyML06DmgD1TTbp9Ul+KL2UJs3vNag0cu8wDEkx27sNxOCVYMvHdQORgXv2n7RYPhR/alsqRy6Ff2l9bqAAAwkEYAGMYxJ09qzPg3ojasfFk7XQRo/HV3dXkaKQH8rlEUnnHmGN8+gxXpXxTtIr74aeK7adVZH0u5+8obBETFWAPGQQCOnIHSkBrPqSLNphJYQ3+UjGwk79hkGTngbUbt1x60eItMGr6Lc2eQkjgPDIRny5UIeNx7q6qw9wKyzqDN4DsNXkktp2itYL6SWPEcbKAruy5+6Nu7GT3xmulVgyhlIKkZBHemBT0XUY9V0u3vYVdFlX5kcYZGBwykdiGBB9xV3HOa5+JLjS/FUg3NJpmqjcq7P8Aj3uUXnkD7siDPOMNGeSZAB0FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADWUMV3fwnI+tOoqC+uo7KzmuZyfLiQucdTjsPUnoKAMKzZdW8ZXVyqy/Z9IQ2aMT8jzyBXkIHfauxc9izjsawvgO5m+G9tcyOZZri+v5JZWOTIxvJhuJ7nAFdnolpJY6XbwXE0k84BaSSTGWdiWY8cdSa4X9ncsfhHpBfduNxe53HJz9sm60gN34k2VxfaDZJaqrNFq2nTvk4IRLuJmI9SADx1Pbng8Z8PXmX9oX4qIxURvFprlepOIMKfbgnj3rrPjGm74WeKW3snlafLPlQCTsXfjn124z2zmuS8NGPT/ANpHxjFJLAZNW06yuokkQrIAiMhCHuPlyenUDtyAXvCurS3Gl+K5JUeGWw8R3aL5EUrthJYyGcKuTlWHyqTlGPXBA5v4u+DBrmiXms+GRBaarsj1iFhy16bcZMUgycuo27HHI3OuQrEnvdFjTTPin4gsJP8AVanbwazaqYcDzUBtrghu5Ci2yP8App7k1rXERt5LTMCqthcGRNo3kRMCnuR9/Pb7h7DkGeN+PPB9x4r+CR1uzlgv9Shu7nxBbRMvnbLed2la2XcOojcHBU/MoAA4I4vwtrF5qSeFtb0SIxGPVbO2lDW7RMyebcrayZGVZZPNurV2LcMqmvW/gnq76NFqPgnVjbx6hoFy1uU80Fzakg28vQbxtdFLYBAMeQCTjjX8ODRtU8X+AUlis9J1IsujNds3k281wPMiTpgKzxP5TAlkkt34JkUOCKfxO1f/AIRv4veH/HGmSRro2uafHDqH2hGfbCk8azfKG4dA0ZKDoUbI656Dxt4b1Kx1+0udOn0+78J+IpRZzSK7l5DPbzRIZmDESKS1uA4O5iidW5bhru+0/WPC9rb+MoHsNSN4/wDay3S4SMSyGzuriFlUxqPtCQ3BXAAlil7Mu7e02y1y68PzeBNQ1IxPZs6W1vLaotpNfxSLMLGRnG/ymUJLAYyhMcjDkw4oA7XQEbS/hzbXmoxXsEuhaslzcQXUfmSWxVlS6ZWzlo/3k8okzyj8jGRUWj6Ktz4R8WfDe32Q3+nyzG1ct8kYdzc2cxwo2qu5FOARuibA9ZdF1ZtZ0KK6d4bzUUhKP/a6xQjUdPZyssM+FK74nLRNgACRQzAJJhvP/HEV1ol9Bqdzqd/FaWBOlR3cZeOYRAiSCG5XODNA/wAw3jbPE6OpZuGBl7+1bfwV8SNTt/EunX2j6brsD2iz3kRn0mKecmRoZclUmhEjSyK6shVbh0cL82yGy8Ozanq9loukeIrbRvif4NgNpbsNz299ZkGWBV3EkqsbqpyGwC2QflI63xLeaf8AEjwxfeHtWvrLTPETwJJFFcrvspZMK8M9vL0cEHgo2drEOjAYrzjxNpWorpf9kWgjsfHdgRe2Ghw/ums5Q+ZJdPmJw8EkYLG2ycMG242FKAPo74d+JpfFPh0XV9ZtYarbSG01Czb71vcIBvX6HIZTk5VlOea6evlCTx7q11daN4q0qe20vx5t/s/UtEvZUtrPU0jLKJGZ3jCyIzMuwkyA4GNoy3qmn/HXw3bCK08a2+qeFtXEQaW31GykCs4HzeWyg7lyOCcZBHc4piPW6jBMYYyvkFvl4xjPAFc3oPxA8KeILWOfRdds73zE3rDCxafaDgkw48wYPXK8delaF34n0CyuhbXmt6Zb3JiafyZruNH8tVLM+0nO0KCxPQAZoA1DMgTexKqCQSwIxj+nHWvjvwSum6h+13rD38skjx6lctZ+WwQNMr4w3ByAofpgkqDnqK+gp/jV4DVp47PWX1KeGEzvFp9pNcEIBksSiFQADySQB3rwf4L6npHiT9qjV9ZtorueC4S5ubCRovLKMwUb3XccKUMgB7llOBnAAPYP2cH8zTvHjYILeLb9sHtkRV6tqMC3en3VvIiyJNE0ZRujAgjB9ua8/wDgHPa3fge7vLAQm2utY1CaN4+fMU3L7WJwCTjAyRnAH0r0g9KAOJ+Dd2uq/CLwpI0TIp0uGBlkUc7EEZOPQ7SR7EVq+B5z/Yn9nSmU3OkyHTpTLjc3lgbHOABl4zG/AA+esH4CmQfCfQYpiGMCy26kHOVjmdFP5KP/AK3SupWOW18Su4kP2S9gH7sgAJNGeoPUl0YcdAIc8c5ALuoWou7Vo/kEg+aJ3QOI5ByrYPcHBqeLf5a+bt8zA3bemfanUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFULtRd3cVuY0eGJlllLAMAynKDB75w2e20Hjirz7tp2Y3Y4zUdvAlvGVjBGWLsSSSSTknnn/OKAJa4f4MOZPAUblHjLajqRKO25lzfT8E9z713FeY/s4SRv8ACmwWFlkjS7vAsqptEgNzKQwGAB16DOMUAd14p0qLXvDOraRcs6Q39pLbO6LuZQ6FSQO5GcivnO/+ICaB8YvAF5dwPLFq+gabFPc3TJG8ZkeZTI5IPI3/ADYI+6fSvqCvnTQPC9pqsfhzS9Wnvpob3StV0QzKu4RvbajG0TYZSFIKHGcj5VAHHKA9P+KiJph0Dxdt50G+DXDjdkWc48mfgZ4XckpyOkXauo1B5LZ7C5kUEeYIbghztVW4DYJ5O/YM9QCfes+W6t/tdzoGrhJ4r0SfZ1uWVhdxFSZIcHAZl+YFf7mCc81z3w2vH0DUJ/Aep/aN2nxl9IuZVPl3ljwVCN3eHesbDrgI3c4BnHfGfSr7SPH/AIe8YeEwIdaZDZ3EfylJssoiEyj5trBpItwyd5hUc7a6nTbfRPiJ4Fi1+zRpby5shZteJJi4RYpdxCvt/wBYki71cLguqnoat39gde0rUNMvZLa/1fTWaCaGOd4DLG4ygc4BXzYyBkZCyKpU7o8jE8P6tH4L1jU0uwotXuVl1q4MYiAkkXEWoKiAhll2hJSNqrJE5wAGJAOA8SaPr48eLa65cSJquoae9naaiQyaTqsh2ArcRhsI1zGqwsikFXhjdNxdNudJdtrHhS3/AOEqhvLbU9PdNA8Rl5R5sCOxNjeSMWUbon2ESnOd0wOAefonxFYadeCH+0bG1udMndHMrtlY5sjy2K5G4EkYI5DBT/tLwd1pmsw6lp1jcyrL4o0tZTpF7PKQmtWOQsttcnGPM2hGOQeQsi5w6gEea6DrV1pGtXWkeK7G2k8RSTXF7A6KkKaosi7GkhdSV3zbfLkgxgkI6gSxlZPQUjtPGGnG80C4ltpSGs/suo/OJmUOZNOuoXbduX5sxt90N5kTgF0PC66tzY6DHB4fSS50b7Wx063e3WTUNHv0yzWIDHaWQjKow/exF4tzZhLV9FA+JHi6PSdWutN0q5bTJvsN9YhXilmEilRbFjukhABLW8gzGQ2NhxsLDOe1DT7rwOt9cWGmx6no4CxajpV5HHcXehFhkAq4IeNh5eyVhgqNrKrBSPS9BtPhx46s4Li5tdRj+y7XdopJpbMIW8ww7vmSNMv/AKttjLtJXGN5zJpNY0a6tLHx5BPda9p0m3TdX0393qO0L8rRSSYjvFfJU27Ey9cpLncOlNl4G8QuNatZ00K/3+VH4j0F/swLyYcpOoz5TsTgpOuSWAVizAUAYPiP4SweNml1PwL4o02/sLuJLeR7qV5pECMWAaVSfNwrKu2ZWbEUY3AgMvL3vhz4x+B9Ht9C3aP4h0aRBFHaztFdQxMWAGBOqMqqBjnKKPTt6bdeHtSvoXi8SWWg+MEjl2tqdvFaxXAOAAJIZECq2cjKzKfm6LxWX4gs30jTzBY3fizwjJKpNtmCfU7dNvJQxRzzxqpBPAUYwe2AQR47qEehPq9zY69deH/CcqTBHtxozyshVFJ8uS3kZQSTtOGU4AJ5xVfUdD+GCXpkn8UaagV1d7aLSdTkmO0YMeXlUYYjqcHngjv7h4SufEzQTrZeOrHV4Awx53hJopF3jhSgeIAEgnv2PQ1q6vZfEZI2vNI17w1p/wC6Z7xJNHa0ji2ncXMrNKCcE5J+UDJAPWmOx5hfm2h+H1peeHdJ0+28K6bGBcvqWnm2Gu3cZPlq0W8vLChJJ8xwobkl9jLWN8Brm8tvit4+1bVp55pYdDurie68loXJLxOGCEKy5AJAAXAxgAYFdVrXinxHqV1/wlWrvoOn6JGsMWma5dTStDFuLedJbWxRZnlkVQoO1SAjlDtYsOV8Erdpc/HO9vbO4ju5NIuGYS2rW8iCYO3MbMxTIIO1mYgDr1oEfQHwEnnn8H34vVRbyPVLlZwqhP3mQWyg4U5PI9ew6V6TXFfCi1ht9E1R7dIUSfV72QCKMooxKUC4IHKhApPcqTXa0AcP8FPJ/wCFYaILeMxKFlDIZN+HErh+R/tbvp0rpfEMZOn/AGmOOSSWzdblFjbDNt+8o9SV3Ljvnt1rmPhBMbj4fG4tihaXUNTkjIIdTuvZyOm0Ecj+7+FdpC6XVojkApInK5yORyKAJhyOKKzdBeVbI2t1Ij3Nq5hfaedoPyE+5TaT7k1pUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGH4y1SXS9DkNmyDUrp1tLJWbG6eQ7U7HgcseDgKSRgGuN/ZyWGD4XWtlbRSRQ2V7eWyh33khbiTBJ6ZweccZyeOlde0UmqeKo5WytlpHKcKRLcOhB6jI2RtjIxkysP4SDxHwVmurLxP8AEnw7cQOIbHXHvYJuibLoGQRqMcbQAev/AC0HApAerV8+X8lnBY+CJHFyrWXxDvLDMDbDmS6uiBnP3MlNw7gMK+g6+avjXZMPAvjWOxke3l0TxVb6krQFT5fnQxMXYdQN07tnHUd8HDA9T8dWeo6n4lg0q1ubOHzLCXUNMeeMFotRgkj2OGOTt2uQygZKlx3NQ+I4bjxp4RtNe8PRJbeLdJ33Wnh0V2guVBjns3YlRhiHib5gOjfwil8Pate+I/AfhzxXqVuLbUrQJfTRwlZd0Lx4kxgE7WjfzAo5yqg5IrkLO91Tw74+1rVNOghuZLi68zVdHsYHIuIWEht7mB8ndMYUclANkhjkX5X8vchnU2/jXSNV8O2nxB0RmNpCgg1mJUPmwwg5dZQFLb4C5kA/umQrkODW54o0O21G2S9spZLK/tS6wXcSmRCsuCwdRxJC52lxxgjeGUqHHBar4fufAviiPxD4J8htM1iYHyWkK25aTJ8hm5CJK7bopcYjlOzBWbA1vhhrlqy22miSWLZLLHYwTuTLYsp/e2E2CRlQu6MsfmTkLiPJAJdG8TJ4Zvryy1+3vbXSTPtkN3J5yaa7dPnJy1q+CUk2hU2uG27GCbPiWwsLiyWy8SzmTQHZJ7LVhcGKWxnGNh84EFWJJ2SAjOSjfeG+vqmiaXJcz3ks0On20KPB9pkcKLYuwZradScNGzMrLyCpY7GXKmqVrqk2g6p/wjWoaYJbWeJvLsPlZLiIZ8xrXIAk2qULwHaQCxQEKFYA5T4gaJdaSt63ibUIvMvdiRa+8AS2u1R8x22oxKVRGBOEuUMZU4IaMjD42vWGnXmo3uj/ABAN7oUt35QsfEMcu+BbtU+SKWXgPIi4KSSpHLsDIW43v6pDOyeHoJfDEUXibwxJmK4sZJN9xFFtRDGnmH5iuGLRyYbJIzkba5G18CaPflv+EM1qSyjuVZbjTLmH7RZyru+eKezba0ePlAKlAuTtC55AKWn+KfFXhGyk8P8AxS0uDUtAjWG2/tPYbnz423Bi4bAnGByB+9AGTHJktVqH4VeEtdsbfxL8PNTbw/cXu4RXFjJ9otLhCfmjkhYgFCFIMfygEEFeCK5e4Nn4LI0u6t/EXgqUfuoM3sl5pkw3sAqzFJUIZWLbZYNw4GVqG3bR01S5/wCEU+IFl4N1UM0xtpVFrbu3+rDPF5jWszEJtJjVf7xXIwQRiXfw08W6drDwWulXLanBEscc0V7LIr2qqV/0eXfEVAwB5DzMwUdCMGr9ssmj+JbAa34i8WaZaNC8l9Z3095p8bbgNhgkWWRnYO3O5mGM5IINd/qms/E/w5phuLvQrPxHBuz9t8NXGyXbkLue3ljfexyD+76YOSBzWBP+0Drlmi3lx4CuE0u4RXivJrxooRkDgyCN0+8cZyPQgGmBU/4SXQ1jhMmuyFGYK63HjXVQuSoJXcsHzY+YdcYAbvisnVdY8N6olpLd28mtwyRtJFZDX9XuUncfwoJISWYqX+UqBjDEgE16F4e+JPjjxDpVzd2vguB7fAjjuNO1mznVZAzB/naTb024GD1ycgjMPjgaRb3Onap4qu9TGo5Lw6ZeJc3SvcGNWS3jWDbCyqzDdgOXAKlgoYUgPKo92la9Z3uoa3Dd+K7y1SOy0rwpYRXVxFb7GCRpOV8mFQnykxqxK5PIzmXwfdF/BfxxuNXtorG9uIwjWkrIZISpljOfLVQQrkDKqBkHiururTWNN0OHVNTvtM8I6TfzNc6nqGsTyy6vquzdtR0iKFVIAPkRv8qnAJG5TnvcSaL+yDfapFbR6VqOqS+aPs0QQFZLzcqrjOE8skAN0BI9KYHuHwZtLqz+F3htdQGLya0W5myCCXlJkJbIHzfPz75rr7qZLa2mnlbbHEhdm2lsADJOByfwql4ZgntvDekwXi7bmK0iSUbVXDhACMLwOc8Dj0rH+K13JY/DLxVcxRPK8emXBCoxU/6thnIIIx1yDnjigCt8G7F7D4YeHlmaJ5ri2+2ymIgoXnYzNtxxjMh6cenFdWk6i9e2eRfNK+ai8AlOh4zk4PU4/iFRaJZJpujWFjCqrFa28cCBRgAKoAwO3SmasFh8i+w5Ns2W2kjKNw2fUDhv+AigC4IUFw0wBEjKEJz1AJI/mfzqSiigAooooAKKKKACiiigAooooAKKKKACiiigAqC9uBa27S7GkIwFRerMTgD2ySBk8DvU9ZfkPea1HdGRhaWissaAsA8rcMxHQhV4HuzegoAt6darZ2iQqWOCzMWbcSzEsee/JNePPc3WgfF/4kWlvH5lzq+hwavYIkhjBaNfs5Ut/CzSbecHA5yOa9qry74mrHYfE/4b6s97HaxSXdxpVwisokuBNGHiU56oJIlz7sMcmkB6jXk3xD0me+1Xx/p8NvKzav4UjNu8e3Lywvcgpj1PnRfnwfT1muZ8RXJi8U+HrWUO1nqKXVlIhbCMTGJRn1bETgexb6hgea/s3+Mre9+GOhRSSuzWJbTboZDtG+/MBIyWCMpKgngEYHAzW5e+H9QTUL3SLA2sF3p0Il8OSSrmM2xCb7V9vI2SRoVOMriFhvKMteYeErxNK1PUNJupotslrax6taWi7XVo5P7PuZVaMZDrLHbTqGHKu+AC7GvT7XxLeWet2PhvUUmivY/9Gg1AqWEzsMrcxptIeJhtVtp/dPJtI2lXpDMnRNb0Wz0eSKS3hTwLezS6fqunXGMeH7wtteJ8HiBnJH91CQQQjAJR8YeFNUW9D6Nfl/EmwQRPfIjW3iCKL94sFwRgpdIq4DEqSFZlwC/l9T4y8Py3Dnxb4QsY5L90a31jSZoFCatbfdeKVDgGVADsYnnlSSrVR8L2VoumwWuiW039lTxn7NMgaVrV02r9nuwWDs0TIAjqQ6rGFBGwswBc8P6nd+KLK/ltrSK4vbaJ7HUtH1OTa7A4PkTJtK5wX2yjKup5HOV057fQPEtlfeHzG3k6UyGS3SVo7zSptoMRj2/MoKlirqSMZUblJA5m/hWbxVZS3DrofixJglprMBBtdUhLEmFgu1ZyCArQuUf5S8ZGMVotrc+raxa6Trhm8I+NoVY2N6Cs9nqC7sMkTHAmQjYxiYJIu4EcrvABJETpt20+p3T2GvJs+0ajHHhbmJFx5l1ECI5FwMGRPugjJh+6M3xHdeGrq80XUPiFpSaNrKMy2ur2sz+Syb9oK3KYKK3m7h5gAUucENhq245Y71hpWtWS6brMTy3Js4pCVlzvQXFnMduxyNzbQQw3OGX5t5otax6ZpklqZ4Rphdh9ttLTzrcyBuTdWqD9yeNzSRlFLB2YxZUEA7v+zrfUdDt9P1OFNYspEUSNeJG+/AyGYAbWOQDkD0I9a8z8T/Di1urqPSrXVbB7mS3Z4tN1u1F8NgBQGK5bE6kFs5LvtyMDaAKwbrw34u8Gywan4KmvItOciSa1gb+2LIqQozGjFZ0/iYlA5bIy3GK67T/Gtn4g8MtD8QNEtDYTERSS2yPe2rSLyfMQxiSAgrkCRRtwMtnGQRhaX4N8SaOkoTwvp8UaeaR/Ymry6Y8hDHy8iBVjlJAAy8aY4yeCa6Kx1ODw9qEty2ieJH1DZ5QjvfEEEyKrMMYSa7wpJUc7c8EdOK6Dwk2l6jLJqPhnxZcarpxLI1oL2O6hWQjOC7K0qnnO3fgA9Olbep6QdT0w2dzdSoGXa5jSMg85+66svGBjIoGctpmsa3NOtnp3hvTdHt2CzmR7+KQthwHURRdSRtUMWABYE9MHAv7fxBp2m6lrniO80fS75ovs97rtwnmrbW5XPk2lsQc/vG2/OxLsA2HHlovodnpen6Es88CReewJLyFEIXqRnAwvy5P0J5ryTUdaE1/LqUAvPFOr2JkEeq+XBbaVZZY/u7Z5nEYkB2IZcTOAG4I+SgDkviB4ffSvBXiHxHb+EWhlFmIm1/xRqL3N/PHIvlhkgG4RSHzMAN5e3jKjGBo+LbZbn4JfDPwpbu6vqEFrdTxZ5aNYg21uQQGnkhUH1I71wnxNvbfxLc22n3r6EdW1fUrWNPsEw1WZrRiQWW7Z28tlZACiJGDuB+YFgPoO2iF98dnjjkWOz0DQo0it40AUPcStnoeAFhjwuPfjuxHpI4rgPjjem3+H89nFIRc6rdW2mQxgZ84zSqrJjvlC+RxkAjNd/XCeJ5DqHxS8IaUWQxWaXGsOhVWyVjaBc5OQcz5Bx/C3XsAdyvAIC7QOBRIiyIyOAVYEEEZBFNbzPPTBHlbTkbec8YOc9Ovb0qSgCppc0ktoouAfPjJjkzjlh34454PtnFW6rxx+XeSvziUL37j27cY/KrFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAeRgHFRWtvDaW0VtawxwW8KCOOKNQqooGAoA4AA4xUtFABXmfxH8O3Pjfw34zt4RLuS0FrpojO1mniYTMykjgNKsUZ/649RXoGsahDpWl3N9dE+VAhcgdWPZV9WJwAO5IFQeGrO4sdCs4L6Tzb7ZvuZOzzN80hHoCxbAHAGBSAh8Gasuu+EdG1VZln+2WcU5kVdgYsgJ+XJ2nOcjJweKzfiNZebpOn6ksnlS6NqFvqKyFwirGrbJtxPGPJeYc+oPasr4b248N+IvE3hCONItPtZE1TTEUqFS2uS+6NVA4CzRzdezr0GK7bVbCDVNLvNPvE32t3C8Eq4B3I6lSOfYmmB88/HzR7Lw58UNC8S6fYTX1/rtvdWV7p/2oRJfqIki2FiwMeYnb5lz8yRgLls1mN47jm0qfw98R/BviDS5VlRb/UbFSRaXbB/9Li248ot87koGEm6ThhuDyTPdeN7b4c+DprqO88RaTqV79t1JbYTy2YsnaON5VY8LJ+5LBj8xA74r1fUtS8faDqQu38KaL4hgcLBLcaVcm2uigYlWMcuRgbmwgkblicjJoA5L4efE2x1fXGuY9atri8WIQatpsDARzFU3DULXcodxtUh4vvgZzny18zuvEvg2S31y88U+FmeDXLiERXkC7Sl9GNuBtYhfNAUBSxAILKSm4SJxK6j8GvEEzRazpen+GtZBW5kj1K1/si8hcNkMJht+bcM/K5/nXM6x4G8XeC7oTWXj/wAUDwns3walDv1D7DGoyEmtgfmQjpLHwMHcgBBCBnt+iazpvibTbmyureNpT+4vdNvUUSDcASskTEkAqTwcgjkFlIY87rfgVraye0soH8QeGbh83Ph/U5vM8lQgUNZyyfMjDbkRu+35jtaPHPE33gf4rXGnzXcWveGdW1HlLXVNklrdtbAh4wskWFOW+bY4ZQTnJzS6Drvx50WBoda8Jadr4wQsy3kMMm7dnLbXwRt3AAKO3pguwCyaTro0idPAd4nijw1HtS58Ja9uivLH7pVElfEkbDAKB8bQAV3cGp/+E/tdT1G0W9t9d8L+IA+Eiv7dYiwxjydz4W5QueFBWU4ypBGazNW+IXirVdfNjJ8HZ08Q28fmxyvqfluURsFo5Ail1Bkx8rEAv71lXHxT8dQR3Wk6/wDCbUtWtngiVI7mN5mOcj94whKyKSwAXAIOQSxJosFzuPDMSXV/ePoUy6ZrflsssO9mtZJnWP70Ssk8TdSRIoYEknJHNrVzqN7q7W3iJrjSLjyd0TtHFJCQpAIt71GikXJ2ttfY5wccVneHfFXjmw0hbHS/hNeJOpYRfaNWRYkizlQDISVAzgRA4UDC4HA3bq++KWt2Lwx+E/CemJINrxatqL3auuOQREmD370WC5veFfB9poct3Ldzalq+rXMcQn1C82CSQRl/LAaMKMgs5BOWAYAtgKBcu9OW5WC0tpPEFqEQFZ4rls4Uj5WMjHJPqcnGeRwa888MeFPivBrDTvrXhfw9pXl+UNOsLea6gBDHDLHIy+XkHojqMYyuc1f8VeD7iPTHvfG3xW1yxgXgSWs0OmQByD8uFGWHopYnjqTzQwJfipe+FvCNhaaj4513VL+y5SLRpHjkS/kXJ3NEFG/buGckICEJG7aa8usfide+JtZe/wDCHw+1HxZqSSDytV1SMCK16kpFGoKQLjIB8ze3G4uRTdI0/wAEWGulPh14D1Hx7cSyO0mr3m6S2gkLHCBpAI2xydxIPI+YnOO+0TS/iz4oc2HiW40/wVolsFx/Yao9xdDg7FYu4iC4+8APTDA8AHH6Tr6/GL4rfDjU/sPkQ6fHd6hcWqzrL9mMbhY2LrgnMiRnBAHPAOST6z8LCL/X/iBrLQeVJc669mGKY3paxRwg57jcsntnPvXm/wCy/Yx+FvGPxI8Kkljp91H5Tsq75IlaUBiw9QUO3oCzepr1n4RSyXXw80rUJ4lil1PzdTaNSSFNzK8+AT/10oA7GuE8L+ZqHxC8Q6rJEZoFIsLO5XlI4olXzE6/eaWSQ5GciPBwVxWv8SPEg8IeBtZ14pG7WUBdEkfYrOSFUE+7ED36Vd8KaYmi6Fa6apDyW6BZpggXz5SA0kpAAG52LMT3JJpAakxVU3sCdnzcdafRUVsCsQjbJKfLknJIHQk+pFMAnjWRVJBzGwdcEjkVLRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUjMFUsxAUDJJ4xQBj6gI9Q1y2099rxWqrfTRlc/NuxDnPH3ldhjkGNTx32axPCtvKIL2/uHYyalcm6VGGPLj2qka9T/Aik+5NbdJAee/FRJdAn0zx1Y79+ikx6lDGoJudPkYCUEdS0ZAlXkAbW/vV3lncwXtpBdWkqTW86LLFIhyrqwyCD3BBzSX1pb39lcWd7Ck9rcRtDLE4yrowwykdwQSK8nudfX4RaXq+jaizf2NBZXF94fuZ7gMMLj/QCWO7erMvlk7tyHHWM5YHF+Al1qx+PXjTUPDPhuTUNG1K9nt5L26nMKRS24BmAOG6zMApxzjjADbfZIPGV3HqtnY6r4R8Q2H2lii3QiiubdWGPvPDI5ReRhnVR16Yr59+EPjjx/4U+HdlqS+FINT8GQGZ5bx7lUuSzSEySbs8qHLZyhxg5YAZHpVl+0Z4MudUWya31iMjJmnEEc0UODglmidsqOu5QVx3oA9AttX8HeOIHsoL/QdfjCiR7YSxXW0EYyyZOOpHIrmrv4MeHVeNtA1DxH4bKhlI0fVZYlbJU9GLAY24AUAcnOcDG4uneBPH9s11Ha+HtfjVsNPGkU7IxAOCwyVbGO4NZp+GENlNDJ4a8UeKdDjgTbDaQ6gbi2T0/dTiQY9gQKALHhjwbq/hHR4tJ8O+IIpNPiMjqNVsjczb3dnJLpJGMZYk/LnPerGpQfEJMtpmo+FJ+VAS4sLiLjjcdwmbpyQMc8DI61T0/wAPfEDT7p5D47sdUgYjEOoaGilRjnDQyR/qDTF/4WqhuC3/AAhEwwBAo+1Rc5GSx+btnAA6459QRHfXHxTs3Rre08JapErLvRDPbO64ydpZmAPUc5xkHnkVt6tqXjCKffpPh3S7u18oEpc6q0E3mdwNsLqV6Acg9elUBc/EvymH9k+DvMz8rf2nc4Az3H2fnj3qkz/Fx5HKw+A4oymFBlu5CGz1J2rkY7dz3FIZHcaj8WTdOLfQPCKwM21N+oTMU54Zj5YyMdgAe/tVqwi+Kcxk/tC88E2alSUEFpdXBVs8AkyJkYzzjr2p0Vn8T3cmfWfCESqflEemXD7hkHnM4x0xx6n2NOfw344upA914+S1GSfL03RoUHPbMzSkgdunvmmBI3hjxZqUciaz44nto5IzGY9EsIrXqME75fOcN3ypXHbHFZeoeE/h/wCDIo9b8XTx3dwuIk1DxFdteSFgdwCCUkBuP4FBwKfdfCv+0Xnl1nxt4zvJpVwQuoLBCjggq6xRoqAgjgEEc8g8Yt6H8I/BmlXsl/LpCapqcyBJr3VGN1JJxjOH+RSRx8qqMcDA4oAx/wDhacuuWMifC7wxqGvpHHiO9ljNlYqQpwoaQBmIwPlVR1HIzVCPw78U/HGneT4x1uw8JafKuJLPQkLXUg3fdeYsQnQcoxBBII5Ir0HxP418L+ELZjr2tafp4iXiFpAZMADhY1yx4I4APBFeMeMf2oNItdN8zwjpU+oztI0Qe7dYkXAU7ygJcqdwAyFyQeeKAOD+Inhub4C+L7e48JvNLpmvaPPpZmvJgGhmYAF94UBcN5UnTnDjgcj618NaZDovhzStLtX8y3sbSK2jf+8qIFB/IV8DfEv4j+JvHFpY3ev31g8cdwZbW1tSqm1OO6jk54OWLEYwNuSD9jfAbxknjP4eWNxIzHUbIC0vA2cmRVBDjPJVlKsD7kdqAJfF0R8TfEPQvDjZXT9LRdfvTtJ811dktouuMFxJIeD/AKlRxnNd6oIlckkqcYHpXHfD3Uo/EeoeJPEEIQ28l7/ZtpLHJvWW3tsrv4JHMrzkEYyu36ntKACo3LCVTuUR4wQT3yMYqSkbO07cZxxmgBaKZC5kjDMjIeQQw54OKfQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVXv45ZbYxQ7AzlVYuMjYSN347c47ZxmrFIFG4tgbiME0AA4IAHGO3aloooAK4X4k21rquteCdIn2mRtYXUclQSiW0bvuBPTMhhQ98SH3ruq8e+3S63+1CLWBvMsvD+hMJQXIEc8zqTjH3iVMfDcfLnqBkA0fiL8H9L8TSSapoV5deHvE4U+XqFjK0QckEHzFUgHdk5YYY8ZJAwfNNd+C/jyHwitnZanoWo3O591qmnQW0bBh8zmQKGaQ7Y+T/cBJyAa+m65f4meLYvA/grUdfmSGX7KFKQzStGJmLABAyoxDHPHy4zjJAyQAfG0Hwn+Kmg3QvLbQL62mjHL6ZeKkuAezRucn5vc4FQr8X/if4SuU0htb1Lz7dik0GpQRzyebuIZd7qXIz0+b2r3DRv2qPDF3qiwajpWoafZFMm5YiQq3psUZx75/Cu3svjD8LvErLby69pjl1dNuowNCu0j5gWlULgjtnnpzQB4N4X/al8S2FqF1/R7XWCrAGaN/sxxg8HCsM5I5xjAxjnNd1ZftL3sunS6hL4CuXsIgN9xaais6IScfPiMbPx9R6iu7XwD8IfFyAWGm+GrxWJA/sudY8kDkfuWGSBVXVv2evAF1HI9jpAtrxmDCaW5uJ1znJJUyjORnv1wTnkEA4mP9rHRPOVZfDWpLFn5mWdGYfQcZ/Ouo0z9pHwXe2c07JqMbRDPkCEPK3BY4UHkAAknoMdaS2/Zu8IWcnmWF9rFsxIZlDQSqcHjiWJ/U/wBc0mo/s8aJcWcsdvq0sU5jdYpH0rT2CsRgFgsClgO43AnsRQA+x/aB068017yLwh4qaKJTJMy28W1F6hgTIMjHOcfzFYumftJf2/qg07wx4Nur68c4jiuNRhtywx15BHHfngZJ6VvaT+zf8P7LTBb3Vjc311gBruW4cP2zhVIUZwe3Ga09B+Anw/0iAxvo/wDaDFpGMl6+9vn4xxgYA4HHHXrzQB5zL8V/H2peJl0y+uvCPhO2yyySvq9pI8RCll3Fnfg/KvEfU59q5DxVqnxK8TWxXR/EV/q9rcTGKdfDlneNGI8sSfNdI0brjCEAgjsBX1PB4Y8J6LbRSw6LodhDbEmOQWsUYjLYyQ2OCcLk98CsTxF8X/AHh8Aah4p053LFPLtHN0wYdQwiDFf+BYoA+a/hj8FvGF4Z7jUvDOnLbmcsh12V4mbB53JGC7KcdCQCec969Euv2X9PurwSf8JDNZ2srA3NtZ2oRXA52rljj5ixycgDaAOM1Q8XftW6fCrxeEtBuLqToLjUHESA56hFJLDH+0prxTxb8cvH/iWT97r0+nQBtywaZm2C8Y+8p3kezMRQB9KN4b+BvgB7jStTGhfbHBWdL+X7VMgODgg5MZwRjAU9/euO8NeKIdD8FXXi7wZfpdWtmZPDuoRzokbNCjyLpt0SQpDIskSMWDAoTxlK8y+HvwE8Y+OrWHV7lodL027xKt1fMxlnRud6IOWz1BYqDnIJr1nS/hvZfDDxhovhmdrrXfDfjO0k07UkkiBxcxjekqqqkqo3HHzEr8zFvlFAH0D4Q0SLw14W0jRLdg8en2sdsJAgTzCqgFyB0LEEn3Na56eteWfAPXLp9D1Dwhrbodb8KzDTpNox5luBiGQcDIKjGe+0E9a9ToAOtFA46nNFAELeYtypAZ43G1uRhCMkHHv0/LjqamoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBHZURndgqKMkk4AFfN3wu8br4bXXfG/jHQNcstO8VX7XMGp7FuYYLddwjWQL+9QDoCVKsNu0AdfTvj14mh8NfDq9D30Vjcaoy6bDcSbiIfNO15cJ83yR7347qK1fh5rvhDVfDllpfhDVbLULGztUgSBZQ0ixKoUb0PzDjGcjvQBb8N+OvCviUxroXiHTL2aQFlgjuF87AOOYydw/EVpeI9D07xJol1pGtW/2nT7pQk0W9k3AEHqpBHIHQ1yOv/B7wJrTNJN4dtLW5Mnmi4sc20ivx8wKEc8Z5yM89TUGn/C1tNvVubHx546jK5CRS6klxGq9l2SxsCB2yCfegDzbxB+yjoFy+7QfEGo6eS2StzElyoHoMFCO3UmvLPEP7M/jvT9Qmi0mKz1a0VQ0c6TpCX4PBVyMHj1xyOeuPqeDR/iJY2+2LxdoWpyDgG+0Rozj1JinAz/wED6VSvNZ+KOlQKX8JaBr0meTp2qtbEj12zJhfXG5vqaAPiGXwT440OUXjeHPENi8GXFwtnMmzBxneBx1657j1qtb+OvF1sxNv4p16EkAEx6hMucdOjV9+6D4i8W3NzaprngaSwinxulttVguRb5xnzAdhwP9jf0rsJoo5ozHNGkiHgqwyD+FAH50WHxb8f2MsckHi7WGZCCBPcGYHHqHyD+NbqftCfE5XBPiQOB/CbC2wfyjr7UPw78FGaSU+EfD5kk++Tp0J3c55+X1qKH4aeBoZHdPCGgbmGDnT4iOuehXFAHxTdfHr4l3OPM8TyqBnHlWsCdf91BXJaj4w8Wa1aywaj4h1y/tcZkjnvZZUA6cgsRjpX3drdv8KtAiubfWbXwXYqTma3mgtlLMAG5TGWPIOMZ5FZtv8Z/hnp7Gw0nU0keP5Vg07TpnBx0C7I9p69j3oA+JNI8D+K9aaNdL8OaxdB9u1o7SQoA3QlsYAPqTiu50b9nj4jakx83R4dPj27g93dRjJ44wpZs89wBxX1FJ8Xp7u5ii8PeAfGGpKxw8z2Jto1PYbn4zyM5xgHNQx678YNblcaf4S8PeG4VyC+sX7XRbBx8ohxz3GRjA+mQDgfAP7LGn20bTeOdSe9uA/wAltp0hSHaP7zMoYk+23Hqe3qUmh/C74aWSPdWXh3RwEYo90EaeRR1Cl8yP9BmlPgjxVq8Uq+J/iBqaRyFHFvoVvHYLGQPmUSkPKwJ/2h3/AAn8O/CDwVodw90NGi1LUZH82S91Qm7mZ92Q2XyAfcAHjnJ5oA5q5+MGqeIwIPhd4O1XWjI7JHql9EbWwwP4wzEFhwRtOw/jxXJ618Nfin4lsrnxD4m8VQw6xZN9u0zR7NGaGCZCWTGCFDgEqCRISG5Jr6C1LV9N0uNn1PULOzRV3M1xOsYA9SSRxXnfiX47+A9EkeC31OTWr1cYttIiNwWB7h+IzjqfmzQBjQ+J003xRpXjmC4gj8OeINKs31SEqA0TFiguSxOAI2khjdQeA7NztJr2uvJfh6mn+I28U+G9Z0Sf+yhP/aNnb6taeTMIrzzGlUIwDALKZ1D8cNgHjJ1/A2qP4XvLjwZ4jvzI+nwJPpl7cAKbmxLCJFdh8pmRysbcDdujOCWNAHodFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZfinXbLw14ev8AWNVmSCztIzI7vnHoBwCeSQOAevSgDgPFtxJ4m+M3hjw5bReZYaCr61qTOF2iRkaO3UZByQWYkccMDnIxWj4u+D3gnxPmW40aKwv929b3TcW0ytnJbKjDH3YGqfwJ+36tpGseLtXjSOfxDeme2XgulmgCQo+ABnh2wOMuTwWIr06gDyGx+Fvirw4yf8Ih8StYS3T5fsmswrfRlBjagyRsHBBKgZ4xjFbNhJ8V7aTzNRtfBOoRKrAwW1xdWzsQflYOyOASMgqRjODu7V6LRQB5dc/EXxbp9qsmqfC7XQ6k+ctjdwXYVccFNhy5z2wMD8q59/2jdEtLtLTV/Cvi2wuy4jeOWyTKMecYLhunOMZ9q9xooA4Xwd8TtF8WJCdNsdfjaWUwjztJnCKR13SqpjUDPOWruqKKACiiigCMwxEEGNCCS3KjqRgmsfVvFnhvRZEi1bX9IsHYfKlzeRxEj2DEVuHmubXwJ4RW2a3XwroIgZxIYxp0O0sAQGxtxnBIz70Ac9f/ABs+Hdlc+RJ4otZpd/lgWsUtxub2MasD9RxWXffGG6ubRJvCXgLxXrSvkrK9o1rCwyRkOwJPQ9BxXqNtZWtsc21tBCcY/dxhePwqxQB4xNp/xp8QXZuH1LQfC9jKQyWkZ+0z2wDdGOzbI2B2YKfTqKqSfA/XtVac+KPih4jvlmxujtR9mTGSSCu9gRzxwAOeK9yooA8g8Ofs7fDzRgjT6bc6tOjbll1C4ZvwKJtQj6qa9K0Hw7ovh63MOg6TYadEcbltYFi3e5wOTx1NatFAHJeMtMtLS/s/GKwzf2ho0b+a0DlWntGB8yJxnDqvEqqf4oxjGTmHx54dutZhsde8KXMFv4n00GSwuHO6G4jbG+CUD70TjuMFTtZSMc9kyh1KuAykYIIyCK4vwCJtCv8AUPB84H2TTI45tKlaTLyWblgsZGc5iZTHn+75eeScgGv4K8Rx+J9CjvfINneRu1ve2TyB3tLhDh4mI9DyDgblKtjBFb1cH4yi/wCEQ1h/G1hDEtm6pD4hRIWZ5bZeEuRtBJeHcSeDmIuOqJjuLeeK5t4p7aVJYJVDxyRsGV1IyCCOCCO9AElFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5L8Z7ObxZreg+ENsf9jq39s6zuu/L821ibAhKqwbDMc7m2qCgIJIOPWqpXlhDOzOsEJmkMQkcjDOiPuCkjkgZbAPHzH1NABo1nFp+lWtrDBHbpGgHlRgBVJ5OAPcmrtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYPia2kjuNP1q3n8o6YZGuF8vcZ7Zk/eR+oIKxyDHUxBehJreooAbG6SxrJGyujAMrKcgg9CDTbaCG1t4re2ijhgiQRxxxqFVFAwAAOAAO1ORFjRUjUKijAVRgAU6gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral displacement of the cervix, which can be documented by visual examination of the cervix on speculum exam or by digital examination, is probably caused by the asymmetric involvement of one uterosacral ligament by endometriosis, causing one ligament to shorten and pull&nbsp;the cervix to that side of the body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Propst, AM, Storti, K, Barbieri, RL. Lateral cervical displacement is associated with endometriosis. Fertil Steril 1998; 70:568. Copyright &copy; 1998 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_10997=[""].join("\n");
var outline_f10_47_10997=null;
var title_f10_47_10998="U-S body stalk malformation";
var content_f10_47_10998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    In this fetus with a body stalk malformation (short umbilical cord syndrome) multiple defects are evident",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 228px; height: 446px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG+AOQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwU6leJOhF1dgK6t8s7g4BB4568V7j4S+J1vrnxNvru4uLXw/oUbvd2+P3LmQyxtI8h+dZJnjQxkEgbM7PmyDwnhXwlpMpt59VMt6J/KMYjyITvRiYyo+YuuDzkAlcY5rZg04T6bpsNiIFjtJjbO6jbHJIeYmYejBipbvnrkVfLctIsWXiy0Gl+J5rt9RRry+1GXSQk+wBL6MoTOCGI2IoZAhPzhgccGvO7fUpjqAgW+u4bdZWLK80mdgGCCd38z15qldX87TGzhi8q2jl2xq45jyw2gnpwRgVs6B4RvtU3R+WreRdiFoJAQMMvzMRw3Yd6EheRsWA1SytjFa3U0ryI4MU1y7Y+XO7G7G3nGe9ZniWa7lumvLa7uyLsJ5SiWX95nhjnd8pOOM8N9eK9P074c6n/YkeohBdRPtRYSQMQFQDkgd2GAOnfjNWta+HOtWVgi3Yhv7a4AsxcBMkW/GwOv8Ask4yOcjnrTHboeCXc+pW2wTz3iM4PDTOCCO2M+4/Oqh1K96farn/AL/P/jXe+K/DKfa7m2t4Ghug4dInJ3E7Tn7x+7tTPXjFeeyRkMyujIw4KsMEfWlYlqxI2pXef+Pi4/GZ/wDGm/2jdk/6+b8ZW4/WqrLg9vwphPPagC6dQuuT5so5/wCejdPzpDfXBH+sk/GQ/wCNU1wM7gQegxxz70h4GMce9AF0Xk7H774Jx941v+E/GuseGbvfaTu9nI6faLORzsnRWzt/2fqOa5QN6Z45zTmc7cDlSdwBPQ96APc9K+Jenahp8VtfyXlrdXMqNLMl1hixLBkdmIITO07lIyM5rp74pfXQtrC9+320joEOnsQu4Y+acbjiMgFQRx35618xls9h+NaWg65qOg30d3pN3LbTpwGjPY84x9QDTTK5j3TWNS1U3cM8SCW/U/aktlUJGsC/NjJIYnPG45GDn0rK8Yard3U9kkU0gZURDEIhgHkfeP3wcfdHA69TmuNsviVciC3j1XT4Lk2ysIpoSY3VmBG4jOGwTkLwOK3LXxv4Tle6a6i1WBEM/wBmhkXzQQVAjBYHcvOSRuO3oOKY7pmlqGotaJBZRW8mZFCRklldZCTh3HQpJ85Ldj+sUF9HELOWQzbi21wpEmNrbpDk/eXIDHOT8vJAFc2PFlj/AKAgnuWZVWORGG2NHXGCMkkAkk7uvHIpt14n09LmOGJyxScsH2goilQMFgPn288gYNIGz0zQ7xxFb3ptZrjUJU2/6S+2MTGTBKsMjYD825juB9DUL2NmEvY57x7yUTpHuYbVGdpcAnoQSQN2M7hjJzXM2+rSy6cE0xoZo2jLxRqqTqu45CyIvKqSvOcnJ7Ut/rs107xxSzSiQtLcQnHmFFkUkyA4JXcxxnJ+UE5GKY7nZaNeQSRTy2SSWzfvU2RNma4gO4NDGMEFgdpz16nJFB0m81F3ju7qUQwp9r2MNrNMMfueVwCvCuBgk9O9c34f1g6ZrqyWEw2FCLpbdQk4BO4sB/BxjBJyx74FaGpX13cH7JbeUUj2LPkNulaTkSAZx8p6k43GgL3M3WbG81TUr5LtmgBkR4pokxMfkTerbjyVwq8/MRzxmsz7FPpeq6jDeII47bKXEkpVkiQHBSNQeoOCWxyODnJrYuROl7bTatZLJLvAiXIGSoIkLKTuP4kKu3AJrOfRtT1iz1uaxWS7vI8M/mEYbcxCFAfvO42gjnO3v1o3EyPVZNP0mzNxfXLXOosB9khhIEJBY+dI+csVCKoAGASTz6eaNdXl/cXBRjJJM291PWQ5+UY7nngdgPar3iyDWbW7ij15G+3XMazorkZKklVIAHfBGO2OlQzpBGu2HzpVskBcco4BxvfOPkBY4wck+1SSyvLcq7DYJVCqF4I5OOT+JzRT4w5jQiEKuBjCgZHrz60UWEe4+Dm89osAxbbK3u8gblcoq79o7N/Fj1JFSyXNpH4a335S1nmmkiWbAwxzkA9sNgEH6VBpM1tp9ro96jAItpDJJEjdcxKHwfyb9Oq1ja/qOmanoGraZFNHMizedaSggNE4w2M/UZHociqNdiv4N8N2DW1rrOozqY72RoJTJjbFOJCwRs9M7uD6HPavRtLl0jSba51Ca4ZHtVktr63PEggbPzA/3kJBz6AHpXi017PYeGdRxM622ozL5sJTciSBjmQd1PPb+mKk0CfU77VgLuSK4aEvDLcFj9yVPl3D+JD2OMqT7Ur2JT6H03pvj7TtNvLcTztOLixjLMSFSZwcbh2DMvOOOQQexrft/iToUkt5bzusC2zhcSk/PFjJkAxyAOeM8CvEPCPhF49Zmt/EdrJNot/AkDyFyzWEpKhJBjqhcD5unzc16QPDenX+nPHqflT6nGVWGRGKqZMYZBnpuXjnp+FFkxNLqdjqNl4Z8Sxh2ksRcSRbUkBRtysMggd/rXg3xb+BWo2w/tLw0JNSkZ5JJhjDsONq4zjgcA+3Pt02v6YtrZ2+uQPeC3to7f7ZHbgxsIldo3cd/kJDMv8ADgkZBrf8OfEk20Nu15MsluMRuxbK7QSAVHUNjaeMqe2MUMLM+N7+1mtLmW1vIZLa5hJWSGVdrofQiqJHzAYI5r7S+MHw/wBJ8QWR1rTbO2up5k8uRRIF8w4Hl7Dxhsn2yDj0x8aXMTRzyo6shV2UqeSpBIwffgikSQNt7fX600ge2PrSt19/TNBUhVYqQrZ2tjAOODQAnGR19etOG3BXjPam8elKTgnb270AB/U0vy8Dbn+tK2MAAAZ7CmE4HIoAUbccdD/nig4PGMfjRnJySBSZA9M0AKQMcDrRkADI6d80h4Gcc/WnHjPTjPQ0ALHI8RLRSNExUqWU4JBHIrpIfFkn2iG6uLKN72JFiE8blMoGztC4IGeh9a5rr2H505SFB5AU9eaAPVvD19a6tLC8Ooxi4s4nEQLMrlS2SsgPVAMksSTnHbgbNvMsNtaiz86CysmE7LdqqtG3VpGI+8h4RSeo+7XjemXdxZXK3FjKEmAI6jDr3VgeCD6V6V4e1g6ta3U1vcI11Fb+WpvEVnRgpKttxtbH8AGAnrmmmUmdbaa2Z7e5a7kEd6qmygsiSBKvDgKAuRGvXBxuyTVHWLa+0VNPm1G7bSZYsB7q3bY4BJAyo5Awdozz361zOiTXqa/pqQveuC4a2tNohYyGMruD9eW3cZBxyeK2PFVhr2pTboJLa8F46yyRxBVkikQY8kP0LFsEqnOcnk07lXuivrT282p6zf6fc3MuqwWJtI2mKlgXG3KLj5OCcHlvxNeYyR/Z7oWrsLeJmSVkbL+U2MnI6nHoa9O1jRriCziubQTtfW85S7ugoRfMwMJgn5UQkZJ5Y81xmtCya0FzNbR29xJMUdwd7blBGFjPOwYOWIBJxSZLM+5slPlObiN5ZUEkgfAKsecdemMH8aKp299NbRBLYRIp+Zhjed2OSSe/sOKKRNjrNKa7uNMKSyt5THyDCgzujIGCF9QTkEdQSp7Gi70eeZkay8t4UXiNAQrYxuA9AcDg8jHsa6Pwbo9tcx2P2rzFUFJD5bbi0fG9VPZx1APpjuK6XxZpE2iXdnNHPGyXm6VZdmEm43JKv+8u4OvUE5x1pl2KnhizsW0eCw1q2dbHU2NobvGRD5g+Tceisj8c/SuT13SdU8PSpbzL5er2TNFNPgj7Rb7gN2COQDyf7vPtW5fatHpGlSWdzNvtb2MLKCMrKoGcg9N4ABB6nb3xit+38Uaf4r0awtfEGYdSghJsr8H+L+HeT/yzdQQcjjnpQDND4c+PYrrQ49P165+z3djH9qt50k2SNGr7Zbdie+AHXPDV2nj/AMTWyf2eNFniv5rydZIGikARXI4J/unkZVuM46ZxXjmo/CrV/t10LeFzdW0SzF9+/wA+DOG6cOQCMY52gYz36+/07SrXTrGDVr1BJZnzVa34aa2JHmLkcFlOx0bHHIPFCBItT6t/bF1NeCae2jWSaCW1Z2i3ShCskQ284LD0/iB4rQ0A2V5ax6Z9kaXTprZgjuqSrDJtDYAGCVIcdMFSPrUXhzwgJZ4dS0e+W6dLv7RZ3sXCA9CskZOckcYBzz3Fc5rU2/VJtS0R57TSrV55LtvLAMUgcZGOGIAJwSu4YwTjFMfkd94Va4+w6ha2l232uAxXIRwR9oAwNpJGN2QAHHsCMV5/8Ufhy3iKwbX9BsjaaoiSPfabGfMNwq/clRV6yLyrqOT1xnr3XhvVLrxR8PVkWSJ77Tp5Yrq7EO24VFHDSQ4AcN8uSOMc4yOOD0yfxFpHjBbpEkbV8tLc2xlMiyyOoVGBPytuBU5ypOcUtxbnz7LE0btHIjI68MhGCD6YqEjoP5DmvePiH4JGs2Vn4k0uEw27RyvcOrB1imDbihzggAhhsb5l5HIrxOWCZ5kRgGnkYgANyxz1P49DxSJaKR6dP6U9YzjPYED3PHpUs8EtvJIHGNjbXJPyg9cHtXa+BvAl3rN5aSalDLFp1x8iukihyzD5DtJBK575wO9ALU4cDqOmegxTG5IwP0r2k+BtB+0XMSrcPbWyC4VVOX3IcSRE4wV3cnBzxxzmvMPFeh3Gg6mbe4VQkuZYWV9ysh5Az6gEUA1Ywz05B9uKXqaUgh8E8j1phxgYOSaBDlxgjA69cc1f0rSbvVmmWyikk8lPMkKruIX1wOT+AOPwqpa28l1cR28IBkkcIvJ4JPUn0969j8PPYaYum20cMjlSYpVcZEDBTvAI++BkNuOOcfSgaVzmNd8I+db2k1jZJZRojJOyuJU3DAXO0ZLEkHp0JPFdZYeEvD/he1h+2iS81SeISy3N2g8m1A/hjVd25yRyWxxxwa0fDdnaaFbW2t6x9vkcJJdWfnS72Uk7N20YUhxj5AM98AVT8GkW0kGm61C8lvPO8Ushj3uY2YkkEHcT2Py5Uc07FJFzVvhC2uWJ1fT1kju5XCSWcMQUM2PvKgHC46+nPWvJtONx4Z1yAajEECzKJoymXRlOCu3qCckA985FfXcanT9ILveuNPeLegL75oYABGhUj5mVlBxkDPrXhXxb8K2ZtV1jQtMntbaciK0E0jPcysuOWGTj/ZHbnJ6Ciwn3Rz/i4QWJl1O2h8poJt6W80x3RjfyAM5yScZHBFdPo2pXOmznUReTT3Fy6yI9opX7MSMtEM4VcL9+ToOgFcBLJDLpttcNYb9SRPsawqvmKSSSzsCSS2Oep98VcTU57O3Fy0X2jTDOY2mm+5uChTlVGWzxnryevoBc9OvnDtdzz3EMNnqFo3lQwOHO08Ap/tnk7ieOuM14f4rtLax1lksnwRGvmRk7mjfuCe5PU9etdR47lvmvNO82ee2iKBYUwGMYHzHZHnOOAAP5Vv8AxD8K2I0m0ksvKikFmtw0jSje5xnkAYx14GSfegb1PNLGe3SHE8JkbOd25R/MUVDa2twYzi1lk56rEXxwDjI6fSilcg+kvBugxPpWiPp9q80729rczCM8ElEDoT0yRgg/TPStv4uTeX4RltDZNIkU5n0+Zo/mSRRl4XXqN3zDPrWX8NrqS1stJuI2kWG8ihtrsk5aLMSqkuO4HrzkAZ6A16V400y61XwczX0MY1pZkjYQnAkdGOHTd3Zedp7HGeAaafQt9Lnl+keE9P1PQVecLJGTGxt5UHmROU3gA9z1Iz15rh/GPw91bSLyfUvDU6IbOMXEdtaoymSMYLyQjkZAIYx/UjuK9V0OwlFzDZ3Lq9hdl1GxsHC/eCA90PzbDyOdp7V0GrJIdG1TTI2hZY7ZQrQD5opwMK6E8YYYO098jjIp7gzi/D/jCVfDWna5dJmKxkRbmOFMrJaSDl4mA4UNgle3bAxXHavCND8VaXDrfn2+m30/k2upsMiGJzuSVW6Oh3DcAVIxz2rrfCYe68NaNp0V9bQXl8DJbSCI7GmUtuQqf4W+cY9iDiuc0PXLnRLC90DU4WksLdWf+xrsb/JJJP7h+TtOCVPzAHjjNIY29tbvw5p6Pp1xcLZSSPJHe6ZLvg1FFbGR0G9CDx3HA7Gp9U8T2mq6Utzc3cbX1mqSR3cSFWuVcbWzjkj7pIOSpyOhxUkes6bfaa2m6bJPZaUssU8kaEkWkhYbJE7mMkjkEFTkHgCuB8RafqVlZlbi3gvdOuXc298kfmBZkb5lbZgxyDPfG5ccHnIDPV/hJYbll8QC9e3A822niG1jbS9QVcexB5GCDzWnrOj6jNr8Op+FA3kPAmUU/IsiEhlaFiSy7SflBIIIxXm3grxdc+HDaayk8MTglbowgPDexE4VnUfdI6buMEYPWvaPDWl6L4k1bVY7eaRbW4dbh4HLIIZTgsISNpCt1K++fejQXmc9Df6k2k2usXF/BLp99cGC6RciFZQ21Q6ty0TY2ktkoQOcVzfxJ8LLcQ+XcaHBpt4sbNasAjLjGSI5RjcB1CnrzjBr1M6bpunG98PzXPlJJG0atcgAuG5wQB8/I64P161yugx3B8K6pp08Yv7CK7b7RGWy1mrAFXTdyMdSOR/KmG587xWksU1rp2oaYyQM6RoHwrNKBkr04ZiMjsce9epeHLeS5l8uwu5JouRKyw/ZXt4jxKryE7VGQu7OcjAVWPFa+neBxBq9pd212L6yaJmj+zsrkSltzFc/dzz1A9K6XxD4csNK0fTZ7O+nh3ThRZuiyHzi2TIP4vOOD+9JJwMHgDCsFraHM6zDH/Y97q1vFC4h1iG1gu1iFu0gEQMysny7k+VRvbLkux+XG2uJ1rRLbxL4c1ZYvsthf2E7SRwvNxN8hKpGAOMcjDHpjgGvdI9CvW8GaxbzxLqmnLLJMllMAbm3J+YhZAdu7PzcHA3Vxtt8PLfWYvt3hHxADeFEla3nhUyRL1J/28/dORjjj3QHy2FZADIpAZNyhuN4Hp6j/CnO+ZGaSNZN/wA3lo2FBI46emegr2PxfoxiaOz1bhgwZLYZ3FXypIzwAvJBBxzj6ZC+CdKl0YTQNNDNHOrRzlg5cZOdwHOBxz+pp2FynOfD2zDR6vfTWzukEOyG4jmEbwy9dyk8EAckHtxXYaXBGmkC2t9bs0S8/wBHbYmwgg7iXH3d7ckEN3/Crej6Tp+mw3itLbLb3BcrbSZXawx++RX3BiRkYBxx/DXc/C3wrompa1cTaxCTZaeqv5edttJxhSy56BsnoQGyM8ZIUlY53UNJm1DQls7CeBbJZkmmeMEXUbMfk5Y/McqQQvAHFanixFu7Vo7C1XdaxqqParvlhbOGAGQSW6ALg1D4in8OxeKnXSPthU3jRTtE5LJJv4USN0B6Dg8Vt31ppln4j0y21DxBChMDs1jZXLOGx/DvIxwMHoST2oGb/wAMdThn8NSaT4jiFg6hlhF0CWkdc5bPIwoIGBnFeda/AdP1mZoru6uoZYwtgqyfvNxIDKD124xk8ZzjPau98CeGR4ku5dS+1sRC8kCZIPycBQRgAFQMnAGSeh61xvxL0+00nUYJtGnjW4slxGhmJikJO4yYHKN1AUeucdKZPU4rUtMSbw1dXFvOttOLjdDZr+7kTacOWxkImQT0Jf61xjXERuo0htE821dIVjuCTFu3biGTHCnso5z616RGv/Ev3/vHN4SWuInCsxAyUGckDpjp6nNcS9hLaCY2Ra2tYHaVfKYSzXDHO0HOTuAzxngdB3pCaIV1i11Hxel4NOvLmaSYLBbI6kBskORnPoMdQOT7V6BbXEtl4bXzlgmaVWUXEajcqDgBB6knbng8cYArgtE1X7TNI1pZsB5IhU/d+ViAdzDooP8ACOce5r0W9NlFps0N5NLFHbx8XDIpe4kxxDGudiRp3z9Tk0DiZtzp+piO2eCOwgt3hVoluCUYr2IA7dfryaK828QajNq2oeeZZ5HVBGxWQIuR/dHpjGD3ooE2evaHqdzFYWcETSJbJZ2pW525MSvGodSo+8MjOPoRzkV9L6XZjV9D05Li+a4jjXLshH73HMbZ65GAcjqc5Hp8veHpHtNO065KwSWF7bxW00JfBiOxdpz1U5BIYcZ4Pt7L4K1h7DVWvJbzfZTIFMCnjIA3MR2k4BPTrzzzQNrQrWcP9maxr32zY1+m94Q33JnwcgD+GRgAQRw3sal0G0XVLSa7tpnF/Mphmgn+UOMDCup7c8NyD9RXYeONNjvzDci2Se0mt5IJZEPUMMruxztyBhxypwehNecaX4pg0fTLddbk8zyuYZ50xJG68PG/H93qpAz8xHpTT6gtdThtNs76GbUPD1xBMbqC6kuraykGTFOpLMFIOVLr8y4PJ55yDWzY6lo3i3RFHieyEerWxEmnahAVE8SnDNvHG8Ag54bjnA61R8eeItD1HxDZa1CLhLmBNs8in9yIlIKOJByVJPDHp0yOKmn03StXHmaheXFrpuo+Y0l3AFb+zZ+0rgj5Vzn5wcAE5IHNIe6Od1jQJdMvrzTtHureSYpJIrRMQryHDfKrd2Hb+90z0rnvDmr3Ed/FqlgZoheq1pfBiPkk/vY5XtgggN075rqtJ8KXukeIItL1eWwuZI1V4LkZKXsIGUliY/K/HysuQwI7jmtvW9B0B9bmu7nUU0nJAcJl4kkIAO7jIU5Xhs4PQ4OKBHEWFnoutXkdsrzaRPJcFWkgizbxygZ3AnlGbjKnKsOc5q7bX2uaPqKJfSSPYJcGIPbqUNygP7t43IIAAJGDkgjpjina54F1G2tLG50K3uZbqR3iEemOJQ6cs6quMg43NsPp8p7V1mj3viTwVpEumQ2dv4p0SXcWtbiIpK5x86OGJAkHpgHjODQB21hPpHia6trXU3utVe5jAhkdcRhwCUywOYpOuGGe/tUOl6XqPhTxDbw65O907KUhmAGZ4wCCAwA3MBjIOB0OBnNcNpKW4e21jwdc3FrMt0hvNEu5gLqAA5Vo0481QD/DyV45Nev6F4qtNdENtdI093tdbsSR7HtSVwXj3DJU+nLDPtii4M5rxZYaTe6RJ4jsC+mi4h+XcvlmcnHYH5Xzxg5PHNYGq2urRWNtLbyzMxkjmSG4RC5Q/eQ8fjwc568c1qeLfC5htf8AiQaxFqlvJMJvLuZBI7OuMxvjG4HPoCD6VpeINanstIZ5NKureZImcRRuDFJkbtu5T6c5xnjqTwXuMPAvi9NMu5NH1NVZZJJJZJccAbclCo+XnsRnODmu9mt9AvrcyuiMt06xJIpEbADhdrLghfSvmue60q08QMTe2mp2ssUsjiZgFcsMlC2CM+5x9BWvoHiy1FvZCOSZN0omkt3JeF0QADLfeCgFQecZx2pWE43PU/G2q2lvLeabeGDUlW0+TyNqz2jEfuyG6ndjsc8e9eEy6eYbm5utOlkgQus9qswPmHjmQeg6joAM9K9+0v8A4RW8tbR447C6Ky+WwgiDtDNKcknjA645Bz+HNbX/AIe6JrUBm0+eFN6GNWtPkKhTwUCkDdng549AKBJpbnh8m60tnuBFJBckHy4zHu83IOcA8/l+JFQ2EkFhFJZ2TtBZ3eUdFJPnPgthd3JGea9D1zws2jtEb9I1QR+asiZMcpB5iZxwCR1GPmzwa4PWXAMsSxrbQupnSKMNjphY0TGep68UF77G7o1nbLZG7Z4w0cccc8kowGiIwMPxhkOceoPWr/imOKwtdOg0KytLdIjDDFdS2p+1BwQwIJIyDnI9e9Ur7Wkk8N6Val1uJYXUy21tamFFBxlw5xnkEE9+eBUXihtVvtSgOoLpzNJGPs/kX8kysOi4cnlwOoHHvTAj1dbrTpLvGovBdGR2kmaEZmLKGDlP4BzgkY54rCcnUdVe+MNtGke1srxNuPyt5a45BxzWgirHaPpdtJNOZnBknKlgkmTnDYOFwck5yelYehavf6dNqei3hkaQvgun7syq2cEEZKqoPfHpk0CHPHcG2eCIrbzxvv2xEcKTkMoIPtnPU8VnX1oqQN9llGBC7rEiEtIT1ZsYwM5yQeemccHbjWbesSWgEjbSImKq4VQQNy9gew9Dk1U8QQiGzt2tLpbq7jEj3MKSMsYY4+VpAMkD8OR0xSBo81uZZBOZFO1LWMGWMyhWkAbPGOBz2HPrVaeW6vrjyri8xCY1JZydn3c85yee/vV/UtLFrqtlDaF57lmErEDiFc8dM4X/AGj+Nbfg74Y6t4qN5JFd2FtZ2yF5r+4mAh3k8Rg92J69h9eKCDjEKY+ZiOwIG7IAxnrRXc3Hh7w/pUpsjrGr3VzD8tw9jbb4hJ3CnbnGMdeaKVgsdPprWV/otrYTW4+1Q2kMcro5ACsitHKrDocgAg9CM1u6Kby2Sz1eOQRefJLBu2/vI5gu1jjHPC89enSsbSjJDY2EtlAXuzZQFPKI3ufLUGJhjDBu2eQeOQcV14k0yXS7S3ggdrW9yfOjkEU0NwOqsvRJQR8p4DgFT2qkWj0P4eeJ7pLsWt5m4sbiFSpBBCsOCy44ZSD2x05A6lfiN4QbXLk3egGH7QqCWS3aTal0oPVWwQGHHXp06GvJ72wRbmxZtRkhvoZ2lXyWMOXHG7aDjnOecDPB4ORqWXxVutLvIYdYUPBDKQNRQ4KsxIxnHBHGVcYIPfGaQmrO6MjWPC95Z2xuIrRIrKKDyLiFgYpLAE44A4CbuGGdo3ZGB0ZoP9qWGnXEeljy7yJgfJdR85VcHaOmdvUcbh61f1b4oTX+py2drNb280EzLGXhB86Ej/ZOGjbsewJGDxXP+HvF1jFO0epWsxsUcRP5MwYoM4wDkElD9xgc4444oHcq6Zq6ad4tAuYrdtOukYPpyZMeVGS8QOfLYdxwCK2LnxBpVtHc2od9NS5JmtJWbcl3Hty0UmcqrDoD0b2NX/EXgCxtFuvFen6p9t0e6OVvySsttJ02S+mTxv65IB6jPD6hot0bMjTbKeXy8SXVq0eVCt/EygEAHJ+dRjpmgLs67wRdawniXSLyynCtPKUTJKQXUO3KqWYfu5sdAeMr3zXo1rq1lrd5rmieLbRZ5bi4VV+5BMrKBsO/IwwxxnvxnBrivBF62haCljbrJqZYSTJDsDtHCOu0ch0HdCSQeRjrWXq2uM+n3l1d6bp4tbh2AeOIkAkj7pPJzx8pHB6YoC3c7/XPDy3lwdbjmD6fHCEhnUBXEsZPUMMq4Ixyeo4OK49fFcUlpqFz4otLqa4vFWCPULYATxYHBkj6MG7N7Yz0xqeFvEB1AWdhZXzK7ZjnkPKswIKiVMbSQRwThsVb8cXem6joLXWomPT760kFpFLYAPDGxIyGQkLk/VeSBTA5jwp4h1nR7M6tYww3mj3G0IyznchBwyzJyYyR3qbx74y8K3skD2EFzZywKxkViZY5cDO3lvlxnPAFD+DLnwzFN4ks7y+k3xCb7VZQlkZwOfMizwuMg5yPbvXmXjHWEvWhNvaspmiZw0DBfMBHLCMDPBOMZDDntSE31Kh1jTpb24kv4ptRgKeXIQm2N2J3KevBxgdPp1rQ0TUYZJEuImV7eOQ7YZlJIA4CKR0I5GD1rg4Z1ggaMQxTIGBk3IQGB/hYdvYjkV0Hhy9WGGJLa5Xz5h5DRzuFWM44cHgsMDGPpSJTPX9JvoEmaSB7cXDBvLSSXCRjII+bI5HzEbvbGOtdtaeI5tNkjZHnewlnwgaUEiPGQzgZA575x9a8fsrmwuAzSshBdJJ3i+YRumMKJCPunAyuPWpW1kXrarPDDOY3l89GgIYbxwY4kAwcYBH4mmaXTPYtX1aDxLot7LZzNDcTTx79ygu+zptUkc+hyR9K4bxJpdlc6wjy31nbx3EW77LgAo4/jLDHzZ/h69+aXwjeXsdvZm8026vfsm+Kc2AAJL42qTg4Gc5A/Tv1s2ir4V0a41HxMpt9Rmy8Nu6xXUSD+7ypYvjuD9KA0RxvjzU5YfDmgWhs9Pt1juER2iX95Op6qMHILDnJA4z9aTWb3RZRNFbNe2FikRRrNJmlVh2KuSfLGcfiOMd93wXprHXbXVIP7DmlsyJHhvJj56SOOm1VO1gOOcdcVZ8fareeJdCuI1Tw7aT3CrKJJLszbcNwANoDMCOgzimJ7nk2o3V/b6dBLp0twqnEdy8Vw5ZkxgKWHf7o9TWHaRRaNr0s+t3F1C8q7mS0jw0mTkqS33s5wDjn61vQwBjINzC5QhDLIhj8wLyZCM/Nk9zyAMe1c7dWE9jqEBUxAi4W6WWSUu02PvZVVO0enIGcfgiWeiWFqpWCbTYdS3ykF4pYTtiXthSC7vjvgAVV17WZxYXc0Y8qyiby7W3WFAIiuQ3mOOcE4Jx9Aa09J1ZrPTZP9NuLcvGu1riUgIWOPmQH5zyfvMRxzWJ4s1kBLuyjYWslvHn7SLcSvPgfeHRQeegBA7DvQU9EcxrltKti8Cotl5yYnKR482MfefccZ6d8KowBmuc1TxHd3b/ZLK6kstJiwYoY1CBNowCdoyTnn6nj1pNQvrm4trOa8vGmt52Dyoo/u/3gOhHbJJJGelYyuBcGRciMncok+f6Z9T3pEXOmtNV1qC3j8zWGhEg8xV3YOD3IA4JorHsr4xRMDFDMS2S07fN+HtRTC57Do9osulaW0JmS4NnC4AYHDBRke4PBBHI6HPBrT0eW5bUPtMaSpqaeYk7ugeMKOAzA9VPCuOqnDKR0POaFd79GsJHQwssKRDJyFIACk9MZxww6Z7iu98NfZ7+5+wz3smlXbEsl05w6yYGEcnAbv1wSMA8gEiNChDZLrevXc8du9pftCI5oWHzwsGyrITkPGTjB44b0znjJrS7k1K++2WrwQtmIyAbVSTJyrI3A9dp4HODgjHeahcX1vqknmXBSfTZPKkmt0+aNjwGZRyIz12kAHoCDzSa/P/bq/wBoWkRs9Yt3AeS3kISXbnG9eq9chyCvYkUxWPCtVOoedJZXZjhvbZiYSqiMumMMi9RyOQOc9s1o+GJtQXVrifTbRdbtJEX7ZYyw4+1JjBAByQ+3OGXuOM10/jvTU1qAarNdWsMu7m4ghzGGHDLIq5CtuGcrwe4yK4vRNcvvDd/HepCGRZt0hR+PYoR93Ocgj5T6VJOzPUrS/vfD0dzrvhS6V9JlUwS2l4wZGHQxzgjKOOR+8GDxg4q14V8PeIrL7L4m8MzXNtqUYa5t7KRt9rcxNksigZwO2FyB/s4rmNb8b6X4knW6miaw1YIoa6TYJHAPSTA2zr7HnB7449R8PeL9LtfD0UtxbwW9kvMr2n7yGN+nmeX1j/3lP1wRTHuR2uvaBqN/aare2C+GvEc8m+1Ks1vBcKewlAMfmj5uo+boevGb42sUtdVv31GJ4TKEkh1G3TEUpb1C7kySOSMD3BrJ8V6za2rXNvY3C3Gn6h8yR+YLq2dyM5U5xyR6hga5TTPiTLpOmx6VqluZrMOC6eTtYAHLJ83Knscj3HrQGiNyTxFb2FtcMPIniunNu8GW2OV53K45jdecE9PcVn2/iG9iYwzNcRXa3DxY2CVZIWGUyxH3uud3yt/DzUGuxaPrWmpL4W1a6LMd72V2winKEf6vcMhzjoevFYWladqtpqxiljcOigra7QwnjHVfLyD05+TB74oC7PSbLxNPpWhQNosksZjZvtaSRS7Vf0ktzkAnnlAo9ua8x8VeNV12Wf7RpmkmaRCEurCN4PmGcNtPG4H0xx3rtr++ENkVtYY7uOVNvlSqyNEBwQWB3rjP8QNea6rYRiUh41NnbPmZISTIu7qykgZ7ZB/rQEjNgkgvfL+1XZhaCPYJXIK5x8p6ZIzxyDgdxW7YWmniK1hvbCLFwqkGGVi7nu3BwMEghvlyDg1jnRmS6VoCt5FFgyqgIfBGR8vU8Y6Zrcg0xLee6f8AtO2kt5tjxBn8tnYfMIzxhW4APTPfFIk6CPw612be10a9TzsENFK2ZNwOVXcAABnBJJ6ZFMv/AAxfyX09vfSW7XZXzLuK1bKOwGcrj5RjGcpycde1UNOdLVjNNctbRyzFgro/7lm5yxBIxnjB9etF3qN5p0LNJercSxnZHCLd4nY55K7uGPPUA9qY9D0Hwb4l1zRCj299DG00e2ZYLUMs5xwSpOQffjrzmtGM+IvEWmTW8s8bWwlmVAS6yQxso+VG4CuvJDH1rlvBmomLR5jNouLt2M0F2Qm9DnORliC+fUHnNdnO8viawuNSvIb6CMp8ki2KuykcBsKQGOewB+tCKRSZ7COO2sDZWOlsJUhea1Zi+FHV+WyxPtjPOa27ix0yxtp7+KGaCS3LRRXGoSM8rueronO1ugBOAaZaf2ToEr3Nzb2t7L5UOFltvKeQsPvjJwHJ/LJyO1Z/iHxbbapK6R2NuYF+T97cMoU+m0YDkfSmhnBQKHsmmsbcOkzOoZ5RHL5pJPPGfUk4xjpVe7iuLW3jW2WBLpiAZSgKgj7pUknoeffj60+3W0bXtTZri6Mrx7niVsQrwAAexPA6E9ay/EWya7yk0sFw0LIoFxsETkDGU6457AfnSIJ9Dsby+xe6lMZLWUhVW6l8tgyE5YpyScjIPQVg+OzdRyLHGAmlJ8okWRjvb3JOW4/DNbPh+0hW2c3V1C1vGrQiCO2HmSMDgln9yepOKWLTWtJ0l1Oa5uRKdtuU2HywOflGCAf9rmgDg4bOZ5J42tvKZF3Oz5jEQxwzE9sdupzUEi5DlcMwPDLwm0dev+fzrsvGF5p9varFDA0d8x3BZR5jgerMec+559q4gu0j7pWdieucf5FIkl/dgDDZ4/KiiJ3VAFyB9aKQ7Ho/huaA26wCdoY2iCzQ3PLRMVA3oejwtjlDyp5BFdLYTahFqktrqEFvcPFGCAZPMMkRUDnP3l9Dk9BnpmuNvLVvslvdRITaR28ImRgN0blBtkU/3STg9OvPFaegSiE2F/buqSRt5aq7blj3feicHop6hh7dRzVFJnWzl7O7GoRynh/syzq5LKuOYZc9Ux/C3GPbmtCe8a71OGCWOYarbp5sQtxtuhHjkoc4lUYJAJyVGMkgCsuDU7WSVgiyFnzDLaSNySPuqp9R1CnOR901Dodw1v5SXtzLtRiba5KZ8ok9MjlSOhA+vNBRvabpzSwSR6YYHMo+0LEi4MgOcyRAgCSM/wAUZG5Tn0rxTxXYLa3v2YQrbQtvmjOSUDZ+YD0U/wDjv616j4i1d4IJLa4uglyhLw3tvIvJPVtpG3dznI256HBrhLK7k8QXP268HmwWqhfKjY7ZZgfmlVj9w45GfpQyZHLPpoaONrcsZGG5bd2GWGOSr/db147e9T6PqV5pFw9xavlJVLSxhcq57gjHB9a6/wAYpptvoO7T2V0dwWiGAEbudvQEjuOf5Vy7ySWyQkWvkEoI/tARAkqngB8naT75B+lBOxSt9ev4G/cuqpksE2BgR6EfxAVBql0LyUXRdRM330AO1T6jPb2rR/sdJXMBR7K+UbkSVCEmXuAcdR6Hn61m3ljLYXRW9jMLq+CoPzfVTjH50hFeWF1eMKQzSr8vluGyD9On0rX03XrrbawX93JNaQSh41lLM8Puj8kfTpUZ0+C7lH2YPE4wrBl2nce+OlU7qwuLacW8lu3mlA2IT5gxzgjHTp0NAHSeI/Et1dzLPHfx3BYMxLxDnsBkZO7HXOAaydEa+uJQlvdvGyHMrl9/lx55O08sPpmsU4DYI8vjDf4kUDIIdGKuvzZU/d+lAXPVrS2uEuFLMt47AYlsyEmdP72TyoHHOD6V162Fo1zNPJpDNEQkVwZAf3YJzvbaSCR1z8o9hXhFrqd1AIVE0mIl2JGc4CnORg8HJP0Ndp4f8cXmnvbw3921xbJHmGTAcRkD7jjGCB046Uyk0el3XhzwjqdshXWkaaJwscJG5eDyVcDg/wCyc/jVbxT4Dgu7aBjrMTpGwe1M04Vlx97cmMoc8DjFcS/i6ySBmvLTT3tZ48vZ20W8Rk85BOPzHFYFzr8zQ3MzvO1tPF8rmQbpG4AHByCB2GMYoHdH0LoXhLR9Nt7J9XtXvWuXEd6gYLbLHzll6EnpxgZ5NXvEmtaVoOkT2Omwtb2WAsUpkkcLk/dBb5gOuD0zXzVaeILwXL3MV9O/2aYNYrcMQITt/wBYWB4HX2OacviO8ttOt2tLvcqvtIYNhMknPHBHuDQK52viOa+Y2exooLKO4aV41nPzREfIXc85B7dea5m+vHmF1I6JLBbSK9vPLE0YRifnJHDDGflOME9c1zSX819KplumaRwWlG5+MHsSf06e9U7e/YStJco12duxleUhuuc5A/WgTdzvYr1bqyuZWnEzTECOOKXy/MwMcIO2Oc9O/Wsq61RLVzkR2kciGFQkIUSKOdo5Jxn+Jjz6dqqeF9YaTV5DMwhkdcRSbPMKoOfLAJHfpV7VbvTreKb7OsiTeYJZBhA0regUcg+/bNAXM25WaRBqFzHLcPcuqxWu6Rdx6AbhgdBnAH5VXuNQeC4860nuYp9pWMvIFSNR/cGWY8561TnW+1CUyxW135Z4SNN8iqOh+Y9Sa0LHwtrFzCPItI1dDkhmAfHuewHpQBzjs8sjSSMzyNyzNyT+NNGduV6njivRbDwTe/2QDdafbwh22iea55lPqicEgfkKw5PCd/EuLaNbuV2KtJGD5cXtubAJPr0GDSsFjnYydvTP4UVsPoM6uy/OWHDeRG865xz8yjGfailYR6to0fn2WnENGHeygiCjpJ+7XOD/AHvVT19DXH3enrDq1213buIgjJJHEgPmQ5BMig8NjoV6jrxwa6LRfHmg29nYRalHceYlrDbbktyygogXd155HIP1BHSqN/4j0S/nnFre3Fo4cNDK0J3JIDg5BPzRtyDzkZquhbsXdIsLLUUiZJ1eCVFgjuGJ+cfwAt1yOCu75ge9Wbu4kje6i1OeaG/t08u4NyoYSgdPOC9Qe0i4IIGRwawLG6nspWgPyQykllhYbljPORnhsE5AI5GehGao6tq6XkMdtq08s99FmG3vYV2yhQeFdTjg9NpyPQ0BczdUj+1SyQxTZ2nbH5jiZBzlSknUc5HzD25q7oP2jTktrkQ2wk80wSW8r+WCx5yh6Zx1U/UCsSy06fUriNbO55uJfKhklGzEuA2Nw6AgdT1I9s132q+DNbu1063t2sGvNVXyvMjuAI5yoz5cwIx5gxx0OeKCUupk65qVv/bJiuoBb7og0aXMSk7unDcLIh+oP8qyoWtNIlk8u/kiuWhCyCUhoDjnagxyBnBUjIBrY/4Q/wARJpF01wsBjtpVDQyOGQs/BBjx8vPVlI9wetVbDRvsltJZrJYLqLth4DMJIpCASD0+Qgcdj9aB6ltbuWDS/sM9uunyToWikt3DW7t28tiTtP8Asntmud1Nvt1vDPey3X2WSPANu6uFkXjayn5SfptPsa15UFrZ+TB9lYXge4mtLktIi7OGIde3Q4Iz3zWJd2UaXkbXMNjbw3zgrLb3RKqRyCTjG31BGc8igTMuTaGs1ngZfMCqk/nsRtz2BHb0rTi1CK0mvJUj+0QzbY2lYHCnoFIGG9/XvUAggubSS8uLq2Sa2mbdbq4QyrnqoAxk4wCOvHTrW9p/h+48TW1rqYuNL+fKyxS3hSQpuwMhgec//WNAWOdjgilmuIXt1jRMYmR3BUnpkEZYe+Miq9tptxcgpbRxSGPJZkk5b/dB5PHoK3G8L+Iyi3aiERzMlstwkxAIZ9i5OPu5HU9Byanuvh3rVnKyvLpr3Qufsqx298sju/svXHB+bpSCzMWDSZ7qwST5vJVyVl+98p6bR6ZHPpUM9rJBashaTaqF9h243Z7YOSPetqHwj4khskktniMDBmVoZyVUBtpJOOBmr8/gzxL9ihur2TTpIgWiikmugHiZcfLyoOeeOtMLM5SET2is9rIRbSACVtmFOexDAjP0qs7RxF1378jJKtwOOMcfgexrtNM8G+IbvWdO0qyg+06u6faraJJQwkjBwwLnCqAQSc/rXbH9nXx3IHD/ANiAElxm7Y4P/fvj8KVxNWPFrNiJk/fNGxGzepBI/wCA9Me1M8mURtIkfypkF0PUZ5Oe4r2uT9nTxzLGoZdE3lsMReMBjjH/ACzrjPE/w98Q+FdWSy1/7Fb+YGdcTghogceYAOVBPQHBPcCi4HCz206osksX7vg7+PmB6fWlVrm8RI082QJwg+8EB9+1drd+Bbu1e3t1MZE6pKZJQu+INkg4HAB9Se/Sug0jRLCJRJOqNe3A5RpCJGXrt2cE4xk0x8rOD0zSFa7ijW8+0oAZZhAWURoOrA/xEewx+Vd/4b+G0+qiSWC4itdMuF3Pd3EyeYuegGckDkn1rqdF8PaOtoNSMd3/AGbPgHyVULnOOVJ4+menJrq5/EWlaPqA0uXTZBPbohVltQZHD4xJFliMDjLbeDxRYqxzUfw3022tIkS5uNY1GI7bf7PE4355O92Iwg78Y4rqZUW00uGGN9GsVcrGzy3BnJx1VFQbMgD6eprSs9Wl1uwvns4ZLawjibMty4DSYxkBeOPciuT1rWLS1sY4pkksvMbyIo7aFXby1BYgHIODtOeFGcACmM6DQdL0K61Ca+U6TfyhfLgSYmU7sZ5AwpPtlgKTVNLt7PfJqVv/AGzqWwvHb3DhbaIdhHbx4GOnzOcfyrzq5+Jdk9laXdst0scZ2orwKVXjO/Ck9uM5zkYxW/a/E7QU05Qlrfy7ghur6W3DRxsxwMoHBZgeOTxSAw7/APtG+uTJLLf7l+XbbIfLTH8KhRgAegorfl8Yxs58qW8WIEhBK6ocZ9EIUD/OTRQB4hr+iNbLJH5gaYSmSI7ceYrDlfqCOK5ouDHkN82fmQjgjtV2/wBQu59gmnZ9hBUnGRgY6/TiqrwM04hhBk3LvTjBKmkZliG72xpEskiglSuWP7phx+Kt6VahsNVvr+yguLaeSeZtsTADewXlgvZjjkf/AF6qSWE8EDzyLlYpPKmVgR5THoG9j1BFdnoevwaXpGm/2hFL5sDPNZOTnODlRu9QensSDxQNa7nVaXoEPhuxu5RqCapZFDK8IRVkSQch1Unggkqyfj3rkD4pNpHAI5mij3+bFGjCTbx86SdwQcYYc8e1N8a+K7PWrC5ktoAk9+8csyYw0EqgZ5/iU/8A1j0rhSf044pjb7HUa94y1TUdWkuVvJGTHy9QHJxgsD1I/wA4rnVubhVmVZ3CzDEgLZDj3qA8cfpSk8e59OlBLY+WaWZU8+V5NgKoXYtgeg9qaGIh8sE7M5K+/Skz/nrSscqOMY9O/v8AWgQZwRk9OOB09MUnpyQR74/GhTx7daM7cMOueMcYoA19P8R6tpsBisb2SKJgfMGdyyg/3geP8ipIPFGpR38F20qySRIY+VAJUkZXI5HQc/41hY4BBz2pcnPWgdzp7TxbdwcIyoHEm4gcLnoF9hxx09affeK7u5sbOGOcxxlk82IneF2dyT/eOSR2rliQTkHnFKfuqecHnOOooC7O6/4WBfWuu2Gt6eUivrKZJrZCxdMjcH3jghWViu1ccd+lfTPgn9ofwhrWn58QTHQNQQZeOcF4n56xyKOR04YKeehxmvisEg43ck8mnA4Bwe3Sk1cHqfbnin9oDwRpOmNNpN+NavWyIra2DKMgdXdhhF9+T6A1806941fxL42l8T3wYPI28rDISEj2FEt9h+8Qe/BJYtxnA89zuXjv3JqHeQrAMRnkgHGcUJWBaHrtnem6FvZSytADarKUlfDSNkER7jyFTI55962LC60/ZHqt5e20lxYxvYKixL5kkuedox234YnPUeleT6fqZa4uLnVNUniKw4jeJVllkYgDYu7hRgcn+ea9H8M+KrTS/DbveyWltc37NHDHbwozIhIG0k/MuATkqOaC07l5fEVoL3SrC8RZrm1+S6glJEcMXJ3JgjjG3J6nPTFackiqbsW9rdFpp7d7mdl2ZtlOWQlSSEK/3T61h6lplheyxy6ffW4ur6HdbSJJhwEIJV1JGVYA8t26DirtrGxsfMvru6i02ISC1SFztlIGSzHGEQE42jO4elMZqazrcSrczaZPFcNLPD9haziCRSKDvUlQxzn7pBz05rnvFc017JK1yHutagSWWaKFSmZHZQwaTj5VyOwGRx0pul299Y3VveQ6bZAXMDxW8swVEESDLPGgJJBIOM+1VI5ZDbXlrpUEsSeYI4luHDF0YbvOkJ75zhPfpxQBleMNPTTtOtrWAG6lkiMFzfxj5UjY7tqLxkZ6tj1rlJm87VHmjufMjDL57KpCSBVG3C/xdMDrnGTXaXEsVva2ujvYPFooXbLcTuPOdScSPnqQeQM468Csb+1baW/dbO2WCKaRobaYj7iKMKE4PPbP1oJZmC4uY8jS45Psp5HmPuOe/I7ZoqPV9KXTb0wTznzNquWHyhsjOQAOlFIRk3gCzfunDDgq2P0IrQtL6ySMl4WjeFhNA6t8yN3jHquckE/Q8Gsy4xnkn/P/ANaog5UhlxnoMjOR6fSgk0tT1OeW5uCrjEybHZekqcEAj1HT2xVE3UptVtd7fZ0cuFPIVj1I7jPpUZztUHJHYdvwojBPTPHTFAxOB9R+oppJz068U8q6gZyAT3FN+XIxTEJnml4A7/QUDOOvfp60MT1yeKADdjofxo6cg0NlTz8uO3eg8AH8aAEzke5yMUZ47UE5z14oBORjOexH9KAD+I8/pQx646+lHfg8EZFKTlv88UAJnk4PHXFB+6cMRnn8f85pdwABBB46YpvQAZH+FADick8Y64Apc5wvU46Yzk0KM9vujNXtN0ye+VZVeOC3WVY2nkJVUJx3HPGR+dAxllYXdysrW8DyJCVMgUZYAnHA6nvW/YaJ5t8liN0ccLvJc3UsYeJtjcKCDjpwRnrn0roPCem3E9lPaaZMJbi7lNrDFlY5CFLDeBjAccnGcHjvV6zSa20cXuk3MY06F3eJbzaYZ9uTJnP3SWBz1HHAoKSI9N07TdNN1INPtr6UxmV4ZoPM8nJwroo6bifuj06Uy5+HLQMI9Oe4lkk3qUktT1A+Z0ccKO2M846Cq8a640aajP5C3mpTCVSMbooAw3Mo6GPnhR83SvWtY8R63BZf2VEtvHpciZR7ZWaTygeMNk7ScZIxwKB2ueQXGkXGhyQxostzpyKJFHkeY4mXPyAYzsJJ6/KD+ujp3jC6uZY7LVyt281i1p5scjRrYAkgOx+6zZ78DjFb5itr1jbvfSJNcQl0mgi3OFfrt5/hOeT/AIVLrPg7TCi2/hSG7kulsd11JJIMhUwV3KOByM++aAt2E1m2+3eGL+7S/b+3LeZY5Fjt/L4XBATHBTHZfU965fT7G/tbny9UsrpZbhvNhZ1IMspU/cQ8qAD1OBirPgPW47nxa0niTVJdOt/O2pbnJ/eDnkgfMefXAyeK7rxHBpNh4kgvD9qv3nlIs0nV1ErNgsUHWQAAcAAUD3POn0a+TwzcJd3cVzcW8TFpWcTCNhkgbuATxwDkjP0rG0q5tFnhgeVILG205ZJHibe0YJ3MqvjqxwCw6ZwK63xFcwW95c2trFJFb7zLPFOolZ5c8L2GenGa58XGnweGftFzZpetd4gAJ2hiWJAwuAAD2HpnNBJSjmnkzIkF4ivhgs8SsQCowAW5Ixj9aKzNS1nUJbnE2oXMJjAjWNMEKo4HTj349aKQjDuPvcnP4VCfugYBIOc+1TXGcj3FQHjGOTQSKOg78U9U4ztI5xTBk4xyM9qsKQvfOR270wGMikEhvxbpUT8Hb/SrIBUqy4Bzwe9RFfbBHrSAiJAAx165FBzx1OaCpDcn86aenHFMBzY28cexoOR0PBPSkJ29emOuKe8RVgpwX4zhgRz0+lADR+g7+lS2koR182MTwZ3SRE4BHsex96d9mmhnxNFLHsbbJjGQfbsa0EsHaW4tiIhcTLvhbaAJFzkhR2agY11sbxZ5oo5oSeFWMq/JPCkcH/gQrNe3mSPc8bbR39B2/DOa1Ev4jFo9s9ssC20mZ50bPmjOCSB2HOauX2ppIusvb3A8pDi3WTHzRs2WHPJ9B7UgObKkDOTz7UnU9OKknUpJsIYIoBQM2cKeRQjBHDOisFOdhHB9jTEX9FspNRvkgQMUyHnk4+RO5JPpXT6XHJa6faGCSH7FeJLEHkB+ZC2F3r/e7g44qLwZYvPDei+Saw0V1YXWoQReYIMDAVickAk4wfWu+8CP4Q/tDU4fEskxljVfIlhZlDO2MDco9MfL0FBSRj+E7KWO+uNDWGDU3huFjttVimCsAVBeIcjC9mOasfEO7sZr2bRzp6W0FwUH7mP7PFGFAJbnJ6jrxn3rV0zSNJ0bwxrVxDatJecyxRXW7yZ37LGV6E+5FaGnaJ4Xv/htqMk11qT64kqTLpcYDzhVcbUVSDvGPcgCgrbQ5yLR9Ss9Ljm0+W6lTS5Imt4n2KMHAZ1Ofl45wMk455rpNFupdLnt9P2fbdCVzNDDCh/dFs7soQWYbiTj39KuaDYQalb3F1qlpEt/afvEbOPOQKWVWjXOwr0OcZIJzWj4S1eJklOkwiNkkWZlttq794BBLsc4bIHsPrQMz2u9KuX3PoiPMNzafiUpHGAeWcHGCDn5enIGKrWGp/29eQ3jXVzDZF/31vfZiDRJ99lPUZP8JGT7V1E+naxrepW9uJtOs761meYJAV8u1Urzxnk4I6d+TW94d0p9M/tFp9asryRo90by2/mFQq/MwB4Az9femF7Hzv4i1Rf7b0rX4NGgtZ5LnNtFP+7DIrY+VDxtx3PHNem3GotqWpWuqXfiO1vNc8vCw2+PLsYSQSEIOWPA6AZNcf8AESCzl8Ope6XHfTXkS5uXPMHlhiSoX+6epPsKofC7WZwl3ZRMlrAo+0Xk0MaqWycYHdjzwCRjjikJaMg8a2SXgkNvFLI1xPuSaeLmFB1ZsHIJ9BWNq0kMNlCupXrXMjsp8r7NhIYc4LonRTgYycnmvW/G2qQWVpY2ejR20Mk8DrELlhLMqnh3ldeFOOAqmvIrGKfT7tRaXJkV32QBQWeQk4LOey9cAdcUCZlpEsIy1paxJL+8jjaIuVQ/dz6cDODzzRW5rlvHBfeWNYFmFUDZuOWPdjtOMk5opCMPxfoz6ReRqrZhnGYsZIPHY+3oeR9K57GfTn616t47s4bCG60+1nYZgEoWQfJLHzgjP3WxxkcZFeWMjKPunI4Ix0piasMySSeTg9c1JC3ODn196nitN9g1yrswjlWKREGWG4fKQO/IwRTLu0ms2jE6D94nmRuvKuvqDQIbuHds5HUUkjjoAR65qPBzkCg5IXPagBrbmxnv2pQjOG2KSRjkHoKUZYqCpJPGB6050lEqKwPmMMgL1x9PWgAUF1kmTb8hDGMA5x6jtiup0XRYLm2aS3niXMTwTSyKQhc4IKnpnt6Vy8YleRYgSHJ27cHk+hA5PFdrphfyre2s5MeQMGKL5yFzlyufvDrlTyKBooLBeXOhq9zGirIB5bSdM9AR6c4Bz/8AXqWwvorS3tbPVbUtPZzEgpglTz1PfP5GtY6JFevHDZNIIyrl2hYGJ2/gLAdPes3VPC1zc2zTqyh4EUFipw+TjnHI/KgZHrP9kXUV3eWkkUU85CSxrkMpznITueOcHmsbQLM3WqiCO6WOdQTHJsLAkfhx75q3ceG5vIi+zTRmRQBKRk7HPZiMhSPXoa6DwppMlvqnn3rA3tuRFHGv3JARnr13etIOpyurae8F8yeQwIDGSJWG0MOrIfpzjtmq2l6ZcalJLHbYBSMzHeOCoOPzr1K7isdXhv4JfJlTcUaNeWjkHZSOc9OenbNP0iwgswxikaKG7VTc+ccmAAYIUY5IHUflTHylGx0yWDwrHbW+qzZuYx5kI/drEy87sn5WB5BzmrHw8FnqOrPHp9nNFNNA8V3ZwHMczbsBt2eoPRh2rS8RX2lTaYqWl3DJY2bD7PdS/LI7HglB3GDjHfniul+H3hC18V6eNft76DyreMwfIGVxzn5tuCDnt0oHoipMt0n2mwuZZj9lwTDd3IEdvhcfInAfOB3q3davYeI/A+m6boGhJb6rHOJbl7jEU+xX+bY3Viw4A6YrkHjkl8QW3lSxzwws0xQwO5aZH4UgZJyM8Hj8a63x746vtW0+wuILS3t76F/NWCGHZJJgFSoDcgAHJB6elAxdJ1qxF/qMNjpt8xZhC6XK7hvAOTvOWKDptHHWqfhLRtdvNEm8Q2Gmb7SHzE+z3KBIo/LbB8tACRz6noK1tH8MX0+mwxyiTT5Bse3ufM2STA8smw9AeDu9uMV7LpeqWdxow0fMdrdbSJY5iWkJzywUfez160A3Y+crCaXTLX+2Z4prYNMCXhLFmY9Ai5A69jgVBqmoXm+V7ppNR1G5ufJgS2lZnTeR+7BGBlvl3fwivT9c8C6LFb3ljJcX2oXDy+fNK6ZXAyQpHoCeAK5Sy1h7WwsR/ZSafqdvCyXD27H9yxP/ACzJJy5GCSc49KAWpxYuNesdMv5NXRFUHEmlmTYUccKig59Mk1wN6JIpopnljtI3l+0OpyVL+m0csB06evrXdeLre28O6TFb2WrzXmu3UpklhLeY6F/4pJMYZtvpxwK84jsJLy+lWFTOsk/kx3Mh2qzc9upY+g6UEM9Ms7l5LSSBgrXU0HmJNJCEkZenAGdijsPzNYi6C8umxacNUlbUEVppXWQ+QgJPy5H1GST6gZrvtO8Catp/hi21fxFfMoOMWVwDGkij7oP8TMfyrmPEUN5/aDpNBFJb6kwMdsrLEkMY6gD7zZHPGfwoKKWmWVqbNASdTZfla4S08xSQMYB9B0AorYj1fR7OKO302wtZoI1C75pCvzDqFA6AdPzopBoZHim/Os2kmnvHKLuyUrbtKm3cmAVVXHp2z1FZEPhdrrTj9vZU1CRcefxtgZeRGwHqO46103xM0W58Lajp2oaTf+bA8SxyLwcANwePvL2z1q14FNjrV5PiKLzWIkvNP83DTYI+aPPU9x64xTFu9TjdJ0qfT5otUuY+bb5FAw21+276/wAJ9DU19a2uuWsl9bRSxxqCJ7Ej95FJ13xj19R0Ye9eleJtLS9vJv7IEzWUS5LhNy7R1Vx1wMYPdcGuUuNPuIHjSFBBOoxDLgMrKegOOHX36/rQDVjzbTdIm1P7Y1kfNhtlBJA+bB6EL1PuKgv4HtZRBdRtHdDlznIZTjGD3+tdTcyyaVrrXl7EyXYzia0H7uUHpkHqfUHGcZBzWtrkcd/ZSNHZx3bKpkmtAxEmP+esJ6+5FArHnJLIU8xS6xnLRupx/unvg1q280t/ND8rAQ8RoE3fJ0IGOWwO3J61Z/sJr26itbS5SaORPMSZjiQ56qV7kHjI9a7BNBgS108HTP38riJ8ymMnb/7Nnt70AkN0XRraeyhuJY47ofdSQLuLY52kjBBGeOAema1rrw1pVtJM9u6Wl9EiSQyiMgsG+7k9Ac8Z5qxpUdjpUj2U199otmlKl5VPnW7d1YE5OPr0ro7wI1pJY6TPbuCQ0ZWUvvUjkpx68Fc0FpIyoo4Lm4T7VBNp2oXDCO6DIE2uOjEdCp554xmk19oBqEenWN6BcWkLSTRSgq5TPO1hkEE9802eNhpqXWnMt1dxPtuILqQK8RH3cc5TPOM4BxVfXtQt9R0iI3NusV7E4crCcsVB5wRjp3BoBlN5LCJXk0yfyJGh230ZgwSDz/wI571Sub+M6jaabbW0c8kJDmQAorNgYG/scfl7109lBbqNtxZ3JSS33o1u4ACnvjnnvzxUmm6fZDwZdXBljWwtwGmxgOpBAUlScjPQg9aAsY+nzQWUSzJbgNPI5llPCyM/8PPDH8ulQLfWRjs7eEuzq7FnaHaqE8bG3fex3X8s0/VdPuLWxllnkjt7G8OII1lwy8ctyT8wPRSKzdQW+gsI4bW0eRpyInnDYkUKPvFlz+eODQK7RkFoIvF+y9M0lhBOqAQJu2u4zgA8Ko7HgjtXuFx4fj8P/DqC70DXHt55yHmhAwZnI+6XHzEjjrk1x/g6HSL/AF6w/wCEk82Oza28po7j5RMhO7axA+YAjPHIx6VJ4u12wt9X1LTjbrrmloyC1maYbYNxwEWXAJK91IP1NAbC6VryeHL+O4sbWO1tQyvcyNHhjJjntjHX07ZqPxjrn/CWGfV4NM05Zov9QTICQOASR3Y9yO1b/gv4i3Hh/wAIXemXVozyAyAai524U52qCVO4jOBxgelecX1xPd3Ecmq2EyXchaW2jQqg2g/eAB6HOeR3pBc9B8BeJEia+LSyzXt15USmRtrWyqMOsa9Hy3Re/c1e8b+K7+w1u3vLbTtQsYpSLZbm4i2SE8nZt/hHvXB6bqcdtqba2mqNDJaptDbTkHuTgYwOnfpVbxJ4iOtX9o9xqV3e3Ej+ZG95KUVUH8SBRtK5GPmpg31Ol1fxJrN5pGnC7ktyyXjOURyBMgzgNtxzg9B3rL8mbwzaxXPiO6MJu1k2KzeY3qNzfwjnGOpNWtL1uys9KeXVY47iFGyEgKqmeudwyT9BXm914gl1C9S5jdLG2EzKI2Jw8ZYHD9SCQMDHrQDdia7SXxJqjpYWuogysESLyAGIxgqhGCo45JHOcV6D4D+GGq6Ak+qXt3p1lfDC2qyuG8gnszHgH2GTXI+BLPVNSlaLQoJb0TzO6xQ5TAychnPIUDv3ruvEWlQaTJaW2r3EplEZmfaweOIr0RF6AcnLnJoEjV8WiFp7SK613UdSv5yoeWGPdGPUIDySTxgdBXnWotBoN7I9zp93cagisw82PzJEXJOW5yEXPGSB7V6Hputar4gt5YtK8vRrHyyl1qLBRJEmP4Wb7pI/xxXLag9qmksmgtcapbwygyzt1nI5wCcDr3Oc0FGVpujLdWi3K2en2xnzKy3Kb5GLclj0AznoKK6DT7TUFs4jLbXSyMu5lS3Mu0nnBfIyfccUUDsjX+Ivhy71Dw7L9jiguYrZi06bfuJnJYKOQR/eXjvivDbiO60nX7ea2MtvIq71lUecCmeSP7w9R1FfV2l6Zb28cQjklLOx+zSdTIuOF3jjdjp2I7V4N8W9Bu7S+a8sBK8UU4MghiwYmYH5io+774+U0Mh9zsfh744tr3U3Sfyba9nRTPuGFulHAIPr79ecGu4bwVbvY3j6a/zySGSC1k5iT+8vqoPt0PNfL76pHCbOWBYpnSRi67MMVOMjPUZ5Ix0Ne1eEvHMGkaRBGbkS2jk+RJPPtIP90senpk0DTuQ694Yj8p5n+0WsLbo8sNzW0wPRh/Gp9R6iuTudHW1ltWv1mR1QvbTwSbzA/Zk6GRPVOo6YNes2nijTNTY3EyFnlBiubaQhX29m29CR2dcgjrWH4l0pY9MvYoPKnWJTNANwOcc70B+8OzJ94UDsjzAwpNdWz3z+SjyMftNlho1kxgn1Xd3U966YWur3VrbR2txHqFu5Lqk67BJgcsOOG6HGaZAnmfZLvTs/ZrxcSQbctbzL1yOu1scd+lXPCbSWoluLLdPDBc+Y9tK25YAQckqeSuc8jpQCRRFtdizjaOKeGeOULJK53BT1UhujehDDNVlSeC9nktyYL1T5k0QQFXHquPutn04NdybnRbfQ5DN9r8yfeuGYFpBngsvQgE8N7ViaXBBbQSWt0YlDkr5rMFQdx3469M0DsS6oNO1PTbPWbJIhdugiuCjlQ+CDjIPQ89K1hpNnGsKLGbC4uIvPt47iMy28gB+b5gCv06H61THhzSXtbVPMS3blSBzDKM/3uAj896ujwuujKDZahbXem8sxlD+V6YbB2q46ZB5zQBtxeEla2S7FnDYSypteS0nkKt6NtU5GD3HFaN54EbUNI+363YLM8MJV5LOVWWQDoWU4Yt0PXiuX1jw7cQWa3tneajYXAIljt45DIinPPl54C966+WK9NnY3N9q9td3EvDYODGh4JeIHnH0P4UC1OB1fSdKg0O6nluYrjVOIYZBFkE87SGzlj0yWGMjrTPCnhvXby0JtkeQRxq8sZPlJJJjJIJ5Bb24Haup0Lw0YdYa0utVshbtuKxrEHO0/3ST932Bq3pus6F4bW7s5YzHf2zkJP57Kr8/eyOn+6c4oAzLq4sLTwlPPe+Gn067jV1SXf5uZACPu4zjPG73rzuHUbPSbeBtQhN1FM4uBZxLne55OZD91cnqD07dqveOfG2r6hcTw2d20dpbr5rCRGk84dcKeNw/A1c+GXiG1i1oX2u6LdR23lgxyriQSnj75xtGOwH40MVztf+FhaRq3h2006C2lLzThXCRhPIBIHyjqxH97gcZrznVdKsbLxX5guEndt0ZUkCVBjjcwOMHuD6VueOdYsfFD36g/YtNQo0UyFVkV1JJXdgE5OBgZxXM2mzc1uIrMb1MivHIRgk8ljn7xx0oGW7jSXmgk8uOFrZt0cku1ynPTBxz+FYuoWkB0W4sRYSG/iUKLoNljFuGc9kXH49a17i8tYdHKGJVeJDIUjncyMq9lTkA8cVyniPUZtRHlwXH2e3uVUmKchGJPPL5AA9e/YUCZhanrZ+yR6dpdwiWNu4VJOSCRyTu/u/hUUGmalNbLCkCrFM6tIW275G6/L/ewO3QdzVDV55bjULmSaePMQCERN8rjgYQd816D4NsYZ7a3Ntax3F2WBEcCNPgH1PRQPU570ErU67wBbpDo+qWlnJY2ca5YxvMd6Hjh2Xgkt2B9qzbaO5vr2a4kT+1bmIOJW8orGUB4yx6AegrduZYtN0SS0trSz/ftsmYHDsxPOWOAD2AGTXO3+mQ7TZzzzmBSMR2FwzGR8cIQOSOefp0oLLeqXN/qkVnbLdW0jgZSM7I7eFe7GNeG6d81p3F6ltHaJZyC5gtiHmLReXA8vckn9B19qZDp0bWKKs9mdoPmtaje4A6qXzxzxijUrySeNZpzDaRQDbHERtWJfUg8F265xnmgaKGtajrOtXa3U16kS7AkSktD8gJwQoZcDk44orB1LVja3joL0DPzYwX/AFopE3R7rPdl3ji0nekODG9uWDqxXoEb06YI5B6iuW8V2sviiwuEtZGtNfnjxbTSfu1lCnDDPTeO4P1r0m1fR7KOWIRG1fe29QgOH9SB1z6jr7GuW1S0t49Ws7kyxz6RqWVZYXJi84D5WV+scgwevXkVQI+XPEuk3Wg309nrNnJFckgCR49gc9T7E+4P1zWPJLJcDad00SZYK3OB3J9+K+jNdsdMvNRv9K8QfbWndAYJ5k3o6gYUjrz2P6GvC9Z0aK21j7Olykdu8pTztjbYj6MOo5/nSJasXNJ8SfuLWG7byPs48uOdDu+iup/gPr611ug+Jv7WulgMghuVk3hJm2lwB96NhkFh79QRXlc0fl7mBBj3FQynIbGfXBIojd0ePy3cYbem1iCD6gjoeKQKTR7zFd24tpHmTypw6kXEQz5Zz94oOmemRxSX8Fpd3hnt9NmNwj+ZMkblSc9WV+o7/Ka8p0rxBOrQG5mHkwuXMj5Z/UbgOoJ4z713Wm+OvPv7UaczW97LG5kErAIRjoWz19DigvmT3OhtGuZXQafb/aYo32WqYXzFP8QU9vdeQewqS1tPs14moXGnB45nJKyEGN2XqmOzj068dKx9F8S2EOnSXC7kLzCO6trhRG0RyNu4jOeehGDW/Yxw67PqGyS6tTIwkeORzJlR7fxEcc9cd6CrmzbeJbK1jWHTLdLm1vZvJa3uXAHHUx5xgjPKE/Titb7RqGp2F3p+lW9nuj+Wa3z5TOp6E4+UEj19K52y0m2vtWljvhDeCArJFOi7JAOwDHv7546V0+nWcGha8upWaypuXy54blQJPZg4IBHsQfrTEzl/sHibTRFYRaXczCMhldZC5C4+7kcE+vUe1C2t/LpiQz+HWGvFjNE8FzgREHg7DyCcD2r1XSfFA+2Q6otpJ5dwWhkVZUJXB+8yg5PTg+hq/qGp6ZpWrrdS6Vstbg5kkkiX5pD02dck8DaSp9M0ibs8Iv8ASL66lt7nVtSWzvZRloWQukrgcrlRle2cD8KraZ4PWC+ElxqhMs7hEa4t3IAJ+4WxyBn5cgV7jr2r6TZ2iaxpOllL8kMjXEPlqgP3gQSNpI9a53V/EFv4q0wpFJptmAvz/MFZDjnB6Ej1BpjTv0OUs/hrqXh2Y3Uc9r9hVjOska7m3987ucdOOlc5ClzrV/8AZraKOAMjM0kIIcsD/dGQAe5xWnqMWuR3iWEWqxiAxlj57ySKV29QT3+lT+FfD+pQ2MF1o2oCK7k5eWTKxMD/AHCFz+ByKBozdV8N2enWPlW9yL2BBvmQId8bvwSecsM9Me9c7bWjQyHSrW1mlkt8IJpSrK5PPI6g89ea9k0XwQL7Vje39uWKIDIpm2SyOM5cjIAU9sY968y8buyazdahAsNhp4IVoAuJEb7oJKnaOeetAtChqc1vdbJbYXcTWx8mRYAsYkdcBgT1IzXMeJJ4rWFtN08Wss90WlIVd7sxPzYccKB6Vox3c2nlntfKuJwpl4k2IR3bdzkn071hOrtaB4EmdhiXyZ5hF5aZ5IAByD9fwoJbMvQPDFxrNyschaBvMMIkjG7zZMkkexA716NGp03SpLWze9NtbsqXHk5jd93HBAzj3J4rLu5jBb272oEslrNHM8MCMikt1IIB55ro5rrY8Swzq7o7XHlmcyqjdlK9Cf8AaNA0hy2Fvdmby7JZlVEaFWdm8hgeWLngd+cd+KXTJDbyXt7BbfZwS0cNsshA2jqxfI+U9fU9DWmtrqF/a262l5Jc299t32xIKs69ccfMBjk9u1Vda8M6hZzaetzd7b+aU7YlKufKA+8SeEHTtmgoi0/U7mzniGnrYQeZlpLi5AMmB0EaDPGepI/KsSGXUdQutRnWOMR3U3ky3cymSYeyg/Kme2OcDrXV6zonka7Abb/SFmtPMimZzh5FPIycAoODx1qhJvg+1QmOOKSeVbi5kDHJdRgbfQn1oC1zzzXtLtrjVrlWSOPyG8gC9mKynaOpG4fhx0ord1CznjvJTK9pJK7GR3uomldiec7uMiikZs91W88PXzSXBvJIxHH/AMfKqdoC9VmjxkFTzuHqKZJcaXLG0eopHK0/zOICcTKORKjDhjjqDz9am03S447eJo5Gt9QVFUzA7kmIGM/Xtg8+5rntajntLhzZRi3urR1kuLfyj5ciN/GP8Rgj+dFJHRwrFcxWv2eeK/tF5gkK7XTJ5SQdvqOOO1cv4o8Irfai95BazCSHlmiA3jjoUPDr29e+as6JeX2n6y19cW5k025UGX7P8/lD++VHJHPJArp9bhk+0284Il0oruE8UpGCR0JHQdOeOetA9mfNHjrw8WkeeziYmQ7lt9uA7DqUB5DeoBOcc+tcLeRoNgT7PI54Bjb9GBwVI9xX0lrNjHqepvpd/ItvbLiSL7bCXR5ATtcOpyrYONykZ/Eg5useCrbxErItpFc3ltnyb2OZVnKgeo+WUcY5AakJxPnVQ0Y3qSjKcgg4I/rSAhdrLt3KchWAI/EHg1ua/oV3aa08H2eT94wEbFMDd3GPwrHmg8qWaNiqvGQCuck8/wAqCDV0TVnsGkCRM9gx3TwhsMFPG5Wx8uPxFezeHfElvZDTyLaKfTpF+S6bCyJx97zF4J7EED6V4GgMPzlA8bZBBHDD+dbmkXEkQWDU4ZBpjj5fM3Ig79R+NIcXY+k4vGMRWAXPky27ygkRZ3lAfvZXqeehGD7Gu78jRL69ieDT3unjVS8Zl+Ug88Anrn1FfNGkX1sNMjt9SBtbonzLG4gkBRlHTkdR0649677wZ4wtrLyJbid54HyN+d657gDBIFMvc9s1vwhpWozwXNvpcMUwZZtwfymd/wC6cdPqOKu6rDoWnKHvFIYYOxgzqrdjnsR6g1xmmanaXmoOIrtmtJSsx0q7YogXghoGAz/wHODnnFd5Pr+nx3lmrTXETyEKkXl5Vs9zjp9c0tSHcranrrxWcMVhNBcTXAOx5HBiC+5xk/rXKXHgW61K4e7e20+BpFy0UcpAnHUjGPlx7evNegS3+mzssKxpdYbBCIrBDnv6Vz3iLxFZWdzIlpciHy43MjKRsBH8JBBwfpihAn2KGjeDxp62lyNPtrRbbcsaSXBaXD8MC3Tnpjn8KtLq8UNvNBpceny2tpP5ckMzZFtgcgADaCPTIrgNa8XbdOKKVuFdfMjKSFxvHTcc8Y/OuZu9bt9S09rm9FxZ3LxmOdo0MkeOrOASNx9z60yuW+50998UZdNF6NKay8xXZj5ykll9iMBR9TXl99rl0TcW1m0KrdkSyPLD5uCTuOK3LOTwtbWEY1K5v7sZDxwpB5azjHG70z9cVX1JtLh02GfS/Dl1p9mkpcskm5cHOcjP60D9DirXUY5bmaC7tWso4jiOMjdJckn72MYwOvA71pS6DI0r39pZ3E91C6rLKcsVXsoGcFR12gY9av8A9radJeKyS/a5QgKBgVEIPfJP4VBP4j1T7CYtPxGbYvi7lwigHghVHOMZ+Ydc0C0LdzosM4tobmS4e5mfP+sEaxr/ABOpU8HtgU+1s9Mt/tSxRRhbeQRg2p2ZPZmzyT7AH61z+m3hlhJs76a7uZBy1pDhF7EJk9c8VNaSTNeTWei27RsCBKwULGjf7bkksw9BxQO53kF9stZryBc3iYjWeVyCB0CqMggY64xUGp6nqFz9qlW7+1XTIkc8rII1tVJ/5Zjj6dyfWuZa4gtLwTkyXt7bnAFsVIL4xgk5GPwrVl8QRJo8rSwvb3DNulklKsWPp/tAH1/AUDui1q8mozapaSMLryLSFpRM23dE/wDDuHvxwORWe0U99o/2gTzRajGpnnURHMYH8RZvlJPXknGRxWbJ4xTQ7JbW0CxXEuZJbi4AOGPQqGPU4/CsG7/t/XIQ2q36RaXkTFEJiRyeQSxwWP6UCbRrx3upQRJu1SW2Eg3hY0Q5B7ksCSx7miuBuLnT45nSR4bgqxHmY8zPP95v/wBVFK5N2fTrXel6pp626XP/ABMSQsKtlftB6gMB/F9MZ9DV6yS412IxRN5eoWnyG3uJNkiD0EmMEHtkV5fFJcWzrZz745Q3nW85wN4H+12YH/69dEniXVpLkyRyx71hIRzFudgDyh9T32kfSqLsaEV69rqD6ReQ3GnTJOJJrSeP52QnAlgI469QCa6qfxBHbW9xBHN/aKBQu60x5hz0DocYbuD3rnQ8Gr6WyiaWW9ci5RZnLhB/F5TryB7HpwCKd4U1ex1CS/j1BWu/sbGD+0Aih0BxiOZRjOCTyRznsaBNFBPFFxpypbXUUtzbQSMpkuY9syjPBI/HBU/UVavri1sYPtujooa9+7HCAyOfoOmf8mqmtaZqN5rEluJY5AkYMayRASOOxUnl17Y5I4wazLCSDSLS4utO1G6hsEbN5aOnnxx9iRn5k/HFIfmauyK9jE1zY2sd1OuX86NlkBXoWH3WHuCDjrWDrHhjT9UWO6vbK2d4nxJbQEbyOhZMjJXHJq54dubl9QEemTG4V0ZreYsRuHUg9Qfpz3p9rrd++qXWm6hpyteAgqigxkA5+ZGAIPvxkUDOLu/CenQyPYaVbtcwuc/Zrhtz564jYcEfWsKXw5bQRNEtve+SG3C2ZyY0bocBuh65Gea6nUdSuJ9WlhkYyNE/lloxgxSDkBsAc9/enRXc11qkm+VY7iXAmSRiqHjAbB6D34oJsjj7fwiLmKSJM+UG3xSRIdnoVPOV/CrFraSeG7eU5uUjL5eOaIs8fuPUfSupvdKbTLkzNZwW0jNmYicmJ/8AaVgeTXJ63qFxepcGDzRDG5V2nkZVix1yOuMHIOMUCasW28Vw3UkSxzreSRqZIzB5ke0DqCG7+gBzWh4I8T3dxPd3NvLFHbQuNqSs+ZO5BJPBznH868ygW5XUFhsnMvlyedG8LfKD/fGBg+nSt9JdSnupPJt47jeQzSrAElDnqWAxx+lAlJnp2v8Ajy41K3tIdREdrbxSbmkQuBMOm0knIqnqHieOwtL5NPvfPc2+VjC7GGf7u4EFu1ec6zqF6Igt1HERCv7yF4VbcP72D938PWqF5qySw6e7sV+UsymPcsfb5MHn8RxQHN0OhPiLBJtJbaR4FFwkylvMlk6GIqDjj+tVZtfv7y4jS7tpLW4lkDNJERt2ntzx36cGsXUW09Nptrkm42/PFariNh1GZPvD16GnJrsyIbf7FDGhXayyrksPUMe/14oFc0pNVGm37/a5rwgg7dqhs89wxP8AhViXxVO/ly6fOSygLsIDFVzy5UcYFc61/CyrbwiO4HADXS7WR88BQpwQPWn2G6fW8TRPI6RtHI0KgckH165GOeKAudjpeqTW8Tf2M1hcXVw3mu4HlgE9Sx55z2Aq3Y2mpSiea/v4zfwsAjsuyLb14U8Hv81QaYby2t4bR7iG1mjULAixIwiU9R7/AFPeptditJY7uOa0nnaSMNM5Zdu0dCxLAdulBXQwbjV5tRu57O7gE1mxJW8idgrEd1J4AGfpUotoIbKxhkuQtm0u0qriQzNngF8Z6+n41kQw293fGyglNuu0zOxlBQqB90nnP4cVoaVeW6RSG2vobgcgvJKY1jyOAq7fmNBJ1mg3F5qWrG0uFtLO2Clo2bEYAHU4J3N+AGfWoPEjafo9z9qsryTVJU4z92GNs/w8YJ+mTXE2etJb2zCJrK1kkbEsxZ7iZh6kEAH2A4xVS71JbgpbaZNd7m+Ut0LeyrwFHfI54oHzF/WLW++1LdXOoLDPIS0rFl/dKDwFzhm+gHWmaBbjVr0vHa3ErQA7biefJZvUhsgf/qqnL4avoru2tpI7fz52GI0JeTHqxGQB75+lehaLdWNmyaSk6Qm1P7944g5Hfaq5AP1JoEl3MlbWz0lVt7i5tI5CN5AUHOe+W5PTrRVHxb4ji/tuZdPgSW2T5VZ8FvxI4/KikDeuh6/p2q6Xd6c9pq9+qyRYPmM6C4hBHyvg8uO/TJH96qeqWNhfFEtNW0eO42l457e4EcdwByHADfI3YrXhniXxDqWvQ6fFrE8V0thD5FsTbxoyR8fKWVQWA2jG4nHOMZOcVbfciOI4trsEDNjG70P+NFyuY9y0d7u01mK4TUbQTRv+9jaVRux1zhsE+4wTXc3lzpGoX63v9oW9jqIADmO6Qh19C3GR14YGvlzTjYRTXC6hb7oJInT5UBMb/wADD3DDn2JqqrJ5agRRj5drYHDc5/w/Ki4cx9QXcOiXpNlql0beOFxNDNaXqhT/ALQG7aDz0BH0NUdQ1yb+02ntr7SLvZGwkkYqjSpjo+Gzn3XP0r5rOwLt2LjuMCkKR4J2Jx64ouHMe86vqulpZRLbTw2j+bujiE6vCjdyrD5k/EYqz4h1W3vrPT7hL5TNFhHB1BUKerdTz39DXz4AgONqj1OKaFQfwJn6Ci4cx7jcakbezeWbU1v54wUM32tNzL2VhnJ/DNWNGjS5t4pLDUdJDqDmO4vBG7A/w5Y4Iz7g14NiPP3V/wC+aAseOUQ/gKLhzH0Rqur2M+lPaXk/kSQKQyExSBuPuhkb9cGvM9aniglUwXsku4f6ieYSRyL6Ecjv7VwmxAPuJ+AFIAADtAAI5I4ouJu5swzzRXX7lZ7XzCSggnCgN7MOg9jW5ax3c6R7YLyW+HEUiHzvN+oGc/ga4vPGO3p2NWWvp3gMe8AEAFkG1iAMBcjsPSi4jpL+11XZb30kcwnQ/K32V9x/2XIBGPrVlIRqcES3Wn3U19JkQxQ2To7cHKxgD5gMHoOOuKs+Efiv4t8L288GnXsE0E7bnivIFlXO0LxnkYAHGce1b9h8dfFcWsQX040uRopAyhLFI2CZ+ePcOQrgc9cEAjpRcDjIvD2qp5qf8Iz4iNu2MKLaYEeufk5qC68PawfMlutE1SytwAu1rCbAzwOSvUmvrTR/2jPBF5YRS6g2o6ddHiS3e0eXYe+HjBBHXB68cgdK8i+Lfx4uPEeqWlv4es0j0Oyn80pfLn7cwUgGRAeEBJIXJJIVjggAJMR48miapL5bPo+oJb5KBjauAcdQOOW9hWjHp7W2k389xFqdtYyYZC1u5JAIDFQRjgkZJPH1q5eePry4sI/9DRL0XKzyXMcsiKTtKhQm7AIAUhuTxzXO6pr2panbvDfXLyQnaNgYqoKknIQHbnnnjtnrzTHodjbeSbmcxalPbwz2ygIJA7kgZOCDkHFM1W71LVEhsRZC5tZgNvlK8j7ezFVBPv2rz0iNmLAKp44POT3Oe1WLG4v7BPtdhNc2yLIq+dCxUBwCVGR3wSR+NAXN+Rbawlew00zXEj4WW7aMs0YxnEajp78HoaybjTLiO5EQsr5cD5PMt3BbgkYG3PIFaug+NNR0zUBdssdy4jMQbaFdU27NqtjCjbkcDv6817FpvxKt/EVm7yWv2vUbKOSS5vplWNhFlW3kZGAAu3IyeMAc0DSTPD08P6vMsco06+XfnJNu+FA69ug4FW4vDWrzMEa0CFSQoePb06kk8ADIzn1Ga+q9WuZta06K9S5nVrgRQxvJEZI7dpHG/AXB4TOG/vYJ6VQ+JWgTyaLp9vHG9vcwyMk00jqonTG5Y1UElmbuByeSSeoYcp886ZpNzb6ZdR3uqJHEzDP2ZzJK5xnYCvPTnA7c1lWk0ttKVMUltZEnbJcRbT68KfUc85rrdXjmhNummQI1w05jG1cM0SqoKyBQCivjbx2GOeaxPFZa6t7+5c2krPdJBMu/97C4UAFUHHlqAV355bPXshMitNHubuLz4bBDG5ypJXkeuWwTnrnpRVE3EtsFtbmwgupLceXvZWZgOoBweDgjjt35zRRcCxqHg3xDbuFuNKuEb7HLfMu5CUhiXdKXwx8tkGMo+HBZRtyQDC1g0HhaO9uFRpUl8kxkD/VuQylj6fe57biOK9d/sz4jRW2oyadoWiKniLyxfrbwNIdQe8jdhMWkzs8sl84ZI0Y8KwNc54y03UvDfgzRdansZrG4ubh0jt7tMuoAIdJUPI3hgwzgnByFO3MxY0jyJgyPtIIYHof880mTg5wSe9aVvpVxcXv2byWULN5byL8yovBPfnAOR7U240x4JJt8crRK+1JEGAVyTuwfYdKokziOw578VJbxNJcRIqsxdgFAXJYk4AA7n2FXFsH877J5Lfa3P7tg/BDAEEkcEYwcgnhq+iPgl4Y0qfRtU8P6hpX2m9kKXkd0JvLmjIHKBudsiOvGOobcMgkUWGj53vtGvrK1+0yQE25XLyJ86xDdtG8/w5I49c1Vurae2kC3ETRsyh1yOoPcV9peDdEt7XxABLLBOLiKS11O0uVjfgMSY5McbgzK3Iwwb5Tg4HmPxn+FQssjRDM1gBLeWkZ5MKYBdMt95RnIGdwHY4ySwWPnTJI+n6UoVmjZgp2AgE+hPT+RpnBwRyPyzTiWcnAyW7CkID16fQ4pO/pT2YO6nZ8o42oTz9Pr/M10dr4PvbjVYrO2Pmh4fOdkIYxD0YA9eD+XSiwznFQnGBnjPB6D3pACRkA4BxnHevXtN+HMh8MyXskcM8dmJPNKSvh2B+RsAYz8xBOSuODiuc1bRbFkubKwsVN5YWwnuNjt5iknDAjgMFIzlc4zj3p2HZnCZIxnr1pVcg9eKRlKEqylWH3lPUU3HpSEWVn+Ucd+T61E8hYgk1GcZ/8Ar0HoAORjJNAgz09aQ/hRj8/rR/nNAB0PI6+lKGIGM8ZzjtSDvzxVvTdPn1G5EMDQoerSzSiOOMerMeBQBAHUq28c7QARxj6jvUts0olUWzHzCQFA/iOflBHQ84ODxxXt3hP4eeE7vTLFNPkuNc1uG5X+0plP+hxx43N5QYBWIUpjJPJ/ANX4UaDdT+JIZLjVUvoDH9lSNg4iLLkiQHJJUjknaPfpTsOxB4O+IdzdWbaJIsseoyFIbcPKqW0MUe53WQt95icnt1A5xz7De64i69fW9sLi7muojclsktaxsEChV5YDbkBR1JycDmvlbxB4b1rw+Ql9bSvYQhXjmKnytrtkYPYkgZAOa9X+FfxSmtrb+z2tEl1G4d0JhQCSfdgA7m+VVHG5m6AYAyc00Vc6rxToCX2iXHiGOPybvTLiWObToVCb5hgiJ5BxsUbcAZLMcnvXjmr/AGux0ic3FkkNql3byTI52rcSqvyxLjkqN3LnjPAAr3nUrLV9TsYpNZeyNjeq0y2Ec5XcwILBXwPlbjJPPGfQV49f6bJ51nPffa4be7uCoPlbhFPEN32ZU5LOA+7djbkjliDgBnNT2WlWOxfEF2w1CVfOaOGQ7YwxJAwAccc4PPIPeir8GtzWweC4u7eweNyPLniaWVx13yFeNxzzRSJPV/hyPHXiDSo9Th1K9msnS6VrUbEGbaNYooQDhf3rZG35R8jFt+OOf+Juh+KE0ZU8R6vbyx6dPGF2v5s10ssqIk7ZQEumwRM0hLHZt2gYZuk8M6FDF4TbTre7uYrvUX2NFdxMv2YNcT25Z7RlyEKo4A8ws0soUgeYCfKvGkGt6NdWFrrGv3muxawDeTwtLOI3kjmMSkLKwd2xEoDMq/LwpYAGoirFOWisFjpo0O6vYZbZ7xLgoYjAOeDxsB6FCOD2BA6ZptnqNpqvlxS6esRmW4iW6kyqQylgMKRyo3YPsWwK1PDbHVpLfVpIzJcxySXaxFj8rjgx5PT5eQcdc5r0HTfCs93eyy2Nm1/oM8fmsIW3SJvPRQPQjGOo+ZSMba0BI8Uud809mNXSdYVlWJAEzIyMDtfK4PJJAKjB24xnivoz9n3V/Dtx4PtbLUJtO/tzTr1oYZlxFO8hGEJJOSzD5fRsYPYFNZ0Cz1LQdEkjtyjWbOtuW+RJGY4ktnzgoSRkA4G4DoSKw/EPhnRb7xJCkqTpc3kMoGoSJgQzEYjZscg5/iHIPNFrisdlpWr6VN8Xzb6glmdYvLcyQ3DptEigKvlkHBBKgeuGTpzzl+N/iLYWvhzUNH8Q2lrJvmlSzhmkLMixzFPnZTwR/Cyk8Yz7+VeK/DV/e6cttczv9pthGbkT4XaTlC+/GCGO3nGOh4ya8w1e2vNIlm0rUrN454nDIJM5QDrt5IKkenHFDB6Frxn4bttH1m9j0fUo9V06Kfy1n6ScgkBh0JwOSPxArmcjGf1qWJ/Jk3qiMByVYZVh1II9OKWaV55C0gBkbJZgMbiSSSffmpEQt8qhlIyBnjPyn/PpX0V8P/B1vF4OTVDdKY5olSeBshwgIIV9x4BOCNo59ea8E0KOOTW7BHDOpmU4QZPXPTv05r2j4mXWn2NtJLpyRiNbZI4zG7oA55yp7MD26+tNDj3PpTTbHQLvT5YrZYjLd2/2mRlQkFcbcFT2HA2n0/GvmvxBYwrdSJbFbmxdghdU3OUPydCOW3Dnpnp1FZ3wk8X3114tezvr9La2u7dkkYSiJpH9S54Oe4PB+tV9fs30i4k1e0unmt4lk8mIuJWfBOTIONqjcCMjHp60w8zzfW9Insp7hikjRrIRuMLL2z3z0zg88VlKpb7oJwCx4rbfxNqrsxkuvOz2mUMAM5rPsQruoSb7O6KzsckK20ZAGO5PGOlIRAltcMiMkMjCQhV2qTuPYY/OrEuk30UUcklnMqvuABUg5HXI/WuksPFSW06me2KPGyhjEN24BcEAEjHOOfSmavrya69ul7dLZ26MzZWLMeT91iPvP3BwPf6FgOSjieWeOKONnlchFUdWJ6YrqdE8EX2onMk9taYY7mnzsVQDlmbtggjb1P05rpfDOhQ6Bc21zLPHNcx7ZnDxh1MWBuO0kMo+b1G4DNd74L02z1CS7nm+yXENq6QGykYqrswyZFI5yFIznIIHHrQkNLueZR/C3V5oLyaKeFoYGCLIEO2TPcY5P0xnuQK4nULB7G7aG5CMVY7WGcOB/EO+D/npX2Brviq3n8P6ZpOkXAs9Ejtm+2QwRlLnYoKhQT8uWfjAyepJr59+Iuh301nDqk1uY/K/cRwW2JoYY8b8PMMKX65A6YAwKLA0aXwy8U6OC1vqkJhaGKRobVGxBI5Hy8HOAoySTzxnNekWgS+sLddJtpY9H1b/AEeS4kkEAmG0jdKADvUZzn6AcnNfNui6Rfa1eCz023aeZxjaDtHPQZPHPQV9C+EtA8S6NBbNdzWphsI1ilBcJgBgDGgBIfPKluuQcUIaZ0eqaCfGPw11G/129M0OlAQbJcxRlIVHzLjo3OcdScKSK+ao7mbw3qNnd6W80dwse+G4YEBiGP7zYw6Y6Kemc9a+qda8XeGNL8D3q3k0cmo3Mk4jfyWETndgmMcDYq4HpkdT1PzT4U0WDxd8R9P0u6uLiLSr28lWOSEgEJhnxHuGBkqB90nngE8EYmdz4V+I0TaZYpqNvDc6jATb2ImfKQM7BpJsH+LG47jzk8DgVH4inlvdTie0lnsoBsKttDNbF22opPCgty2CeM8gmo9O+G+lLrWqWgub67iju7K0lW3YCTTopofOkubgvEp8qNh5bArCeG3bDha7TwZ4f0vUPB2j6xez3lzFqUtpGtr9mP2eTfPHayK8jJtOZWfCZDiLkfMNwLi5jiYLDXbnzG8Owi009XKruh+0STHqZZJGI3O2c+mCKK7Wxu9SgFzD4asbwWUdzMrSJBEwlk8xtzDI4A4UKMgBQO1FMuyMf44adJ/wjFlrhWK0uTNJBOVXalwShViD90sVU7l7gZ5Irx3SLWdYTd6baSTMk0UbLtGw7uY8t0ViUYKe54Hofo/x9q1zpkWi2zFf7LlnIvb+0thcuQ8s7Wsm0EsoWf5lyvzPGfvY2nkh4smutE8cXFhoN1a+HtSv7iOKcv5YtzKkMTeZCBy6+WhTB2o8gViCwBlyJa1sS+FdBvrW9giikiuNI1ULNCrkK0oZh50LD+EoSMjOQSCOM4+iPDGi2mk2MGnadDAI1mZ5fJJBVzyHZe27YAy5xnBFfP3hK2uNW1QTWTPF9r/eXULr5iQyDrIijkL345AYg/d4908FyahDeayt+vmNCqs7oB5oLDOFHXIC8g9eCpOTVDlsU/GuyS41nTo0D/bYFaQMTgOBjHvwAQw5BGPTHm0l7/ar3llqGpNFqDpG9nMF2g/KciRRxvBXIYDkduteiahrejTyWkZvUN75+FuUUqWZTkhu+B94HnoR651fHvhG38R6IJbVVhvtyyrJAVUysCCCH7NkAq3rweCaL20Enbc8Rhmlvp1M2oW13ashgMT7fIidjh0LYPysduAcYBGCDitrTtA0C4gf+2obZ7ixXZLC7NlFGQWyDkZXHPIx24zUGteH59S1SWOMf6RFB5lwrwhItQjb5T5qjhWDcEg4PXA5rd0jw/eQRWd3qtnNfIkP7smMvJZ8YGCvBUc/MOcZDAUF6HnWqfC3wrdTX8ejvfW8cbqqhtrS2743FAA2H+XDD1BI4NYHib4SRaXpX21b9YPMQxxjBKzOTlGUdQjDI9iCD619Da54MNjfWmueFhuZI1d7aM480E5DRtnBZeoDZyOMiqvh/SW1C8uLu7u5764VGaexb5hHI3doG+aMjqCORk9RzQrE6WPj6ax1Xw3dg31r9mlVcKZAu0HOeT/Loa6bxpqDyQafJM7RxXCqZWl4R8ZzkAn5ueMYPua+gr+/0GHU0jaA6dq0DiO5h2/f3YwHjIZZFzg5HTPQda8l+JNjaS6ot7p+mC2w/lTTafGShXB3N5Iyp56kY4PtQK2hxXhjTWgguNQZZCLTJI2fcZGJKjruGDncACM12XhTTdDuNHtovEwuY7i5ZWMkhzHFGRncHX5hhht2kEc8mqvgzwxfTWEty2pR/Z7ePK75GiiQM2Dg4JXcMNkgrjPIr1G38Cw6dOyWduyssKTQ3wmeKK0ulYnYHBYYYEnJBHPSgEjwfxn4Q/s+KHUdK2yWtzEzmADc0WDggdyABnJxXEswZwUQKo4ABJH619DkRQ3tyJCq2pyzTT4eORlbgO33iDnG5QAe2K8l8Q+FJ40OoaY0FxaT+dMYozh7dVblWB578ewpDkrHIZ2qQDheM+lW9IiiudRt45JYEjJyzSqWTAGcEDBP0BFaNrpIt5x/bMpsVwJFyf3mMj94oAIZRzW3HcPI9nfaOt21zGHiaIxoZJvmDM/TgY6sM46YosSen6foukX/AIgtNJsp7mGykSKzm3fPE5IwTn+84yBzxxnjiuq8X+BdE0mCGK80lRaQyFFhimP7+NBnzJmHzIOB8qjJwOag1fUE0640jUdE0+OO6jY20dtdIB8hAMnlE5IwN3zNjkitC31f+1dS02KDTJrVn5vIDK3zrjdxnhWZduSeSM4NUWNbwjaalo07z3Vz5mlujWcMMCqAGTbGm45OFBK4bg9eetcLrthJrmkXWj+Y3mpKsk9pPKAECH/lmqfePbCk4zzzmvap9R0nSo9fmj8jTvMeJhBM2YppFA3AnpyAASD8o5xXnGmuln4huBFqlrvQCZRZRbo/OcE+VCxAICrnk9RngmgE7mL4I8G2Hh3wvaXGo5jv7m726jOJpA0SIzEQxIAOSMZYsCM/hXtV9daLb2cF7BFHaW8MRjgS6TAST5dqli2MkDHcjsD0rzPRGsLnxLcS6zJrt6k0PlxxxQIpbLAKMHlQpzhjjk+uK7rw74NuV8lYEitLG03JaTXRZ5Ic/eMQbqcZG8geo44pbCaOe8XXWi6jpmo3upxAXUsqW9wyLubzeNkaB+dq5BwQBnnBxXkPjbwrJdwWsVtBbxpFsxtUqjoc5fJ+Z++GOATyBivraDw54aWGK6WGHau4+YJASzMfmJZT8xOMdfavIvF9hF/wltpZILS3tZ9TjinkMp3rHMdrQrknE2AACMbQTjGMkvcV0z50n0ay03WrSG7WSS0nfzIoMZmKEEpu7FS38vrXX+GtXnjktgbq5iv7QeYPIVZPLZQdwjHTe+45b+H+9kDHmou7rVJ7JDJLLIqRopYgvkDt9T0z6V1XgiQ/2nd3cun3l27yLlNwES56GRj8xx3XgUhI72C60y/82WbTNTuW8x/lXUEtVhySxQBjl+SWMh+8zMaK5S+vG03ULuCKKSZzKXlc2gmyx5+8ecY28cfSincrmR2niXWLjwdqvhW21qa+k0bT0mgWCzkUNPnzMTiQ4IlXzT/ECoO5GBJJ4K78dX+oQeIYJrWGKK/vri8LKGY263E8cskW4EDYzwwjft3DbwQCRXUeOpIPsF5p7mGext5vPtWkk8xUIJDIkn8SH+6eVzwTgiuQ8NWwntYw7xLC7SloXf50J4ILjkLwD36n0NLlQnues/B3TpPtN9ft51tq9qGuF8s/N5jBv3mOkq44YDBI5+vtev3iWdpB4p0q5R7qO0C3NvHgi4hHX5Qc5UtkEdOnIOK5D4eR5i23Fq8lykFvvmtsCWLb9yXj/WLkBWKjPHIIPE3xJsbq5+0rpgktZbZleS3SH5ZgwP3W/hycdM8r6ZFNK43vY84vdUXWvEFjObiOFLhiLeRk8tXdOQZGHCkqcAkfiRXpHw88T29vc3FnqUl8UVvLt4nOTDnh1znlNwBDA4B9OKyvCHw0WV5Ibl7kafdRJcwSzMJEyT88DA8hlOSGBGPfBqp480GTw1DZW9vNdC4tZv8ARTaKQTEw53ZzkjrnpkfhRux3T0O7fS1TxQ17pcrv5kJka337LjDk7mRm+9zzjJB/KuevtSfw7rEyQ6ibd/MdxbyEAS7ucqnT5sHK9yARzWT4en1mJNM1JRLdmRHiXyfkgkfdjmFiCjHAJKEYPzAYNdZ4q1XSLlUm1C0Z0iQwX6JAWmjLYwTgZHOTkgigQzwzr+s/YvsqyacdjfuYgfKCI3KDDDOOdoYEjIA46V1M9m87WOqSQg38LKq3SxDzpIzktEduDtPtkDGSOprwzXIzp9yLjTLn7XaWkbvaTXOwMkZIBEbbsjHGc/KccYPXX8C+PZNP1K3g1/UZ3ijDvJHfZjaLONj5I5I5X6HvQwa7HdfEXSrC4iku7mzaa8jXNo8kpSRWJ5XeOqjIyrcrzjtjhfAnifTdH1uXTddLPC4LRPcxRsVyTuDYI5zjBGM+lWPiF4/ivdFu43SwunUOILi1vFIOOQZAAQMd1YA+leS6W1tLfTS3CzEpP++e5ia5Vg43NlR0UHHA5HBFAltY9U16bQrDXnaC2Mek3U+x450DiZZAQyAZI2Z+bnBGDgc10up6b4je3KWmuWN1ZwIAEy0LuN2Au4ZL+mCV5x65ri9ISaTT1tmtUudNkJezupMCJickgscEHrtLYPY11Hh19Ltp7ZgsOjXEuYmtYGZmMgGQ6gN8hx2HHagpmJfeEncxiQrcXkpEaxwAxyTKCC5f3HTYMEirMnhny7/UGuEe10y2VPLWaMTyRtsO7C8Asem0ZJHvg11Gs+HHvp2ntL6aW9uSAnlzheiEDcuQN2fm9cim3vh67klQS65ftb2sSEMxP72ccZbJO4A+vT6GmK55re6dY/atKk1TSNLuYyJJJLiOFUS5OCykIWKrFtG4nsVx1q/f+Hr27vbMafo6peTxb/36xbJMD5Cg2jjAHJJ6jOa7GbRtahsPKv7axvpzK8jXE0AW3lQ8CLI5hQcHIJ3AYxzmta61HxJeam66WmnyQW9v/pCNtATjlYjjcP16DvSC/Y5yWXQNO0k6Vrfh3ULMSKJyG2iR2BP712HIG4HB68dMVXc2i6lciKaSZr+Pzo2gkDW0e1PvzHnk42gDPTH02fF/h6dTHdme4tH+yPEjAPOrIRgLJK5J3ZPA6cHNeYaXeyTX4u77UwllErwLaRIBM+0Y+TgqoB/iI6dDTGjc1WzvbrT7eGfUYIksUV0aKfzRM5HzEs+AuT+I6ZFYskUIt1gt7We6k0nzbuDkOquwGT5i4L5GRt5OBx1qlpt419MI/D2mv/a8U2IpChkd43YguQRtOOgzgHPHrVDX7PxfoSX+gnVUSJ0DzQWKgBUZj8nmL/y0OOVGABgnrSC5Z8IeJUj8V3hbWbyC1CeYl75O+WaTAJwCdqIuSo64I9a9d8J69ca/otxa2U+m2mnwzeVLI84lmuXzllwQMkn19e4rjfBPwbi8RabYXuqX01nbkZa2thvnuAGOwvI3G1O2FIJ5z0FeseHtG0Xw1pKWVtZafY+dJ+6WFfNnl9ZGcnOT1LE8dcjpQS2V9O0S6mguY47ny9R3sUuMoygdAoQcEKOBwBwT04PCeL44NBuNGh1G/S+1W2vorphZ2yzzwbHDF3+6X3kYdQQ2TlMYKt6heafZTqZLHUhbwxRgj7MN2Ru+YFgcnJ7fz5rzvxRpOnafrdrqs9xcnTb5StzIyts+VeAABnk5JOcHG3jNDVxLXc+bf7Om1q+ktPDukPaaLpcbszyFTIAMZllmwQ0mVBIXhQCqj7xPfeFI4rLw3aatrV+Z7KecywLhoxvxtluACAxLYVc45OM4GBXWeKtDa6t5I9Bl1RrK7iQIi/e4JwCFARE5/wBXkcAk8GsOytZ4PhvZWUtnaS3VuxWJGcETNHJgyMB+8dQNy9UClvl+YKwLdR25VoVtKin062aOKyhuDJI8rkSsNpZiQp4PIXbnk85ora1fxaLvWr660+1kit5TEPs8CxvHbMkEcbRK3AYKyHBXj6HIBUe1l/KzP2sv5GeYa1dPNcSQSSQT2l0ZGLJ8q43nLY9sjI4I/lycL3enahHeWaS20kOVDOdwDKdrKx7rz37HvXXyWcD3clyqyG2kna4hm3lWjYkhlY/xccgnDdRzWBrmnzWDTTyPMrqQm6NBsmB4zxwDjGQQAw5HcVZR9CfBPxTY6jpsmm3d5HaaoqLPazRKVkgkxsZcchkyBwOCOSO46rxj4wvfDsjx+I7cgSRKbS7hI2OxyHjc5wUJxjup/MfKfhrxBc6FqFvLbtsltmBTblkkU4+Ujrg+o5HGORz2Xi/4oT+I9B/sy4hSW3nfbLDO42q4PUjqCOCHAGec45FIq59HeDvGP9oWk+5IbaMhlIuBlA4xgtg4AOeTx2JHUmDxR4utJkspxMktqhkS4gkXbPChXazo/wDy0CnBIXt7ivmTwpq8i3UVhDf3lpM3yRQiYeVuAxlJBjbx0zx82OOldfqu+K4t9L16KW3KTJcJqRQAoM7d00S8SL2Lpzz81PzHZbmjdXktpdTG4V7+ESBpLW0cq0hz8joFOxjna2R9MDNdr4Ta+ZhdXE9t9r1C3ZbK6ViJ2wSfLkjcjpnGBgjpzXDLoLxJdXmh3mnMI8G4tI+oTHEsXQuCMZ7jHIrqNB8b2Mnhv7LqVvcQ6la8xzTRCTc3QkN6sPzyOtNDY8+GZpdW0621WwubZpkaCIx7AHYEsU2MoBGAeO4qu2leLtBvr1NKFncpFF5f2W8ty0ciAZA8tiSB2+Vsda6jR/FGm+JtDt2tZbpL6PLSWGpSGMyqGzuzjh1xkMADxXP2vjoxGb7SDqcSyYJ1IK5VfVHXB4GeQOaQtWeNeKzpV/PvGi6fpty6+ZNbiQjaTxlOuADkgZ6V3nw717R4obuSO9F48qfZ/JvmZHMwA2lZUHHb7wIPrzXN+LpdP8Taio0e2+wXcZ3eYknmBkJG1owRyfvDqOfwqx4N0Wygiih+woYhMP3k2E82ZSCEckgB+MjoCenpQC3PQ9S8RzJpjjXrD+zrkhYxcQ4McjE4xIoODnHcAd8ZqK71bTrYiTTi9/OwFzPcrOsscCk4Cxhhz9FwO+RyKp6reafJ4jnk1nTb6Q7cqFYH5gciQAgZHYqfrmjwvHpcGnSpcaDcjURMZoGjiEVuFHO1iclV7k89jxQM72w1GxHhnT75b5okcsJUaDcZUYkEKwwBICF5PI5rOj8daYJpY3uo7aOcgrdwt8x2AkBg3Rv72Bk85rhL9b+PTZZ7RpriKdypt7edSqrn7qYJD5554/Gjw/pMeoz3L3ultqKR5kaOTKeXsXON2MRntu4P060wsd5a+IpdcE11d6nYRaIsojcxSSPJO5A+Vo9ysTyMLjA7ZxUN38QdJ8PMunW8twbuBWZ9samYHJ2gluSvTI4OPWvOW0fWblL250y1kjsJ4/8ASfMbZKiq3Bz/AB4AAB54/Kq+l2NrDeQ3V/ZSXUDLj7VNdmJt3oXVS/vjgHFArHceHvGb69pf9n38DW7GJhay3UzuFbnqNxIH1ycenSuK1CK2bVgmoXKpa2kkUbxQqGikIHVY1I2uVYndn65PFdZ9i8J2NrHd2bWpeKJlmR/nV2PJaIBTuOe/euTvrW5sbyAz2jG1HzEhVEUxY5DZUclfTj0pDNDwPCLgRX2pvqFzpUshtxp9tIYriOZHZVbaPmYkY6dsmur1z4eQweIP7ZvbmRtKs0YOgjwkhbAEe44zggfPwecVi6R4Q124MkrPZKt1MLlTGjSyRocY3u+PLJ5IwCeuK3PFV9ea5fx2lvZTNfRTrFFdfaAIYgoyTGDwW/22PsKLCPSPDF+B4bW/1GYT+d8sVvAAUj4wY9yklx8vU8dqWTR38RIb+O1sdO1FWb7PJIyzEPtxuMa/KDjsS3uK8/8AserW+qva+JXuf7DuAoF4kpKuQAAh2872LHkckDtW7psi6XcLZaPY3OqzuBBIiso8qM5yUbOFXJ55OOnJp2E12LVl4Qv30+x07U9QvdXeG4kmkvGujHG6EY5CYHOSAnoM5FUfGOjQ+KLG60yIqLQ8bTI4wVOAGbsMgYQckd8dWa1r+tXE02n6dFBp1pp4VftBkYfOcjy89AoHpyenHWrnhLzbS2fT9RtLq9jjAWEykJGAf4s8szHOSegGBQGph+FdYhvPDGo6dG99BFFL/Z73iKEii24BWJjyxDfwoOSeT3rj/FV7Fpt1fXGhW76lptpOhc3cQkVbgLtyr9XOOdmSm7LbSeab45tLe28R/uoTd7ZPNisLBmETyKMB5QcqFGeM4HXqax9T1ZteMWlXRj0y3VQRCZAEWQ5JIQYy2AT5jH2C0thmPPoV/fSGVnsLfAACzvHuORnPJzjJPUDp0xRW4hgRpIdM8OyTW8LmMTzB5GmI/wCWmQy4B64wfck0UaBy+RyGppcwakL3RIo2t2uHElsmV3ncc4B6D1U9D+tqGzuNS0eJLe4aK8jU4gkiX97HzhWXofw7jjB6S6k4stUntrm4aNr6WQxXCJmOJlYjEq9gRxuXpwak8LySNqs0d5eW1xawA4tZyMOjdTuzxz0OeDyCvIoEjy/VYGimR3ieIMu3YzFgrKcMFPXA9DyKdbzwXb+XqdxJEcYS5A37T23jqw9+tdn8QdKjljjubawuBeSyMFdOWYAZ2yg9WA6Ecn/aBFecZ5Az16UmK1iVXKxmM4aMnO3sT2PtXSaP4subWzbTb2K0v9OmbL/bUaR4s8MUbOV9/XFcru9CcfSl3Y6kfjSuB7tpk2kyaZY3+j6jbb4g0Zs2XzY2HaIq3IJxkEHAP92uXF3PaFbSXTnZbmUOjrL5ap1yu5skEdMMO5HNcXoHiG+0Zn+zSRmJwQySRJIP++WGGHqD+GDzXfab4t8M+Ir5YPFBm0VNmyK5t4/tEW7gAspyyjvgHjpnFO473LeuahpvnRw6IRbtGyyzWayfKzZ+YjGdo74XHI+oqnrE66oUjsvttqcfMVYvuJI+YsvcH6+hFa+ofDUzie5sr/T9ZmZVkgudJmAlwPRON2O4HzVw2pWevaXdTQSg3EKhd7Mm9kVuqsnyluOxGR26Uwdy5a+GdakcyYls7dbhUiuJAbiKRy3Cu6/dGeeRxnsK9f8ADmj6/oMF0b3SUtpJsr9l1DbPHcADhkOSn4Eg/SuU8CfFG30K3aC50+e1RkVTcB8qw6YcnPHpuBHbIrpG8VXHiW7toLq9itIIJC0VsX8mJ/7rBskZIJGcFfpQNeRT0yfUdGNs9xBHbx5EdtbCI+XyxLAnJx6ZyQPWvUvC9tPI900um3NvFMu4FrZEa22ngB8tkdwQAB6Vw9xa7raSGW7vEF0D5KXtsAyc9Ek7rkYyCcj0re8OyyhG01bFrgsRFc+ZcbfIYjgxl2AcEcgDPpTG9jUuY4msXthZHS7fzvNEhI3RqeT8gBG4nJ6kHPFJqaeRBCdJvZZbGNi85jBUXStjcmUyAfUP17Y5qtNor2FmxvtXvtJhIaDy7JCySP1RwDkkYzkdj045rOs31W1Vv7OgAl2g/aZG2AL3Z4cqWz3HfOc0CHeLBf6Bol9JJotxdwSPve8G7ESYG0EpjJzgcL9TXkpkla7gaASTxyyF2hnTBhcn7w7ZXJUADOO9e16IJb3Sb23isVltLhN7aYznypTnko+eBxnaMciuf8PeC/D1/p19r8NxeafDErEW0MxiMYU4MgLE5UHjK8AjGcg4AOEN3I6SX2r3+mFoyGktIQyLweN7dAOnAqe/8VzyXoVmhlEbK1sdMPlQQSBduWRh855wORnpXoMfhvTbexsZRpEk6uRLLPPKzcdgUcAbiD1J6jpXBeJtHs9QaXT4HgW2Vwywq6o2evLrgYH/AOqkPc6rwz4quINJ0+x1eziuLZXFqXuJxsgbON0gyCTjsOh6V1lrqugpdRXGiWtlY6HbBozeTRM8skpz8kaEZLZwc+5NeEjwjrFpdwi4utOewnJmWSzcySDZgnByA2OpxkdRxmu8ttRnsrBYbRfIHJllG0uUYEl8Kfl5PQY6d6ASubmq6rJqF8um69cvY6TOhJunjXzAM5Ma4O0cdT0A6kmu3mGmDR1t7G9aRZFCsYGWSaRf4dz8IgA7YxXkPmXVvp6rbzXlzNOWCqgUFjnkF5ASq9zivR9K0wz+G0Njpu7gJLd3V3hY/wC8yLjHT8TTE0dBf6ba6kqRw3lrc3BIG6eXzBHkYGwKNu7vgA9OtczeaHqOk+LDBbS3F6ssbSM0kweWRxjBKjkAjOASAAMnkgVm2Wq2ejSXmqS28jX8Ez20UNqWZ2iRclt7EYG3JJA46ZFdnpunp4h01ZrN3FlehZ2lhlEbMucjcwBwvsMk9z3oFscR8QoV1XR4pGVLFLKNpZ7qYKXQH+GOMEIM/wB5jx6t0rwy51NXYW9pPYXIm1AXkmoXkbHYVUKq+YT8+MEhVX7xOBivWfFZ8H/Yrhf7Wa4t5pt5j3krO4PISPODnGMse3AHBrw+8zNrLpHZGCzhcxBQ4SK33cgGQ8KoHJA9QPmNJhsem6brGm6fZpFcSXskzEuzJp3nsST1dm/iPXA4AIFFYVprV9CZoYrswRRSFEUv5ZIwOcFMnPrx9KKLlc3mVNR1IXd0tqhCu7ShSdxVm3NsdCecHp1DA+o4rV05bXXdEiXXdG8jUoXCR6hap8skn9xx2Y46DOcfgczVdMtr6BrvTy1vG00zoVGfJbzD82P7ufvL+OKv6OblkYahZtN5Y3S7dyhwoHzZBwygd+GXgg8YoEvM0r6e8/sKWyEMD20kWEtLhiUVx/FDIPmj5wcHIHt0rxjxHZ3VpeKLxmmZox+9IBDeoyOCQeM19HLpejatM8N1bXlrMyqzmUbo5C2APMI4BJ4EgwDnnGcVynibwJbarpN8dKgddThzK1or4fA434J+ZT03c89Tmhg0eDc5zg5p208tzx1P8qsX9hc6e6JdRNG0gyoYEdOo9cjuKq8H1BzUkjh1xSjHJHXvzTM88E0uee49qALdpezWcgkgd1YAj7xx7fzrQbxFqt1GlvfalJPAq7V+0r5gX0IP3gfQ5rF3dfSkyQCe2e1MR12haZPdSyDQdRtbiV2JNqf3bOMejAgnrwD+VbPhyWK81WbTn054rsqY2XadqkdQADgEHnFYXgqwtLqSWSWaByuI3glDLkN0Kkck8HjFdBfWesaJZ7LmCa8s2/em5S3zb8nH3jghumeT2pjR2Xhe+N7o8lpe2+ZLVtkM8VxJHLPtJ+eIZKtJgcgdelaOh3gi1eyiskNvF5olkklgMTToRg55KsB/dGORXL+Eby8srSWLTlW3imTfHKLcK9rIvOCNx3A9Bnkda9G8JT6BrPhNbx5P9ItGL3KXowFccsBNGQR1/iHWhFpkPiu6020muZU8V3N3b3koc28EIMsTgYPl427QAOQT64zWHe/EDS9Gupp7G5m1i5mhMcb3MLo0ePmOD9w469K898ZeNmvb1vsMFkNLnUlFiUeZt6HeDnDcEjr6964W1WS4u44rYu1wzhYlVSzM2flChQSWzgAAcmi5Lkd9q/xIvrtSkQhuYJUHms8jKZTnqyrj2ratviFqln4Y/wCEo82BNYudcSGJDHlQlvbPl0HHQ3IUj7uCqgYyK82i0rWtUvxbWum6ld3coabyobWSR3IJV3CKueCCpwOCMHmqNy11bK+n3RuIfs0z7rWbcvlS8K+UP3X+UA8Z+UA9KT1Fdnu1l+0Tf2kASLw7pDOBlnVHPHbuOOce1cZ4s+Mmv+JNQjmv7eyS2ibMcEKbcDvzzknvnPtXmwYEYPSo2YepwPSgLnpUniDUtYhW4eSCO3mKruA8xoiDwqkcEcYJx7V0VzqWq3MMS6rAjahNwI0kiJVRziPAIOB1HJ5ryzw7dX2+6WyL5EYO4n5IVB5YqflYkZAzz3r0rT5YLpId1vDtZcGZnykSd/nPKjp2BPvTGmddHdanb2ELSaNO2YwuZWEIRCT02ABD9ck+1Z01/HaWHn21tDZzedkTqHdD/tPI7Yb09/pUAttOSwjumit2kjZgkk6k2cEeT+8+Y5djjjgnrxVi+1G38mO++0211fttA89W2RRqOqqQADn0wKZZqWniq51RELXMHlQxun2q6QguehwijG3J6cjgHk4qaG51KGyisLO+82zWLa9zdr+4tU74TJ3EZwFbHJ59Ko6TM2pRJOLS7VQQ8+oPFH8/91EBY+3OAPrWJ4h1mD7cti0M8dq82y3toWLO8hzmZ8fIozwCMnvQLQk8V6dpdy0F497eyLbPmA3J8vcx4BCqOAe54AHAya5690g3OjypcpbO0TrILwyOFiQA7lWEHGSTneSX7DArTmsr7MUOqQW6zr8yqwMrIAP4EIA+rPnr+FVbkTW0V4JLzytsfnAzHEcSk/xMBx7AcngAHrSEzzcTwXUs011cXBd3JUuA7Fe2Sf5UVoatotxouozWWtxzWt8AkrQ4CFFdFddykZVtrAlTyDweQaKkzujqdFv7xdUlgtnt7dpruUOHUqJGErAuD0WXH4OOCCa6+xl1Cz12+sIZk090AmixlYmbjLqCMKD/ABL0znp1rKjsdKOoXV9YTTPDFfypKjsQhzIfXIIPXnoV/Gui1W4WxvlnWJbpFTaqlzGdxHykjnb04IyrDkYwRVGq2NW31C7vY4ZbiC1mthw8cJKyQHo/lnuOc4yOOKoSxJobL/ZziSKQllllGGjYnuy/dz03YOc855rlNGupbvU45reRBbA5uI35YL2GBzkHPzDOR+VdTau8NxCthaSX9gDve3MY3oG4OxzwQDjgkejAZFAyhrXh+x13SLi9dVu7ad9xjUlZ7WTHKl1zjkHaSoHbJHFeRal4SuI5JWspVkgChkFwRG8nXIHYkfUZzkV7Hf3Etn4g+1WN3LbQvGI/LZPKliz/AASRsBkHsRwfY1zV9DpMz3cEiXyRxkeaDELu2RyOvTdGGye3B6jvQS0eO3EMttKYriJ45B1Vhj/9eaj7E4OB1PpXU+IPDsllbiePzJrHJEM8Lb1yezITlee44rlhlSQzEHGPx9PpUtEicZ6GlJ7jO09qQ5/mKUD8aBFzTLqG3uB9oW4aIkbvIcK315BB/GvefC3jG/ttNktNJujNpoi8y7hmVRKiZwWG0kHtwVyexr57HTBOV/StfQde1DQ3MmnyxLk5IkiVwfx68/WmmNOx9DXd1o76dbWNzqkUtuE862mnaOJjwSVV1yJCM8q2Pzrx/wAVa1Z7DDbP9rt5ozJBKE2FecEHaR6cZ3DvXLavqK6rcrL/AGfa2srMSy2u8I7HqQhJAP0qOG4tP7PkgniIm3b45o0Bb/dJJ4HvRcG7lWWRnYu7OznkknJJ96s6HqP9la5p2pGHzvsd1Fc+XvKb9jh9u4crnGMjpVAk556/WjjIz09qQj0Sb4oXdx490nxRcafFJc2EN1F5KSCISLM9w3JRAAV+0EE4y23J5bjzpcrGoGeBj60rDHer6aVcP4euNZBiFpDeR2Lgth/Mkjd1wMdMRtk5644oAobuevHvSFsnPQe9a39hy/2Zo1+91Zx22p3ctpG7uw8lozGGaX5eF/fKcruOM8cYq3r3hS48P38NrrF5YW0rvOrAM8hjEU7wMSFXnLxvtA6hcnFAXK+kXF3ozxzTWSCG5IVJbyFjF65B6E8+/wBK9F0S9jlUyqLTB4jdYipZug+Tg8/3iM+1cz4T1bSdJTWZbSMxxQ6ZOkZunDSX9zIvlR/uM7AqFzJjDFQnLE4BxNG1PT4w41qzkvX24ScOxkGMDbyQMY+vehMaZ6VaXd5FHNBf2dvqlzLuHlWrbzgnu2MJge/tVzSdO0rSk/s7+z4na7fzDM8yssJxhVDEkBfbknmuJh8ayyobNLWJdPjj3RWlrD5ZZhzsJTHA/Wty0vdQMTS/2XNeX0g3/M6wQWox0TJ3E+vOaoq5148ItBbQXN+4s7AFpZ5odx3N2G5zuOeygfjVa3uGZp/sE8NuVlMVvMiMTHF3YtwAfUjPpnvWPZ31/fxWGp69P/okZaCKO6MixswyAI40PI9WOc4revpNOWO1gt4ZWknbdLKn7vKjnCRdSPduBQNGVr+oz6QseS96LxdkTTRCBQex2gktxk/xe+K5zVbqO8LWlvdzecoAkCFGjGQPlRMcTbskvu4GBgEZrpdQubPULm7lkilKwKIiZZy7IxHRuNwXHbCg1g3Gm6ZBZJ/ZVudQvp8qkrSeVGXJ+Y7V5IGOnHTB9aBS1JtZ0F/E19/aetaldy6i0UUMslvF5m/y41jDOzZ3OVUFiMAnJwKK5a68+K5livb92nRtpEXmsq/7OI8KuP7o6UUJk6HoUWrtpHiPV7XUbdZrcXMxl8j93cRq0jAt5RyJYzwTjuCeDWvqLW2o2U0VjfRyiJQ8ErJhs8EowJ7+/X+8ai+IVrHPNLewRRTW++4jdLoEyJiQ8pIDkfj7c1geHr6K2m8vyfMm2eWGn/ehlHIDZwfbNMpdhtza6zoam/lt2v7UAtgYG1TyGDDOMZwc9O/emaH4zmt9WlW7jkVMj9ww34GOSSvKsPbPHTNS3moJNYyCaNzbm5WJtr4Me/jKg5zz1GQCO1c7rXh5Yba8l05YYVg2tzkE7fTup9CD7YpCemx3WqXz64IjYaqltahcqs0ZmMJ9Q45CHnIIx7d65a+sbOC6ZvtKWV6cyNKodPMHqSD2PQj1rjZr++82C4WcxlGXayMQ3+fUdD3Fas+qOwKaoZPPXMkE9ueF4Gcqeh6cqwoC9ye+tRMHea+F8s53AJMwOP8AgJAfp1Az9a4e5jVZWWNiVBOCcH/D+Vat3LJ9pmaJYVilPzoUyjn+9sOQp+hrO+zs2SSOvqetIkq4ByOQPejH8+vrVg27Ejkc0C1fbu3DAwOppAVh6mnj/wCtUptmBPIH4ml8g5OCMD1oAizjpnI7g0zGf/1dasC2Y9xjvSC3YcfL+ZoAgwcccUDqcCrJtHJ4K9M8k0NaOvOV/M0AVmwDxz9PpWrpev6lpmmahp9pLELO+2/aIpbeKYMQrKGXerFGCu43IQeevSqBgbsRj0pfIYDgigCW51K8utHstMmlD2Fi8ssEWxRsaXb5hyBubOxepOMcYp+tatf63dRXOq3ct1PHBHbLJJjIjjUKi8dcAdTyTkkk1X+zt3I64pTbt3IoArgYHOOfanRhu2c4x0FWFtWboVzwOa1bXRZIlluJWhdYiVClSQzY5zQkBW0lbd51jkMtvLn/AF8chXA9AB3P1r0qwtzCipBPJBD9+4M7K5n9BySyKPQAVleENAhFvJegYlPAZnZgDnB+TIH61b0i7ltDcTWFwbm4t8u5vIFCAj+6inHr15qkUjRkGIpdQumdcLgPbRksV7JDGTu6dW2ge9Z2l62/2xmhtXtkVMCKaTyX56BwuZH+gAHvUF14y1vVr9bQyIJpD88zuTx/shQMH86bq9xJpkMdmAolvgWkli+RyOnzP95ifwA9DQF+xc0qxjvdG1GJdtxDIrtPKLfyEXthQSOmPvMc1Hpi6bb6Sp1EzWU6ALHb2iKzuo4BeVpECKTzsQc8ZJNMaG6s2TThIsc0UKtIYmIjROoRAACSccsx/CsfxMW1K5jijYQxx8k7cn0Pf/DPc0CM2e8jgkK/bLm4Y8s1s2yNW7qvIzj1xRU9poaSwK8bARn7u/JbHvjA/D+dFFmI/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the upper and middle panel the fetal spine demonstrates severe kyphoscoliosis. The lower image shows the abdominal wall defect with ectopia cordis (HT) and the omphalocele.",
"    <div class=\"footnotes\">",
"     Liv: liver; Bow: bowel.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_10998=[""].join("\n");
var outline_f10_47_10998=null;
var title_f10_47_10999="Acute complicated cystitis and pyelonephritis";
var content_f10_47_10999=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute complicated cystitis and pyelonephritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/47/10999/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/10999/contributors\">",
"     Thomas M Hooton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/47/10999/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/10999/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/47/10999/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/10999/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/47/10999/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H91340417\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infections (UTIs) include cystitis (infection of the bladder) and pyelonephritis (infection of the kidney). Most episodes of cystitis and pyelonephritis are generally considered to be uncomplicated in otherwise healthy nonpregnant adults. A complicated urinary tract infection, whether localized to the lower or upper tract, is associated with an underlying condition that increases the risk of failing therapy, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetes",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      History of acute pyelonephritis in the past year",
"     </li>",
"     <li>",
"      Symptoms for seven or more days before seeking care",
"     </li>",
"     <li>",
"      Broad-spectrum antimicrobial resistant uropathogen",
"     </li>",
"     <li>",
"      Hospital acquired infection",
"     </li>",
"     <li>",
"      Renal failure",
"     </li>",
"     <li>",
"      Urinary tract obstruction",
"     </li>",
"     <li>",
"      Presence of an indwelling urethral catheter, stent, nephrostomy tube or urinary diversion",
"     </li>",
"     <li>",
"      Recent urinary tract instrumentation",
"     </li>",
"     <li>",
"      Functional or anatomic abnormality of the urinary tract",
"     </li>",
"     <li>",
"      History of urinary tract infection in childhood",
"     </li>",
"     <li>",
"      Renal transplantation",
"     </li>",
"     <li>",
"      Immunosuppression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute complicated pyelonephritis is progression of upper urinary tract infection to emphysematous pyelonephritis, renal corticomedullary abscess, perinephric abscess, or papillary necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34278?source=see_link\">",
"     \"Emphysematous urinary tract infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=see_link\">",
"     \"Renal and perinephric abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to acute complicated cystitis and pyelonephritis will be reviewed here. Issues related to acute uncomplicated cystitis and pyelonephritis in women are discussed separately, as are issues related to UTIs in pregnant women, in men, and in the setting of indwelling urethral catheters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=see_link\">",
"     \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15479?source=see_link\">",
"     \"Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12415021\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microbial spectrum of uncomplicated cystitis and pyelonephritis consists mainly of Escherichia coli (75 to 95 percent), with occasional other species of Enterobacteriaceae, such as Proteus mirabilis and Klebsiella pneumoniae, and Staphylococcus saprophyticus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The microbial spectrum of complicated UTI is broader and includes the above organisms as well as Pseudomonas, Serratia, and Providencia species, in addition to enterococci, staphylococci, and fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, organisms causing complicated cystitis are more likely to be resistant to commonly used oral antimicrobials recommended for uncomplicated cystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/5\">",
"     5",
"    </a>",
"    ]. Colonization and infection with antibiotic-resistant organisms develop because of the selective pressure exerted by exposure to antimicrobials or by contact transfer of resistant organisms between patients because of poor infection control practices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12414267\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of acute complicated cystitis may consist of dysuria, frequency, urgency, suprapubic pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/6\">",
"     6",
"    </a>",
"    ]. Symptoms and signs of cystitis can be subtle in the very young and very old. Cystitis is considered complicated in the circumstances outlined above. (See",
"    <a class=\"local\" href=\"#H91340417\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinical manifestations of acute complicated pyelonephritis consist of the above symptoms (symptoms of cystitis may or may not be present) together with fever (&gt;38&ordm;C), chills, flank pain, costovertebral angle tenderness, and",
"    <span class=\"nowrap\">",
"     nausea/vomiting",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/7\">",
"     7",
"    </a>",
"    ]. In some cases, the presentation may mimic pelvic inflammatory disease. Patients with acute complicated pyelonephritis may present with sepsis, multiple organ system dysfunction, shock,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute renal failure. In some cases, complicated pyelonephritis may be associated with weeks to months of insidious, nonspecific signs and symptoms such as malaise, fatigue, nausea, or abdominal pain.",
"   </p>",
"   <p>",
"    Acute complicated pyelonephritis is progression of upper urinary tract infection to renal corticomedullary abscess, perinephric abscess, emphysematous pyelonephritis, or papillary necrosis. Risk factors for progression to complicated pyelonephritis include urinary tract obstruction, urologic dysfunction, antibiotic resistant pathogen(s), and diabetes (particularly for emphysematous pyelonephritis and papillary necrosis). (See",
"    <a class=\"local\" href=\"#H91340417\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=see_link\">",
"     \"Renal and perinephric abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34278?source=see_link\">",
"     \"Emphysematous urinary tract infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic pyelonephritis is an uncommon cause of chronic tubulointerstitial disease due to recurrent infection, such as infection in association with a chronically obstructing kidney stone (possibly producing xanthogranulomatous pyelonephritis) or vesicoureteral reflux. Affected patients can present with weeks to months of insidious symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link\">",
"     \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16804?source=see_link\">",
"     \"Xanthogranulomatous pyelonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12414281\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of complicated cystitis or pyelonephritis begins with assessment of the clinical history, guided by the clinical manifestations above. Physical examination should include assessment for fever, costovertebral angle tenderness, and abdominal examination. A pelvic examination is indicated if factors suggesting vaginitis or urethritis are present. Pregnancy testing is also appropriate.",
"   </p>",
"   <p>",
"    Patients with acute cystitis or pyelonephritis who have persistent symptoms after 48 to 72 hours of appropriate antimicrobial therapy or recurrent symptoms within a few weeks of treatment should have evaluation for complicated infection as discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2922567\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory diagnostic tools consist of urinalysis (either by microscopy or by dipstick) and urine culture with susceptibility data [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/8\">",
"     8",
"    </a>",
"    ]. Pyuria is present in almost all patients with complicated UTI; its absence suggests an alternative diagnosis. White cell casts suggest a renal origin for pyuria. However, pyuria and bacteriuria may be absent if the infection does not communicate with the collecting system or if the collecting system is obstructed.",
"   </p>",
"   <p>",
"    Urine cultures with susceptibility testing should be obtained prior to therapy to evaluate for antimicrobial resistance. Urine Gram stain may be helpful for guiding the choice of empiric therapy pending culture results, particularly in the setting of enterococcal UTI.",
"   </p>",
"   <p>",
"    Issues related to interpretation of urine culture colony counts are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24214?source=see_link&amp;anchor=H3#H3\">",
"     \"Urine sampling and culture in the diagnosis of urinary tract infection in adults\", section on 'Definition of a positive culture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2922574\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent clinical symptoms after 48 to 72 hours of appropriate antibiotic therapy for acute uncomplicated urinary tract infection should undergo radiologic evaluation of the upper urinary tract. In addition, radiologic evaluation is warranted for patients with pyelonephritis who also have symptoms of renal colic or history of renal stones, diabetes, infection with a particularly virulent organism, history of prior urologic surgery, immunosuppression, repeated episodes of pyelonephritis, or urosepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomography (CT) scan and ultrasonography are useful modalities to evaluate for the presence of an underlying anatomic abnormality, to detect a process that may delay response to therapy (such as calculus, papillary necrosis, or obstruction), or to diagnose a complication of infection such as a renal or perinephric abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT scanning is generally the study of choice to detect complicated urinary tract infection; it is more sensitive than excretory urography or renal ultrasound for detecting renal abnormalities caused by infection and in delineating the extent of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. CT without contrast has become the standard radiographic study for demonstrating calculi, gas-forming infections, hemorrhage, obstruction, and abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/14\">",
"     14",
"    </a>",
"    ]. Contrast is needed to demonstrate alterations in renal perfusion. CT findings may include localized hypodense lesions due to ischemia induced by marked neutrophilic infiltration and edema (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62046 graphicRef69393 graphicRef51244 \" href=\"UTD.htm?5/51/5944\">",
"     image 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/13,15\">",
"     13,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal ultrasound is appropriate in patients for whom exposure to contrast or radiation is undesirable [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/11\">",
"     11",
"    </a>",
"    ]. Magnetic resonance imaging is not advantageous over CT except when avoidance of contrast dye or ionizing radiation is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resolution of radiographic hypodensities may lag behind clinical improvement by up to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/13,15,17\">",
"     13,15,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12414288\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric antimicrobial therapy should be initiated promptly, taking into account previous antimicrobial use and results of recent urine cultures, with subsequent adjustment guided by antimicrobial susceptibility data. Anatomic abnormalities demonstrated by radiography should be addressed with the involvement of urologic expertise when necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2922187\">",
"    <span class=\"h2\">",
"     Cystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with complicated cystitis who can tolerate oral therapy may be treated with an oral fluoroquinolone such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg orally twice daily or 1000 mg extended release once daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (750 mg orally once daily) for 5 to 14 days. Short regimens are appropriate in patients with mild to moderate symptoms and rapid clinical response. Although resistance is increasing, the fluoroquinolones provide a broad spectrum of antimicrobial activity against most pathogens (including Pseudomonas aeruginosa), and achieve high levels in the urinary tract. Studies of complicated UTI have shown that the fluoroquinolones are comparable or superior to other broad spectrum antibiotics, including parenteral regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the newer fluoroquinolone",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    attains lower urinary levels than other fluoroquinolones and is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for the treatment of complicated cystitis.",
"   </p>",
"   <p>",
"    The choice of an empiric regimen also depends on previous antimicrobial use and results of any recent urine cultures.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     Nitrofurantoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6724?source=see_link\">",
"     fosfomycin",
"    </a>",
"    and oral beta-lactams are poor choices for empiric oral therapy in complicated cystitis because of the high prevalence of resistance to these agents among causative uropathogens. Use of these agents is acceptable if the isolate is known to be susceptible. In the setting of diagnostic uncertainty regarding cystitis versus early pyelonephritis, use of trimethoprim-sulfamethoxazole is acceptable, though use of nitrofurantoin, fosfomycin and oral beta-lactams should be avoided.",
"   </p>",
"   <p>",
"    Parenteral therapy may be warranted for treatment of patients who cannot tolerate oral therapy as outlined above or for patients with infection that is suspected to be due to resistant organisms. Parenteral regimens that may be administered once daily include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 g), a carbapenem, or an aminoglycoside (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/19\">",
"     19",
"    </a>",
"    ]. Monitoring of aminoglycoside levels is warranted in the setting of unstable renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=see_link&amp;anchor=H22#H22\">",
"     \"Aminoglycosides\", section on 'Monitoring serum aminoglycoside concentrations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of gram-positive cocci is suggestive of enterococci and requires treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    (1 g every six hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (500 mg orally every eight hours). Issues related to management of infection due to Enterococcus are discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of enterococcal infections\", section on 'Urinary tract infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After clinical improvement is observed, parenteral therapy can be switched to oral therapy, guided by antimicrobial susceptibility data. The duration of treatment for acute complicated cystitis is 5 to 14 days, depending upon the severity of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Short regimens are reasonable in patients who are not severely ill and have a rapid clinical response. In a study including 619 patients with acute pyelonephritis or complicated UTI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (750 mg intravenously or orally once daily for 5 days) was as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (400 mg intravenously",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ciprofloxacin 500 mg orally twice daily for 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2922196\">",
"    <span class=\"h2\">",
"     Pyelonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with complicated pyelonephritis should be managed initially as inpatients. Broad-spectrum parenteral antibiotics should be used for empiric treatment of complicated pyelonephritis as outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef60091 \" href=\"UTD.htm?18/0/18444\">",
"     table 1",
"    </a>",
"    ). Patients with illness of moderate severity may be treated with cephalosporins or fluoroquinolones; patients with immune compromise, incomplete urinary drainage, or high risk for resistant organisms may be treated with a combination beta",
"    <span class=\"nowrap\">",
"     lactam/beta",
"    </span>",
"    lactamase inhibitor or carbapenem. In the setting of normal baseline renal function, use of aminoglycosides is acceptable for patients with highly resistant organisms not susceptible to a beta",
"    <span class=\"nowrap\">",
"     lactam/beta",
"    </span>",
"    lactamase inhibitor or carbapenem. &nbsp;Previous antimicrobial use and results of any recent urine cultures should inform the choice of an empiric regimen. Antimicrobial therapy subsequently must be tailored to individual patient circumstances with consideration of the results of susceptibility testing.",
"   </p>",
"   <p>",
"    Underlying urinary tract anatomic or functional abnormalities (such as obstruction or neurogenic bladder) should be addressed in consultation with an urologist [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/10999/abstract/5\">",
"     5",
"    </a>",
"    ]. Antibiotics alone may not be successful unless such underlying conditions are corrected.",
"   </p>",
"   <p>",
"    Antibiotics should be administered for at least 10 to 14 days; depending on patient circumstances, a longer duration of therapy may be warranted. Treatment may be completed with oral therapy if antimicrobial susceptibility data and clinical circumstances permit; acceptable agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The treatment of pyelonephritis in the setting of pregnancy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=see_link&amp;anchor=H24#H24\">",
"     \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307532266\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up urine cultures are not needed in patients with acute cystitis or pyelonephritis whose symptoms resolve on antibiotics.",
"   </p>",
"   <p>",
"    Patients with persistent or recurrent symptoms within a few weeks of treatment for acute complicated urinary tract infection should have a reevaluation for other conditions that may be causing the symptoms, repeat urine culture, and empiric treatment with another antimicrobial agent. Treatment should be tailored to the susceptibility profile of the causative organism isolated. In addition, initial or repeat radiographic imaging should be performed to evaluate for factors that might be compromising clinical response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=see_link\">",
"       \"Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2923745\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complicated urinary tract infection, whether localized to the lower or upper tract, is associated with an underlying condition that increases the risk of failing therapy. These conditions are summarized above. (See",
"      <a class=\"local\" href=\"#H91340417\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The microbial spectrum of complicated cystitis and pyelonephritis includes organisms associated with uncomplicated UTIs (mainly Escherichia coli, with occasional other species of Enterobacteriaceae, such as Proteus mirabilis and Klebsiella pneumoniae) as well as Pseudomonas, Serratia, Providencia, enterococci, staphylococci, and fungi. In addition, organisms causing complicated cystitis are more likely to be resistant to commonly used oral antimicrobials recommended for uncomplicated cystitis. (See",
"      <a class=\"local\" href=\"#H12415021\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to clinical manifestations observed with uncomplicated urinary tract infection, patients with complicated infection may present with sepsis, multiple organ system dysfunction,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acute renal failure. In some cases, complicated pyelonephritis may be associated with weeks to months of insidious, nonspecific signs and symptoms such as malaise, fatigue, nausea, or abdominal pain. (See",
"      <a class=\"local\" href=\"#H12414267\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A urine culture and antimicrobial susceptibility testing should be performed to guide treatment. Patients with persistent or recurrent symptoms within a few weeks of treatment for acute uncomplicated urinary tract infection should also have reevaluation for other conditions that might be causing the symptoms. In addition, if the patient has pyelonephritis, radiographic imaging should be performed to evaluate for complicated pyelonephritis. Computed tomography (CT) scan and ultrasonography are useful modalities to evaluate for the presence of an underlying anatomic abnormality, to detect a process that may delay response to therapy (such as calculus, papillary necrosis, or obstruction), or to diagnose a complication of infection such as a renal or perinephric abscess. (See",
"      <a class=\"local\" href=\"#H12414281\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with complicated cystitis who can tolerate oral therapy we suggest empiric treatment with an oral fluoroquinolone such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (500 mg orally twice daily or 1000 mg extended release once daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (750 mg orally once daily) for 5 to 14 days (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Parenteral therapy may be warranted for treatment of patients who cannot tolerate oral therapy or for patients with infection that is suspected to be due to resistant organisms; reasonable regimens that may be administered once daily include levofloxacin (500 mg),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (1 g), , a carbapenem, or an aminoglycoside (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      ). Empiric treatment choice should also take into account previous antimicrobial use and results of any recent urine cultures. After clinical improvement is observed, parenteral therapy can be switched to oral therapy, guided by antimicrobial susceptibility data, for a total of 5 to 14 days, depending upon the severity of infection. (See",
"      <a class=\"local\" href=\"#H2922187\">",
"       'Cystitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with complicated pyelonephritis should be managed initially as inpatients. Broad-spectrum parenteral antimicrobials should be used for empiric treatment of complicated pyelonephritis as outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef60091 \" href=\"UTD.htm?18/0/18444\">",
"       table 1",
"      </a>",
"      ). Previous antimicrobial use and results of any recent urine cultures should inform the choice of an empiric regimen. If antimicrobial susceptibility data and clinical circumstances permit, treatment may be completed with oral therapy; acceptable agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      . Antibiotics should be administered for at least 10 to 14 days; depending on patient circumstances, a longer duration of therapy may be warranted. (See",
"      <a class=\"local\" href=\"#H2922196\">",
"       'Pyelonephritis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/1\">",
"      Echols RM, Tosiello RL, Haverstock DC, Tice AD. Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin Infect Dis 1999; 29:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/2\">",
"      Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007; 45:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/3\">",
"      Warren JW. Catheter-associated urinary tract infections. Infect Dis Clin North Am 1987; 1:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/4\">",
"      Nicolle LE. Catheter-related urinary tract infection. Drugs Aging 2005; 22:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/5\">",
"      Nicolle LE. A practical guide to the management of complicated urinary tract infection. Drugs 1997; 53:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/6\">",
"      Bent S, Nallamothu BK, Simel DL, et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA 2002; 287:2701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/7\">",
"      Fairley KF, Carson NE, Gutch RC, et al. Site of infection in acute urinary-tract infection in general practice. Lancet 1971; 2:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/8\">",
"      Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:e103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/9\">",
"      Sandberg T, Stokland E, Brolin I, et al. Selective use of excretory urography in women with acute pyelonephritis. J Urol 1989; 141:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/10\">",
"      Kanel KT, Kroboth FJ, Schwentker FN, Lecky JW. The intravenous pyelogram in acute pyelonephritis. Arch Intern Med 1988; 148:2144.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.guideline.gov/summary/summary.aspx?doc_id=13683&amp;nbr=007017&amp;string=pyelonephritis (Accessed on September 14, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/12\">",
"      Johnson JR, Vincent LM, Wang K, et al. Renal ultrasonographic correlates of acute pyelonephritis. Clin Infect Dis 1992; 14:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/13\">",
"      Meyrier A, Condamin MC, Fernet M, et al. Frequency of development of early cortical scarring in acute primary pyelonephritis. Kidney Int 1989; 35:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/14\">",
"      Kawashima A, LeRoy AJ. Radiologic evaluation of patients with renal infections. Infect Dis Clin North Am 2003; 17:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/15\">",
"      Tsugaya M, Hirao N, Sakagami H, et al. Computerized tomography in acute pyelonephritis: the clinical correlations. J Urol 1990; 144:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/16\">",
"      Demertzis J, Menias CO. State of the art: imaging of renal infections. Emerg Radiol 2007; 14:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/17\">",
"      Soulen MC, Fishman EK, Goldman SM. Sequelae of acute renal infections: CT evaluation. Radiology 1989; 173:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/18\">",
"      Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991; 324:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/19\">",
"      Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993; 329:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/20\">",
"      Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/21\">",
"      The prevention and management of urinary tract infections among people with spinal cord injuries. National Institute on Disability and Rehabilitation Research Consensus Statement. January 27-29, 1992. J Am Paraplegia Soc 1992; 15:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/10999/abstract/22\">",
"      Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 2008; 71:17.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16109 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_10999=[""].join("\n");
var outline_f10_47_10999=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2923745\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91340417\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12415021\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12414267\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12414281\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2922567\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2922574\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12414288\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2922187\">",
"      Cystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2922196\">",
"      Pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307532266\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2923745\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16109\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16109|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/31/40432\" title=\"diagnostic image 1A\">",
"      Ultrasonography of acute pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/30/10720\" title=\"diagnostic image 1B\">",
"      Computed tomography scan of acute pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/25/13712\" title=\"diagnostic image 1C\">",
"      Computed tomography scan of bilateral acute pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16109|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/0/18444\" title=\"table 1\">",
"      Parenteral regimens in pyelonephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15479?source=related_link\">",
"      Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34278?source=related_link\">",
"      Emphysematous urinary tract infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=related_link\">",
"      Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=related_link\">",
"      Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=related_link\">",
"      Renal and perinephric abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=related_link\">",
"      Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24214?source=related_link\">",
"      Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16804?source=related_link\">",
"      Xanthogranulomatous pyelonephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_47_11000="Temozolomide: Drug information";
var content_f10_47_11000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Temozolomide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/60/32709?source=see_link\">",
"    see \"Temozolomide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/37/31319?source=see_link\">",
"    see \"Temozolomide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Temodar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ahi-Temozolomide Capsules;",
"     </li>",
"     <li>",
"      Temodal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F225300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent (Triazene)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F225272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anaplastic astrocytoma (refractory):",
"     </b>",
"     Oral, I.V.: Initial dose: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days; repeat every 28 days. Subsequent doses of 100-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days per treatment cycle; based upon hematologic tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage modification for toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     on day 22 or day 29 (day 1 of next cycle): Postpone therapy until ANC &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; reduce dose by 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for subsequent cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ANC 1000-1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets 50,000-100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     on day 22 or day 29 (day 1 of next cycle): Postpone therapy until ANC &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; maintain initial dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ANC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     on day 22 or day 29 (day 1 of next cycle): Increase dose to or maintain dose at 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days for subsequent cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Glioblastoma multiforme (newly diagnosed, high-grade glioma):",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concomitant phase:",
"     </b>",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 42 days with focal radiotherapy (60 Gy administered in 30 fractions).",
"     <b>",
"      Note:",
"     </b>",
"     PCP prophylaxis is required during concomitant phase and should continue in patients who develop lymphocytopenia until lymphocyte recovery to &le;grade 1. Obtain weekly CBC.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continue at 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day throughout the 42-day concomitant phase (up to 49 days) as long as ANC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelet count &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , and nonhematologic toxicity &le;grade 1 (excludes alopecia, nausea/vomiting)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage modification for toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ANC &ge;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     but &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     platelet count &ge;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     but &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     grade 2 nonhematologic toxicity (excludes alopecia, nausea/vomiting): Interrupt therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     platelet count &lt;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     grade 3/4 nonhematologic toxicity (excludes alopecia, nausea/vomiting): Discontinue therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance phase (consists of 6 treatment cycles):",
"     </b>",
"     Begin 4 weeks after concomitant phase completion.",
"     <b>",
"      Note:",
"     </b>",
"     Each subsequent cycle is 28 days (consisting of 5 days of drug treatment followed by 23 days without treatment). Draw CBC within 48 hours of day 22; hold next cycle and do weekly CBC until ANC &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelet count &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; dosing modification should be based on lowest blood counts and worst nonhematologic toxicity during the previous cycle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cycle 1: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days; repeat every 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cycles 2-6: May increase to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days (if ANC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and nonhematologic toxicities for cycle 1 are &le;grade 2 [excludes alopecia, nausea/vomiting]);",
"     <b>",
"      Note:",
"     </b>",
"     If dose was not escalated at the onset of cycle 2, do not increase for cycles 3-6)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage modification (during maintenance phase) for toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or grade 3 nonhematologic toxicity (excludes for alopecia, nausea/vomiting) during previous cycle: Decrease dose by 1 dose level (by 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days), unless dose has already been lowered to 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day, then discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If dose reduction &lt;100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day is required or grade 4 nonhematologic toxicity (excludes for alopecia, nausea/vomiting), or if the same grade 3 nonhematologic toxicity occurs after dose reduction: Discontinue therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Glioblastoma multiforme (recurrent glioma):",
"     </b>",
"     <i>",
"      Canadian labeling (unlabeled use in the U.S.):",
"     </i>",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days; if previously treated with chemotherapy, initiate at 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days and increase to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days with cycle 2 if no hematologic toxicity (Brada, 2001; Yung, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Ewing&rsquo;s sarcoma, recurrent or progressive (unlabeled use):",
"     </b>",
"     Oral: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1-5 every 21 days (in combination with irinotecan) (Casey, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Melanoma, advanced or metastatic (unlabeled use):",
"     </b>",
"     Oral: 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days (for up to 12 cycles). For subsequent cycles reduce dose to 75% of the original dose for grade 3/4 hematologic toxicity and reduce the dose to 50% of the original dose for grade 3/4 nonhematologic toxicity (Middleton, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Neuroendocrine tumors, advanced (unlabeled use):",
"     </b>",
"     Oral: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 7 days every 14 days in combination with thalidomide (Kulke, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Primary CNS lymphoma, refractory (unlabeled use):",
"     </b>",
"     Oral: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days, initially in combination with rituximab, followed by temozolomide monotherapy: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days (Wong, 2004)",
"     <b>",
"      or",
"     </b>",
"     150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 7 days every 14 days, initially in combination with rituximab, followed by temozolomide monotherapy: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days (Enting, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Soft tissue sarcoma (unlabeled use):",
"     </b>",
"     Oral: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 6 weeks (Garcia del Muro, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F12704784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/37/31319?source=see_link\">",
"      see \"Temozolomide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ewing&rsquo;s sarcoma, recurrent or progressive (unlabeled use):",
"     </b>",
"     Oral: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Neuroblastoma, relapsed or refractory (unlabeled use):",
"     </b>",
"     Oral: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1-5 days every 21 days (in combination with irinotecan) for up to 6 cycles (Bagatell, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F225273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"     <b>",
"      Note:",
"     </b>",
"     Patients &ge;70 years of age in the anaplastic astrocytoma study had a higher incidence of grade 4 neutropenia and thrombocytopenia in the first cycle of therapy than patients &lt;70 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F225274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;36 mL/minute/m",
"     <sup>",
"      2",
"     </sup>",
"     : No effect on temozolomide clearance was demonstrated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;36 mL/minute/m",
"     <sup>",
"      2",
"     </sup>",
"     ): Use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dialysis patients: Use has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F225275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hepatic impairment: Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temodar&reg;: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temodar&reg;: 100 mg [contains polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F225249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Standard antiemetics may be administered if needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Swallow capsules whole with a glass of water. Absorption is affected by food. Administer consistently either with food or without food (was administered in studies under fasting and nonfasting conditions). May administer on an empty stomach or at bedtime to reduce nausea and vomiting. Do not repeat if vomiting occurs after dose is administered; wait until the next scheduled dose. Do not open or chew capsules; avoid contact with skin if capsules are accidentally opened or damaged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infuse over 90 minutes. Flush line before and after administration. May be administered through the same I.V. line as sodium chloride 0.9%; do not administer other medications through the same I.V. line.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F12705157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Normal saline",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F225247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of newly-diagnosed glioblastoma multiforme (initially in combination with radiotherapy, then as maintenance treatment); treatment of refractory anaplastic astrocytoma",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling (not an approved indication in the U.S.): Treatment of recurrent or progressive glioblastoma multiforme",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F225296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of recurrent glioblastoma multiforme, low-grade astrocytoma, low-grade oligodendroglioma, anaplastic oligodendroglioma, metastatic CNS lesions, refractory primary CNS lymphoma, advanced or metastatic melanoma, cutaneous T-cell lymphomas (mycosis fungoides [MF] and S&eacute;zary syndrome [SS]), advanced neuroendocrine tumors (carcinoid or islet cell), Ewing&rsquo;s sarcoma (recurrent or progressive), soft tissue sarcomas (extremity/retroperitoneal/intra-abdominal or hemangiopericytoma/solitary fibrous tumor), treatment of pediatric neuroblastoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3402099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Temodar&reg; may be confused with Tambocor&trade;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Temozolomide may be confused with temsirolimus",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F225298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     With CNS malignancies, it may be difficult to distinguish between CNS adverse events caused by temozolomide versus the effects of progressive disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (34% to 61%), headache (23% to 41%), seizure (6% to 23%), hemiparesis (18%), fever (13%), dizziness (5% to 12%), coordination abnormality (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (55%), rash (8% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (49% to 53%; grades 3/4: 1% to 10%), vomiting (29% to 42%; grades 3/4: 2% to 6%), constipation (22% to 33%), anorexia (9% to 27%), diarrhea (10% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Lymphopenia (grades 3/4: 55%), thrombocytopenia (grades 3/4: adults: 4% to 19%; children: 25%), neutropenia (grades 3/4: adults: 8% to 14%; children: 20%), leukopenia (grades 3/4: 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (7% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Amnesia (10%), insomnia (4% to 10%), somnolence (9%), ataxia (8%), paresis (8%), anxiety (7%), memory impairment (7%), depression (6%), confusion (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (5% to 8%), dry skin (5%), radiation injury (2% maintenance phase after radiotherapy), erythema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercorticism (8%), breast pain (females 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Stomatitis (9%), abdominal pain (5% to 9%), dysphagia (7%), taste perversion (5%), weight gain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Incontinence (8%), urinary tract infection (8%), urinary frequency (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (grades 3/4: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (9%), back pain (8%), abnormal gait (6%), arthralgia (6%), myalgia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (5% to 8%), diplopia (5%), vision abnormality (visual deficit/vision changes 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (8%), upper respiratory tract infection (8%), cough (5% to 8%), sinusitis (6%), dyspnea (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alkaline phosphatase increased, alveolitis, anaphylaxis, aplastic anemia, cholestasis, emotional lability, erythema multiforme, febrile neutropenia, flu-like syndrome, hallucination, hematoma, hemorrhage, hepatitis, hepatotoxicity, herpes simplex, herpes zoster, hyperbilirubinemia, hyperglycemia, hypokalemia, injection site reactions (erythema, irritation, pain, pruritus, swelling, warmth), interstitial pneumonia/pneumonitis, myelodysplastic syndrome, opportunistic infection (eg, PCP), oral candidiasis, pancytopenia (may be prolonged), peripheral neuropathy, petechiae, pneumonitis, pulmonary fibrosis, secondary malignancies (including myeloid leukemia), Stevens-Johnson syndrome, toxic epidermal necrolysis, transaminases increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F225252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, allergic reaction, anaphylaxis, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis) to temozolomide or any component of the formulation; hypersensitivity to dacarbazine (both drugs are metabolized to MTIC)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Not recommended in patients with severe myelosuppression",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F225236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myelosuppression: May occur with use; an increased incidence has been reported in geriatric and female patients. Prolonged pancytopenia resulting in aplastic anemia has been reported; concurrent use of temozolomide with medications associated with aplastic anemia (eg, carbamazepine, co-trimoxazole, phenytoin) may obscure assessment for development of aplastic anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pneumonia:",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP) may occur; risk is increased in those receiving steroids or longer dosing regimens; PCP prophylaxis is required in patients receiving radiotherapy in combination with the 42-day temozolomide regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Rare cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; has not been studied in dialysis patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temozolomide resistance: Increased MGMT (O-6-methylguanine-DNA methyltransferase) activity/levels within tumor tissue is associated with temozolomide resistance. Glioblastoma patients with decreased levels (due to methylated MGMT promoter) may be more likely to benefit from the combination of radiation therapy and temozolomide (Hegi, 2008; Stupp, 2009). Determination of MGMT status may be predictive for response to alkylating agents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May enhance the adverse/toxic effect of Temozolomide. Divalproex may increase the serum concentration of Temozolomide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May enhance the adverse/toxic effect of Temozolomide. Valproic Acid may increase the serum concentration of Temozolomide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F225266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food reduces rate and extent of absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F225255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause fetal harm when administered to pregnant women. Animal studies, at doses less than used in humans, resulted in numerous birth defects. Testicular toxicity was demonstrated in animal studies using smaller doses than recommended for cancer treatment. There are no adequate and well-controlled studies in pregnant women. Male and female patients should avoid pregnancy while receiving drug.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F225280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4152325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F225256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The incidence of nausea/vomiting is decreased when taken on an empty stomach. Take capsules consistently either with food or without food (absorption is affected by food).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F225254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Temodar Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (5): $64.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (5): $260.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (5): $1301.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     140 mg (5): $1822.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (5): $2342.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (5): $3254.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Temodar Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $565.94",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F225244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets (prior to each cycle; weekly during glioma concomitant phase treatment; at or within 48 hours of day 22 and weekly until ANC &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for glioma maintenance and astrocytoma treatment)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F225257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Astromide (NZ);",
"     </li>",
"     <li>",
"      Dralitem (CR, EC, GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Temo (IL);",
"     </li>",
"     <li>",
"      Temodal (AE, AR, AT, AU, BE, BG, BH, BO, BR, CH, CL, CN, CO, CY, CZ, DE, DK, DO, EE, EG, ES, FI, FR, GB, GR, HK, ID, IE, IL, IN, IQ, IR, IT, JO, KP, KW, LB, LY, MT, MX, MY, NL, NO, NZ, OM, PA, PE, PH, PL, PR, PT, PY, QA, RU, SA, SE, SG, SK, SY, TH, TR, TW, UY, VE, YE);",
"     </li>",
"     <li>",
"      Temodal IV (SG);",
"     </li>",
"     <li>",
"      Temozam (PH);",
"     </li>",
"     <li>",
"      Temozol (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F225235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temozolomide is a prodrug which is rapidly and nonenzymatically converted to the active alkylating metabolite MTIC [(methyl-triazene-1-yl)-imidazole-4-carboxamide]; this conversion is spontaneous, nonenzymatic, and occurs under physiologic conditions in all tissues to which it distributes. The cytotoxic effects of MTIC are manifested through alkylation (methylation) of DNA at the O",
"     <sup>",
"      6",
"     </sup>",
"     , N",
"     <sup>",
"      7",
"     </sup>",
"     guanine positions which lead to DNA double strand breaks and apoptosis. Non-cell cycle specific.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F225251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Parent drug: 0.4 L/kg; penetrates blood-brain barrier; CSF levels are ~35% to 39% of plasma levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Prodrug, hydrolyzed to the active form, MTIC; MTIC is eventually eliminated as CO",
"     <sub>",
"      2",
"     </sub>",
"     and 5-aminoimidazole-4-carboxamide (AIC), a natural constituent in urine; CYP isoenzymes play only a minor role in metabolism (of temozolomide and MTIC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 100% (on a mg-per-mg basis, I.V. temozolomide, infused over 90 minutes, is bioequivalent to an oral dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Mean: Parent drug: 1.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: Empty stomach: 1 hour; with food (high-fat meal): 2.25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~38%; parent drug 6%); feces &lt;1%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agarwala SS, Kirkwood JM, Gore M, et al, &ldquo; Temozolomide for the Treatment of Brain metastases Associated With Metastatic Melanoma: A Phase II Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(11):2101-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/15169796/pubmed\" id=\"15169796\" target=\"_blank\">",
"        15169796",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagatell R, London WB, Wagner LM, et al, &ldquo;Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(2):208-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/21115869/pubmed\" id=\"21115869\" target=\"_blank\">",
"        21115869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brada M, Hoang-Xuan K, Rampling R, et al, &ldquo;Multicenter Phase II Trial of Temozolomide in Patients With Glioblastoma Multiforme at First Relapse,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2001, 12(2):259-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/11300335/pubmed\" id=\"11300335\" target=\"_blank\">",
"        11300335",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Casey DA, Wexler LH, Merchant MS, et al, &ldquo;Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 53(6):1029-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/19637327/pubmed\" id=\"19637327\" target=\"_blank\">",
"        19637327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Enting RH, Demopoulos A, DeAngelis LM, et al, &ldquo;Salvage Therapy for Primary CNS Lymphoma With a Combination of Rituximab and Temozolomide,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2004, 63(5):901-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/15365145/pubmed\" id=\"15365145\" target=\"_blank\">",
"        15365145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan HK, Rosenthal MA, Dowling A, et al, \"A Phase II Trial of Primary Temozolomide in Patients With Grade III Oligodendroglial Brain Tumors,\"",
"      <i>",
"       Neuro Oncol",
"      </i>",
"      , 2010, 12(5):500-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/20406900/pubmed\" id=\"20406900\" target=\"_blank\">",
"        20406900",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia del Muro X, Lopez-Pousa A, Martin J, et al, &ldquo;A Phase II Trial of Temozolomide as a 6-Week, Continuous, Oral Schedule in Patients With Advanced Soft Tissue Sarcoma: A Study by the Spanish Group for Research on Sarcomas,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2005, 104(8):1706-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/16134177/pubmed\" id=\"16134177\" target=\"_blank\">",
"        16134177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegi ME, Diserens AC, Gorlia T, et al, &ldquo;MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(10):997-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/15758010/pubmed\" id=\"15758010\" target=\"_blank\">",
"        15758010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegi ME, Liu L, Herman JG, et al, &ldquo;Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(25):4189-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/18757334/pubmed\" id=\"18757334\" target=\"_blank\">",
"        18757334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jalali R, Singh P, Menon H, et al, &ldquo;Unexpected Case of Aplastic Anemia in a Patient With Glioblastoma Multiforme Treated With Temozolomide,&rdquo;",
"      <i>",
"       J Neurooncol",
"      </i>",
"      , 2007, 85(1):105-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/17505778/pubmed\" id=\"17505778\" target=\"_blank\">",
"        17505778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kesari S, Schiff D, Drappatz J, et al, &ldquo;Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2009, 15(1):330-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/19118062/pubmed\" id=\"19118062\" target=\"_blank\">",
"        19118062",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kulke MH, Stuart K, Enzinger PC, et al, &ldquo;Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(3):401-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/16421420/pubmed\" id=\"16421420\" target=\"_blank\">",
"        16421420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marchesi F, Turriziani M, Tortorelli G, et al, &ldquo;Triazene Compounds: Mechanism of Action and Related DNA Repair Systems,&rdquo;",
"      <i>",
"       Pharmacol Res",
"      </i>",
"      , 2007, 56(4):275-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/17897837/pubmed\" id=\"17897837\" target=\"_blank\">",
"        17897837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Middleton MR, Grob JJ, Aaronson N, et al, &ldquo;Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(1):158-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/10623706/pubmed\" id=\"10623706\" target=\"_blank\">",
"        10623706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mikkelsen T, Doyle T, Anderson J, et al, &ldquo;Temozolomide Single-Agent Chemotherapy for Newly Diagnosed Anaplastic Oligodendroglioma,&rdquo;",
"      <i>",
"       J Neurooncol",
"      </i>",
"      , 2009, 92(1):57-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/19011763/pubmed\" id=\"19011763\" target=\"_blank\">",
"        19011763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Central Nervous System Cancers,&rdquo; Version 2.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/cns.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Melanoma,&rdquo; Version 2.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN) &ldquo;Practice Guidelines in Oncology&trade;: Neuroendocrine Tumors,&rdquo; Version 1.2011 Available at file://www.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Non-Hodgkin&rsquo;s Lymphomas,&rdquo; Version 3.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Soft Tissue Sarcoma,&rdquo; Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry JR, B&eacute;langer K, Mason WP, et al, \"Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(12):2051-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/20308655/pubmed\" id=\"20308655\" target=\"_blank\">",
"        20308655",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stupp R, Dietrich PY, Ostermann Kraljevic S, et al, &ldquo;Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(5):1375-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/11870182/pubmed\" id=\"11870182\" target=\"_blank\">",
"        11870182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stupp R, Gander M, Leyvraz S, et al, &ldquo;Current and Future Developments in the Use of Temozolomide for the Treatment of Brain Tumours,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2001, 2(9):552-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/11905710/pubmed\" id=\"11905710\" target=\"_blank\">",
"        11905710",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stupp R, Hegi ME, Mason WP, et al, &ldquo;Effects of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-year Analysis of the EORTC-NCIC Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2009, 10(5):459-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/19269895/pubmed\" id=\"19269895\" target=\"_blank\">",
"        19269895",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stupp R, Mason WP, van den Bent MJ, et al, &ldquo;Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(10):987-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/15758009/pubmed\" id=\"15758009\" target=\"_blank\">",
"        15758009",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tani M, Fina M, Alinari L, et al, &ldquo;Phase II Trial of Temozolomide in Patients With Pretreated Cutaneous T-Cell Lymphoma,&rdquo;",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2005, 90(9):1283-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/16154858/pubmed\" id=\"16154858\" target=\"_blank\">",
"        16154858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Villano JL, Collins CA, Manasanch EE, et al, &ldquo;Aplastic Anaemia in Patient With Glioblastoma Multiforme Treated With Temozolomide,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2006, 7(5):436-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/16648049/pubmed\" id=\"16648049\" target=\"_blank\">",
"        16648049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong ET, Tishler R, Barron L, et al, &ldquo;Immunochemotherapy With Rituximab and Temozolomide for Central Nervous System Lymphomas,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 101(1):139-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/15221999/pubmed\" id=\"15221999\" target=\"_blank\">",
"        15221999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yung WK, Albright RE, Olson J, et al, &ldquo;A Phase II Study of Temozolomide vs Procarbazine in Patients With Glioblastoma Multiforme at First Relapse,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2000, 83(5):588-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/10944597/pubmed\" id=\"10944597\" target=\"_blank\">",
"        10944597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yung WK, Prados MD, Yaya-Tur R, et al, &ldquo;Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(9):2762-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/47/11000/abstract-text/10561351/pubmed\" id=\"10561351\" target=\"_blank\">",
"        10561351",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9699 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_11000=[""].join("\n");
var outline_f10_47_11000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225270\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225271\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225300\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225272\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12704784\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225273\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225274\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225275\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225246\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225232\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225249\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12705157\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225247\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225296\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3402099\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225298\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225252\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225236\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300110\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223210\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225266\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225242\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225255\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225280\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4152325\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225256\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225254\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225244\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225257\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225235\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225251\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9699\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9699|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/60/32709?source=related_link\">",
"      Temozolomide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/37/31319?source=related_link\">",
"      Temozolomide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_47_11001="Childhood lead poisoning: Exposure and prevention";
var content_f10_47_11001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Childhood lead poisoning: Exposure and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/47/11001/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/11001/contributors\">",
"     Dean A Lee, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/11001/contributors\">",
"     Richard L Hurwitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/47/11001/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/11001/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/11001/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/11001/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/47/11001/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/11001/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/47/11001/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elimination of lead from the environment is essential to the prevention of lead poisoning and its sequelae. Primary prevention efforts focus on removal of lead from the environment so that exposure cannot occur. Secondary prevention efforts are designed to minimize absorption of lead and deposition in the mineralizing tissues, where it functions as a source of chronic exposure. Tertiary prevention reduces the morbidity associated with lead intoxication through chelation of lead from the blood and soft tissues of an exposed individual. Chelation can reduce the immediate toxicity associated with acute lead ingestion, but has limited ability to reverse the neurocognitive effects of chronic exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/1\">",
"     1",
"    </a>",
"    ]. Primary prevention is the only way to reduce the neurocognitive effects of lead poisoning.",
"   </p>",
"   <p>",
"    Aggressive environmental remediation has the potential to benefit children by reducing their exposure to lead. However, the efficacy of aggressive environmental remediation largely is unproven, the methods are controversial, and the costs are high. In addition, political and economic considerations to environmental remediation exist that are beyond the scope of this review. Nonetheless, complete removal of lead from the child's environment is considered to be the only effective preventive measure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sources of childhood lead exposure and strategies for primary and secondary prevention of exposure are reviewed here. The clinical manifestations, diagnosis, and treatment of lead poisoning are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"     \"Childhood lead poisoning: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children are exposed to lead in a variety of ways. Since the removal of lead from gasoline, lead-based paint has become the major source of lead exposure for children in the United States. Other important pediatric exposures include elevated maternal blood lead levels during pregnancy and breastfeeding, soil, food, or water contamination and excess lead in toys.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prenatal exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead exposure during fetal development may result from mobilization of bone lead stored from past exposure into the maternal bloodstream",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    from direct elevation of maternal blood lead levels caused by acute or chronic environmental lead exposure during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/3\">",
"     3",
"    </a>",
"    ]. In utero lead exposure is associated with impairment of postnatal neurodevelopment with an increased risk for developmental delay, lowering of IQ, and behavioral abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, blood lead screening is recommended for pregnant women with important risk factors for lead exposure, including recent immigration, pica, occupational exposures, and culturally specific practices (eg, use of lead-containing cosmetics, cooking in lead-glazed pottery). A maternal BLL over 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    is a marker of significant exposure to lead above background levels for pregnant women in the US population.&nbsp;Because lead crosses the placenta readily and a toxicologic threshold for adverse effects to the fetus or newborn has not been identified, maternal BLLs elevated above background warrant follow-up testing in the mother during and after pregnancy and in the newborn infant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link&amp;anchor=H1099602#H1099602\">",
"     \"Childhood lead poisoning: Management\", section on 'Prenatal exposure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H1318049#H1318049\">",
"     \"Adult lead poisoning\", section on 'Pregnancy and breastfeeding'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Providers for pregnant women with elevated blood lead levels should ensure that the maternal lead level is known by the provider managing the newborn infant. Levels of both the mother and infants should be documented in both of their medical records.&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ingestion of lead-containing dust is the primary source of lead exposure in children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/4\">",
"     4",
"    </a>",
"    ]. The major sources of lead dust are oxidation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mechanical disruption of lead-containing paint and soil. In addition, lead dust may be carried into the child's environment on the clothing or skin of adults who have hobbies or occupations that expose them to lead (",
"    <a class=\"graphic graphic_table graphicRef53953 \" href=\"UTD.htm?9/3/9277\">",
"     table 1",
"    </a>",
"    ) or who live in households that have been inadequately decontaminated.",
"   </p>",
"   <p>",
"    The normal progression of developmental skills and the behavior of young children places them at risk for lead ingestion in lead-containing environments. Young children spend much of their time on the floor as they learn to crawl and then to walk; during this time, their hands often are in direct contact with lead-contaminated dust or soil. Young children also have normal hand-to-mouth and mouthing behaviors, especially when they are teething (between 6 and 24 months), that increase the likelihood of ingesting lead-containing paint, dust, or soil.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Paint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the removal of lead from gasoline, lead-based paint has become the major source of lead exposure for children in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/5\">",
"     5",
"    </a>",
"    ]. Before 1955, the lead content of white house paint was as high as 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/6\">",
"     6",
"    </a>",
"    ]. After 1955, the lead content of paint was reduced, but lead was not eliminated until 1978, when the Consumer Product Safety Commission (CPSC) restricted lead content to 0.06 percent for any paint intended to be used on residential surfaces, toys, or furniture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/7\">",
"     7",
"    </a>",
"    ]. Despite the elimination of lead from newly manufactured paint, paint that was applied to homes before 1978 remains in place. In 1998, 25 percent of homes in the United States with at least one child younger than six years still had significant amounts of lead-contaminated deteriorated paint, dust, or adjacent bare soil [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of data from the National Health and Nutrition Examination Survey (NHANES) determined that children who live in or regularly visit a home or daycare center built before 1950 are at risk for lead exposure and should be tested for lead intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lead content of dust in homes is typically highest in window wells and windowsills because of the mechanical disruption that occurs with raising and lowering the windows [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Soil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contamination of the soil surrounding residential areas can be an important source of lead dust inside the home as well as for the child who plays outdoors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Soil contamination typically is restricted to 2 to 5 cm below the surface if the soil is undisturbed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/15\">",
"     15",
"    </a>",
"    ]. Soil contamination may be increased in homes at which car repair activities are performed in the home or yard [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/16\">",
"     16",
"    </a>",
"    ]. The accepted safety standard for lead in bare soil is &lt;400 parts per million (ppm) for play areas, and &lt;1200 ppm for nonplay areas. Information about testing soil for lead can be obtained from the National Lead Information Center (",
"    <a class=\"external\" href=\"file://epa.gov/lead/pubs/nlic.htm\">",
"     epa.gov/lead/pubs/nlic.htm",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Water",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead in drinking water probably is absorbed more completely than lead in food and may account for more than 50 percent of the lead that is ingested by children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/17\">",
"     17",
"    </a>",
"    ]. Municipal water supplies are controlled and regulated to prevent contamination at the source [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/18\">",
"     18",
"    </a>",
"    ]. However, once the water reaches the home, it is rarely regulated, tested, or treated. The EPA action level for lead in water is 15 parts per billion (ppb).",
"   </p>",
"   <p>",
"    Most lead-contamination of household water is caused by copper plumbing that is joined with lead solder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/18\">",
"     18",
"    </a>",
"    ]. Lead pipes may contribute to lead-contamination, but lead plumbing usually is old enough to have its inner surface coated with mineral deposits, which prevent leaching of lead into the water supply.",
"   </p>",
"   <p>",
"    Other potential sources for lead contamination include storage cisterns, sources of water that are outside the municipal water districts, and aging water coolers and water heaters, particularly in areas where the water has a relatively low pH [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/5\">",
"     5",
"    </a>",
"    ]. Acidity and elevated temperature increase the ability of the water to leach lead from the solder or pipes, as does standing in the pipes for extended periods of time (eg, overnight).",
"   </p>",
"   <p>",
"    Additional information about lead in drinking water is available on the United States Environmental Protection Agency's Web site (",
"    <a class=\"external\" href=\"file://epa.gov/safewater/lead/index.html\">",
"     epa.gov/safewater/lead/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Food",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful dietary history in children with lead poisoning may help to identify dietary sources of lead exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/9,19,20\">",
"     9,19,20",
"    </a>",
"    ]. Food can be contaminated with lead during production, processing, packaging, preparation, or storage [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Produce that is grown in lead-containing soil or exposed to exhaust from vehicles that use lead-containing fuel can be contaminated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/5,6,15,17\">",
"     5,6,15,17",
"    </a>",
"    ]. Although lead has been banned from petroleum products in the United States, the soil along certain major transportation routes and in inner city cooperative gardens may still be contaminated with significant amounts of lead. Lead-based petroleum products continue to be used in many developing agricultural countries from which food is imported.",
"   </p>",
"   <p>",
"    Canned food can become contaminated with lead if lead solder is used in the canning process. The lead is leached into the food during oxidation, which begins to occur once the can is opened, particularly if the food is acidic.",
"   </p>",
"   <p>",
"    Food may be contaminated during preparation by the addition of lead-contaminated spices (purchased in other countries and not tested for purity) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/21\">",
"     21",
"    </a>",
"    ]. Food also may be contaminated with lead if it is stored, prepared, or served in lead-glazed pottery, leaded-crystal glassware, lead-containing cooking vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/22\">",
"     22",
"    </a>",
"    ], or plastic bags decorated with red or yellow lead-containing pigments (eg, bread bags) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/6,23,24\">",
"     6,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11089643\">",
"    <span class=\"h4\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levels of lead in breast milk are up to 3 percent of blood lead levels in the mother and are directly correlated with maternal blood lead concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/3\">",
"     3",
"    </a>",
"    ]. Based upon estimates of infant blood level elevation occurring from breast milk ingestion, breastfeeding should be encouraged for all mothers with a venous blood lead level &lt;40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef58503 \" href=\"UTD.htm?32/21/33116\">",
"     table 2",
"    </a>",
"    ). In the United States, infants whose mothers have a BLL &ge;40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    should not breastfeed initially. The mother should be instructed to pump her breast milk and discard it. Breastfeeding should be instituted if the maternal BLL falls below 40",
"    <span class=\"nowrap\">",
"     mcg/dL.",
"    </span>",
"    Whether the risks of breastfeeding for mothers with a BLL &ge;40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    who live in a developing country outweighs the benefits is uncertain. Continuation of breastfeeding is based upon whether there is evidence that breast milk is contributing to infant lead levels on the follow-up maternal and infant screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link&amp;anchor=H1099610#H1099610\">",
"     \"Childhood lead poisoning: Management\", section on 'Breastfeeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H1318049#H1318049\">",
"     \"Adult lead poisoning\", section on 'Pregnancy and breastfeeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10106941\">",
"    <span class=\"h3\">",
"     Leaded objects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingestion of leaded objects (eg, fishing weights, curtain weights, buckshot, recreational items, folk remedies) in children may be associated with a sudden acute rise in blood lead levels with the potential to cause lead encephalopathy and death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Inhalation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exposure of children in the United States to lead via inhalation decreased after the elimination of lead from automobile gasoline products in 1978. However, children who live near industrial plants where lead is used, smelted, or mined and children who live in countries that have not banned lead from petroleum products may continue to be exposed by this route. Children also may be exposed to lead through inhalation during home renovation or if they or their parents engage in hobbies that involve the use, melting, or spraying of lead-containing products (ie, target shooting at indoor firing ranges [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/7,28,29\">",
"     7,28,29",
"    </a>",
"    ]) (",
"    <a class=\"graphic graphic_table graphicRef53953 \" href=\"UTD.htm?9/3/9277\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Leaded gasoline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before lead was removed from petroleum products in the United States, automobile exhaust emitted millions of pounds of lead into the environment each month [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/5,30,31\">",
"     5,30,31",
"    </a>",
"    ]. The elimination of lead from gasoline was a successful nationwide primary prevention measure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/32\">",
"     32",
"    </a>",
"    ]. Between 1976 and 1989, the amount of lead consumed in gasoline in the United States decreased by 50 percent (",
"    <a class=\"graphic graphic_figure graphicRef60319 \" href=\"UTD.htm?24/52/25422\">",
"     figure 1",
"    </a>",
"    ), and blood lead levels (BLL) decreased by 37 percent.",
"   </p>",
"   <p>",
"    The European Union banned leaded gasoline in 2000. The World Bank and the United Nations Commission on Sustainable Development called for worldwide elimination of lead from petroleum products in 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/33\">",
"     33",
"    </a>",
"    ] and worldwide elimination is almost complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Children's products and toys",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children's products and toys provide another potential route for lead exposure. Lead may be present in any of the following forms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Paint on the surface of the product",
"     </li>",
"     <li>",
"      Pigment throughout the product",
"     </li>",
"     <li>",
"      In jewelry",
"     </li>",
"     <li>",
"      In vinyl or plastic (eg, bibs, backpacks, car seats, lunch boxes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lead in these products is not absorbed through intact skin and cannot be inhaled if the toy is undamaged and intact. The risk of lead poisoning from these products is low unless there is significant mouthing, chewing, or swallowing by children or the product is damaged or deteriorating [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Consumer Product Safety Improvement Act (CPSIA) of 2008 reduces the permissible lead content of toys and children's products from 0.06 percent (600 ppm) lead by weight to 0.03 percent (300 ppm) by 2009, and &le;0.01 percent (100 ppm) by 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/36\">",
"     36",
"    </a>",
"    ]. The CPSIA also requires third party testing of children's products to ensure compliance with the safety standards and to the extent possible, the placement of permanent tracking labels.",
"   </p>",
"   <p>",
"    The CPSC standard applies to toy jewelry, but not to costume jewelry, which is often given to children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Artificial athletic fields",
"    </span>",
"    &nbsp;&mdash;&nbsp;Artificial turf playing fields made of nylon or",
"    <span class=\"nowrap\">",
"     nylon/polyethylene",
"    </span>",
"    blend fibers may contain unhealthy levels of lead dust [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/37\">",
"     37",
"    </a>",
"    ]. With wear, frequent use, and weathering, the nylon fibers break down into dust that may be ingested or inhaled. This potential exposure route has not resulted in any reports of elevated blood levels in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prevention of childhood lead poisoning involves the removal of lead-based hazards from the environments of children (eg, lead-painted surfaces, including windows, lead-contaminated soil, lead-soldered pipes). Secondary prevention involves early detection of lead-poisoned children and minimizing exposure and absorption (",
"    <a class=\"graphic graphic_table graphicRef56262 graphicRef63418 \" href=\"UTD.htm?27/16/27916\">",
"     table 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Family education regarding methods to decrease exposure and absorption is recommended for all children with childhood lead poisoning. Education is the major intervention in the management of children with BLL between 5 and 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24 and 0.96",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and in the prevention of lead exposure for children with BLL &lt;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/12,38\">",
"     12,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"     \"Childhood lead poisoning: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Paint and soil",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, lead contaminated house dust is the major source of lead exposure for children in the United States. The age of the home is important in determining the risk of exposure, particularly for homes built before 1950. Unfortunately, parental awareness of the age of the home may be inaccurate. In a survey where parents' answers about the age of their home were compared with information in tax assessor records, only 52 percent of those living in housing built before 1950 accurately identified their home as such [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, the identification of homes needing abatement should not rely solely on parental report.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Abatement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional cleaning, paint stabilization, and removal and replacement of building components can interrupt lead exposure in children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, extensive onsite removal of leaded paint can raise the concentration of lead in house dust and in resident children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/41,42\">",
"     41,42",
"    </a>",
"    ] and abatement that is improperly performed increases lead exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of properly performed lead-based-paint remediation on lead levels in affected children is difficult to quantitate. The results are confounded by elevation of BLL from continued release of lead from tissue stores",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exposure to increased lead dust during removal of lead-based paint [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The observable effect of abatement appears to be related directly to the pre-abatement BLL [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/41,44-46\">",
"     41,44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data are available regarding the efficacy of environmental remediation in reducing BLL or preventing the neurodevelopmental consequences of lead poisoning in children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/11\">",
"     11",
"    </a>",
"    ]. Well-designed studies are difficult to perform because the expense of lead abatement prohibits a study large enough to document a clear benefit.",
"   </p>",
"   <p>",
"    In 1993 and 1994, the US Department of Housing and Urban Development (HUD) provided funding to address lead-based paint hazards in low-income housing in more than 12 jurisdictions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/41\">",
"     41",
"    </a>",
"    ]. Information was gathered before, within 6 weeks of, and 6 to 12 months after the intervention; 2682 dwellings were treated and had final results. Additional data were collected two and three years after the intervention for approximately 40 percent of the dwellings. Interior intervention strategies ranged from cleaning and spot painting to full lead removal. The exterior building was treated in 70 percent of dwellings (eg, paint stabilization, paint removal). Soil or site work (eg, application of",
"    <span class=\"nowrap\">",
"     mulch/seed/sod/plants,",
"    </span>",
"    soil removal, structure removal) was conducted at 13 percent of dwellings. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lead hazard control activities reduced the floor, window sill, and window trough dust lead levels compared with preintervention levels (by 78 percent, 89 percent, and 95 percent, respectively); reduced levels were maintained for at least three years.",
"     </li>",
"     <li>",
"      All interior strategies resulted in decreased average floor dust levels. However, differential effects between strategies were identified. Full interior abatement was associated with the greatest reduction, whereas window abatement and full paint stabilization were associated with the smallest reduction.",
"     </li>",
"     <li>",
"      Nine percent of children who had BLL measured before and immediately after the intervention had increases of BLL of &ge;5",
"      <span class=\"nowrap\">",
"       microg/dL",
"      </span>",
"      (0.24",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"     </li>",
"     <li>",
"      One year after the intervention, geometric mean BLL were 2.7",
"      <span class=\"nowrap\">",
"       microg/dL",
"      </span>",
"      (0.13",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      lower than preintervention BLL (9",
"      <span class=\"nowrap\">",
"       microg/dL",
"      </span>",
"      [0.43",
"      <span class=\"nowrap\">",
"       micromol/L]);",
"      </span>",
"      two years after the intervention, geometric mean BLL were 3.8",
"      <span class=\"nowrap\">",
"       microg/dL",
"      </span>",
"      (0.18",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      lower, reductions of 27 percent and 37 percent, respectively.",
"     </li>",
"     <li>",
"      Geometric mean BLL among children with preintervention BLL &lt;10",
"      <span class=\"nowrap\">",
"       microg/dL",
"      </span>",
"      (0.48",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      declined by 20 percent one year after the intervention.",
"     </li>",
"     <li>",
"      Factors that modified the effects of lead-hazard control included preintervention BLL, parental reports of previous lead poisoning, child's age, and the season in which the child was tested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Attempts to remove existing lead-containing paint from surfaces can create more lead dust if not done properly, increasing the risk for lead exposure and causing at least temporary elevation of BLL [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/7,41,43,47,48\">",
"     7,41,43,47,48",
"    </a>",
"    ]. The Occupational Safety and Health Administration (OSHA), the EPA, and the United States Department of Housing and Urban Development have established guidelines for the safe removal of lead-based paint, which can be accessed at",
"    <a class=\"external\" href=\"file://www.hud.gov/offices/lead\">",
"     www.hud.gov/offices/lead",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Incomplete or temporary remediation can be performed by painting over existing lead-based paint on walls, doors, and windowsills using nonlead-based paint. This remediation is considered temporary because over time, lead dust will reaccumulate because of further oxidation and mechanical disruption of the lead-based paint. Home restoration or remodeling of the home will re-expose the lead paint. Nonetheless, interim control strategies have resulted in decreased lead dust content and modest declines in the BLL of resident children 9 to 15 months after the intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/11,49-53\">",
"     11,49-53",
"    </a>",
"    ]. Certain measures can be taken to limit exposure of children to lead-based paint in homes that contain such lead-based paint (",
"    <a class=\"graphic graphic_table graphicRef68214 \" href=\"UTD.htm?15/46/16107\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thorough cleaning of the home by professionals trained in a lead abatement protocol is another temporary means of reducing lead dust contamination. In one study, professional cleaning reduced lead dust levels on windowsill surfaces by 89 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/54\">",
"     54",
"    </a>",
"    ]. However, within three months of cleaning the levels returned to precleaning levels.",
"   </p>",
"   <p>",
"    Removal and replacement of lead-contaminated soil has minimal independent effect on BLL in children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/49,55\">",
"     49,55",
"    </a>",
"    ]. Like paint abatement, soil abatement may cause transient elevation of BLL [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, disposal of the contaminated soil is problematic, particularly the large volume of soil from industrial sites. Certain measures can be taken to minimize the exposure and absorption of lead from contaminated soil (",
"    <a class=\"graphic graphic_table graphicRef82132 \" href=\"UTD.htm?1/33/1563\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Education and dust control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the expense and lack of proven efficacy of lead hazard abatement, families who are unwilling or unable to have their homes professionally abated must receive information regarding alternative interventions. In the United States, education is the primary type of intervention recommended by the Centers for Disease Control and other organizations for households in which children are found to have blood-lead levels (BLLs) between 5 and 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24 and 0.96",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/38,56\">",
"     38,56",
"    </a>",
"    ]. Certain measures can be taken to limit exposure of children to lead in homes that contain lead-based paint (",
"    <a class=\"graphic graphic_table graphicRef68214 \" href=\"UTD.htm?15/46/16107\">",
"     table 4",
"    </a>",
"    ). These educational measures are often supplemented by dust control interventions (",
"    <a class=\"graphic graphic_table graphicRef82254 \" href=\"UTD.htm?42/36/43595\">",
"     table 6",
"    </a>",
"    ). Although the use of high-phosphate detergents (eg, TSP) was recommended in the past, other cleaning products work as well. The use of high-phosphate detergents is no longer recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the benefits of lead exposure education and dust control measures are unclear. A meta-analysis of 14 studies (2656 children) did not show a significant impact on mean blood lead levels six to 18 months after initiation of household education, dust control measures, or both (mean difference in BLL between intervention and control groups 0.02",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [0.001",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/57\">",
"     57",
"    </a>",
"    ]. However, a subanalysis of four studies (520 children) that evaluated educational interventions alone did show a positive trend towards reduced numbers of children with a blood lead level &ge;15",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.72",
"    <span class=\"nowrap\">",
"     micromol/L,",
"    </span>",
"    RR 0.60; 95% CI: 0.33-1.09). Neurocognitive outcomes are highly heterogeneous with regard to BLL, and the studies included in the meta-analysis did not evaluate these outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H7#H7\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Neurologic'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, the cleaning methods that were used in the dust control studies were labor intensive, expensive, and not likely to be followed outside of a study setting (eg, biweekly wet mopping of floors, damp-sponging of walls and horizontal surfaces, and vacuuming with a high-efficiency particle accumulating (HEPA) vacuum) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these limitations, most experts still advocate that caregivers of children with elevated BLLs receive education and perform dust control measures as part of the overall approach to reduce ongoing lead exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Water",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of lead solder and other lead-containing materials to connect household plumbing to public water supplies was banned by the EPA in June 1988. Regulations regarding the lead content of drinking-water coolers in schools went into effect in 1989 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/6\">",
"     6",
"    </a>",
"    ]. However, lead-contaminated water continues to be a potential problem in homes built before 1988. Removal of the source of lead is the most reliable way to eliminate water-based exposure to lead.",
"   </p>",
"   <p>",
"    The ability of home water filters or purifiers to remove lead depends upon the type of filter. Ion-exchange, reverse-osmosis filters, and distillation are effective in removing lead, but the most commonly available home filters (glass fiber and carbon) usually include packaging material that specifies that they do not efficiently remove heavy metals. The efficiency of lead removal by newly developed specialty filters for small home units is being investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Water to be used for cooking or drinking should come from the cold tap because hot water is more able to leach lead from the pipes. In addition, the water should be run for some time before it is collected; this flushes the water that has a higher lead content (caused by standing in the pipes) down the drain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Food",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Department of Agriculture (USDA) has established guidelines for the maximum lead content in processed and canned foods. The United States canned food industry voluntarily phased out the use of lead-soldered cans between 1979 and 1991. In 1995, the United States FDA prohibited the use of lead solder for all food cans, including imported products.",
"   </p>",
"   <p>",
"    Education regarding the way the food and beverages are grown, purchased, stored, or prepared can help to diminish the dietary exposure to lead (",
"    <a class=\"graphic graphic_table graphicRef54388 \" href=\"UTD.htm?21/24/21899\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Independent of food contamination, diet quality may influence absorption or retention of lead from other sources. The diets of children should include adequate intake of iron, calcium, and vitamin C since adequate iron and calcium stores may decrease lead absorption and vitamin C may increase renal excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition, diets high in calories, total fat, and saturated fat among toddlers are associated with higher lead levels [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/59\">",
"     59",
"    </a>",
"    ]. This association may be related to food handling with lead-contaminated hands, since many of the high",
"    <span class=\"nowrap\">",
"     calorie/high",
"    </span>",
"    fat foods ingested by children are \"finger foods\" [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/59\">",
"     59",
"    </a>",
"    ]. Nonetheless, parents of children who are at risk for lead exposure may be counseled regarding the merits of a well-balanced diet that limits high",
"    <span class=\"nowrap\">",
"     calorie/high",
"    </span>",
"    fat foods while maintaining an adequate intake of these nutrients and the importance of washing the child's hands before meals and snacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=see_link&amp;anchor=H12#H12\">",
"     \"Dietary recommendations for toddlers, preschool, and school-age children\", section on 'Dietary guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Children's products",
"    </span>",
"    &nbsp;&mdash;&nbsp;To minimize the risk of purchasing children's products and toys that are contaminated with lead, clinicians can advise parents to avoid [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Purchasing nonbrand toys",
"     </li>",
"     <li>",
"      Purchasing toys from discount shops and private vendors",
"     </li>",
"     <li>",
"      Purchasing old toys",
"     </li>",
"     <li>",
"      Giving costume jewelry to young children",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using commercial lead test kits to identify potentially hazardous products is not recommended because commercial kits may give false-negative results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Artificial athletic fields",
"    </span>",
"    &nbsp;&mdash;&nbsp;To minimize the risk of lead exposure from worn nylon or",
"    <span class=\"nowrap\">",
"     nylon/polyethylene",
"    </span>",
"    artificial turf, clinicians can advise parents to [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/37,60\">",
"     37,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keep children younger than six years of age off of worn, dusty, artificial turf known to contain more than 400 ppm lead.",
"     </li>",
"     <li>",
"      Wash hands and bodies with soap and water for at least 20 seconds after playing on artificial fields.",
"     </li>",
"     <li>",
"      Avoid eating on the field.",
"     </li>",
"     <li>",
"      Keep drinking containers in a bag or covered container when not in use.",
"     </li>",
"     <li>",
"      Avoid tracking of contaminated dust from the play area by removing clothes worn on the field and turning them inside out as soon as possible after leaving the field. If clothing cannot be removed, players should sit on towels or blankets in vehicles. Contaminated clothes, towels, and blankets should be washed separately from noncontaminated items.",
"     </li>",
"     <li>",
"      Keep shoes worn on the field outside of the home.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various United States agencies have established standards for lead detection, toxicity, or methods of abatement. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Department of Housing and Urban Development (HUD), Office of Healthy Homes and Lead Hazard Control (",
"      <a class=\"external\" href=\"file://www.hud.gov/offices/lead\">",
"       www.hud.gov/offices/lead",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Environmental Protection Agency (EPA), Office of Prevention and Toxics (",
"      <a class=\"external\" href=\"file://www.epa.gov/lead\">",
"       www.epa.gov/lead",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Centers for Disease Control and Prevention, Lead Poisoning Prevention Program (",
"      <a class=\"external\" href=\"file://www.cdc.gov/nceh/lead\">",
"       www.cdc.gov/nceh/lead",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Alliance for Healthy Homes (",
"      <a class=\"external\" href=\"file://www.afhh.org/\">",
"       www.afhh.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Center for Healthy Housing (",
"      <a class=\"external\" href=\"file://www.centerforhealthyhousing.org/\">",
"       www.centerforhealthyhousing.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Occupational Safety and Health Administration (OSHA) (",
"      <a class=\"external\" href=\"file://www.osha.gov/SLTC/lead/index.html\">",
"       www.osha.gov/SLTC/lead/index.html",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      United States Consumer Product Safety Commission (",
"      <a class=\"external\" href=\"file://www.cpsc.gov/\">",
"       www.cpsc.gov",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Library of Medicine, National Institutes of Health (",
"      <a class=\"external\" href=\"file://sis.nlm.nih.gov/enviro/lead.html\">",
"       sis.nlm.nih.gov/enviro/lead.html",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Abatement funding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safe removal of environmental lead is a costly process. However, because the identification of lead intoxicated children in the United States is incomplete and the treatment of lead intoxicated children cannot reverse the neurocognitive effects, environmental remediation remains the gold standard for prevention. Although the Medicaid program and other third-party payers often cover the cost of blood lead testing in children, they do not cover the cost of environmental lead testing or remediation. The United States Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP) has recommended that Medicaid cover the cost of testing the home environment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Financial reimbursement for lead remediation of the environment is available from government sources, but it is limited. The Health Care Finance Administration (HCFA) has approved some pilot programs and other money is available primarily through the United States Department of Housing and Urban Development (HUD). The Lead Hazard Control Grant program allocated $60 million in fiscal year 2000 and lead hazard control is an eligible activity for HUD Community Development Block Grants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cooperative programs between local government and private sector organizations in high-risk communities may be designed to help fund the high cost of lead abatement. These programs are effective and may lead to increased abatement rates and more complete abatement interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/63\">",
"     63",
"    </a>",
"    ]. In addition, compensation for the high cost of lead abatement is being sought from manufacturers of lead-based paint through the court system [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11001/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1037656\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children are exposed to lead in a variety of ways. Since the removal of lead from gasoline, lead-based paint has become the major source of lead exposure for children in the United States. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other important pediatric exposures include elevated maternal blood lead levels during pregnancy and breastfeeding, soil, food, or water contamination, and excess lead in toys. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary prevention of childhood lead poisoning involves the removal of lead-based hazards from the environments of children (eg, lead-painted surfaces, including windows, lead-contaminated soil, lead-soldered pipes). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary prevention involves early detection of lead-poisoned children through appropriate screening and minimizing further lead exposure and absorption (",
"      <a class=\"graphic graphic_table graphicRef56262 graphicRef63418 \" href=\"UTD.htm?27/16/27916\">",
"       table 3A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link&amp;anchor=H2#H2\">",
"       \"Childhood lead poisoning: Management\", section on 'Primary prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tertiary prevention reduces the morbidity associated with lead intoxication through chelation of lead from the blood and soft tissues of an exposed child. Chelation can reduce the immediate toxicity associated with acute lead ingestion, but has limited ability to reverse the neurocognitive effects of chronic exposure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"       \"Childhood lead poisoning: Management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attempts to remove existing lead-containing paint from surfaces can create more lead dust if not done properly, increasing the risk for lead exposure and causing at least temporary elevation of blood lead levels in family members. The Occupational Safety and Health Administration (OSHA), the EPA, and the United States Department of Housing and Urban Development have established guidelines for the safe removal of lead-based paint, which can be accessed at",
"      <a class=\"external\" href=\"file://www.hud.gov/offices/lead\">",
"       www.hud.gov/offices/lead",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Abatement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Safe removal of environmental lead is a costly process. However, because the identification of lead intoxicated children in the United States is incomplete and the treatment of lead intoxicated children cannot reverse the neurocognitive effects, environmental remediation remains the gold standard for prevention. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Abatement funding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Families who are unwilling or unable to have their homes professionally abated should undergo education regarding ways to diminish their child's exposure to lead and to control dust in their household (",
"      <a class=\"graphic graphic_table graphicRef68214 \" href=\"UTD.htm?15/46/16107\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef82132 \" href=\"UTD.htm?1/33/1563\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef82254 \" href=\"UTD.htm?42/36/43595\">",
"       table 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef54388 \" href=\"UTD.htm?21/24/21899\">",
"       table 7",
"      </a>",
"      ). However, the benefits of these interventions are unclear. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Education and dust control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/1\">",
"      Rogan WJ, Dietrich KN, Ware JH, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med 2001; 344:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/2\">",
"      Jackson RJ, Cummins SK, Tips NM, Rosenblum LS. Preventing childhood lead poisoning: the challenge of change. Am J Prev Med 1998; 14:84.",
"     </a>",
"    </li>",
"    <li>",
"     Ettinger, AS, Gurthrie Wengrovitz, A (Eds). Guidelines for the identification and management of lead exposure in pregnant and lactating women. National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; Centers for Disease Control and Prevention, Atlanta, GA, 2010  available at file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/4\">",
"      Lanphear BP, Matte TD, Rogers J, et al. The contribution of lead-contaminated house dust and residential soil to children's blood lead levels. A pooled analysis of 12 epidemiologic studies. Environ Res 1998; 79:51.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Preventing lead poisoning in young children: a statement by the Centers for Disease Control, 1991.",
"    </li>",
"    <li>",
"     Agency for Toxic Substances and Disease Registry. Case Studies in Environmental Medicine (CSEM): Lead Toxicity Cover Page. www.atsdr.cdc.gov/csem/lead/pbcover_page2.html (Accessed on January 02, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Children with elevated blood lead levels attributed to home renovation and remodeling activities--New York, 1993-1994. MMWR Morb Mortal Wkly Rep 1997; 45:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/8\">",
"      Jacobs DE, Clickner RP, Zhou JY, et al. The prevalence of lead-based paint hazards in U.S. housing. Environ Health Perspect 2002; 110:A599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/9\">",
"      Screening for elevated blood lead levels. American Academy of Pediatrics Committee on Environmental Health. Pediatrics 1998; 101:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/10\">",
"      Campbell C, Osterhoudt KC. Prevention of childhood lead poisoning. Curr Opin Pediatr 2000; 12:428.",
"     </a>",
"    </li>",
"    <li>",
"     Environmental Protection Agency: Review of studies addressing lead abatement effectiveness: Updated edition. Washington, DC: Environmental Protection Agency; 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/12\">",
"      Binns HJ, Campbell C, Brown MJ, Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning Prevention. Interpreting and managing blood lead levels of less than 10 microg/dL in children and reducing childhood exposure to lead: recommendations of the Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning Prevention. Pediatrics 2007; 120:e1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/13\">",
"      Mielke HW, Reagan PL. Soil is an important pathway of human lead exposure. Environ Health Perspect 1998; 106 Suppl 1:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/14\">",
"      Mielke HW, Blake B, Burroughs S, Hassinger N. Urban lead levels in Minneapolis: the case of the Hmong children. Environ Res 1984; 34:64.",
"     </a>",
"    </li>",
"    <li>",
"     Environmental Protection Agency. Air quality criteria for lead. 1986; EPA/600/8-83/028aF.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/16\">",
"      Trepka MJ, Pekovic V, Santana JC, Zhang G. Risk factors for lead poisoning among Cuban refugee children. Public Health Rep 2005; 120:179.",
"     </a>",
"    </li>",
"    <li>",
"     ATSDR (Agency for Toxic Substances and Disease Registry). The nature and extent of lead poisoning in children in the United States: a report to Congress, 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/18\">",
"      Brown MJ, Margolis S. Lead in drinking water and human blood lead levels in the United States. MMWR Morb Mortal Wkly Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/19\">",
"      Romieu I, Palazuelos E, Hernandez Avila M, et al. Sources of lead exposure in Mexico City. Environ Health Perspect 1994; 102:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/20\">",
"      Srianujata S. Lead--the toxic metal to stay with human. J Toxicol Sci 1998; 23 Suppl 2:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/21\">",
"      Woolf AD, Woolf NT. Childhood lead poisoning in 2 families associated with spices used in food preparation. Pediatrics 2005; 116:e314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/22\">",
"      Shannon M. Lead poisoning from an unexpected source in a 4-month-old infant. Environ Health Perspect 1998; 106:313.",
"     </a>",
"    </li>",
"    <li>",
"     Agency for Toxic Substances and Disease Registry. 1999. Toxicological profile for lead. Atlanta: US Department of Health and Human Services.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/24\">",
"      Mushak P, Davis JM, Crocetti AF, Grant LD. Prenatal and postnatal effects of low-level lead exposure: integrated summary of a report to the U.S. Congress on childhood lead poisoning. Environ Res 1989; 50:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/25\">",
"      Mowad E, Haddad I, Gemmel DJ. Management of lead poisoning from ingested fishing sinkers. Arch Pediatr Adolesc Med 1998; 152:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/26\">",
"      Blank E, Howieson J. Lead poisoning from a curtain weight. JAMA 1983; 249:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/27\">",
"      Gorospe EC, Gerstenberger SL. Atypical sources of childhood lead poisoning in the United States: a systematic review from 1966-2006. Clin Toxicol (Phila) 2008; 46:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Lead exposure from indoor firing ranges among students on shooting teams--Alaska, 2002-2004. MMWR Morb Mortal Wkly Rep 2005; 54:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/29\">",
"      Centers for Disease Control and Prevention (CDC). Children with elevated blood lead levels related to home renovation, repair, and painting activities--New York State, 2006-2007. MMWR Morb Mortal Wkly Rep 2009; 58:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/30\">",
"      Centers for Disease Control (CDC). Childhood lead poisoning--United States: report to the Congress by the Agency for Toxic Substances and Disease Registry. MMWR Morb Mortal Wkly Rep 1988; 37:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/31\">",
"      Needleman HL. The removal of lead from gasoline: historical and personal reflections. Environ Res 2000; 84:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/32\">",
"      Needleman HL. The persistent threat of lead: medical and sociological issues. Curr Probl Pediatr 1988; 18:697.",
"     </a>",
"    </li>",
"    <li>",
"     Lovei, M. Phasing Out Lead From Gasoline: Worldwide Experience And Policy Implications. World Bank Technical Paper No. 397. The World Bank Group, Washington, D.C, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/34\">",
"      Shannon, MW. Minimizing lead exposure. AAP News 2008; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Lead poisoning from ingestion of a toy necklace--Oregon, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:509.",
"     </a>",
"    </li>",
"    <li>",
"     Consumer Product Safety Improvement Act of 2008. www.cpsc.gov.cpsia.pdf (Accessed on August 25, 2008).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Potential exposure to lead in artificial turf. www.cdc.gov/nceh/lead/artificialturf.htm (Accessed on August 13, 2008).",
"    </li>",
"    <li>",
"     CDC response to Advisory Committee on Childhood Lead Poisoning Prevention Recommendations in \"Low Level Lead Exposure Harms Children:  A Renewed Call of Primary Prevention\" file://www.cdc.gov/nceh/lead/ACCLPP/activities.htm (Accessed on May 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/39\">",
"      Schwab LT, Roberts JR, Reigart JR. Inaccuracy in parental reporting of the age of their home for lead-screening purposes. Arch Pediatr Adolesc Med 2003; 157:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/40\">",
"      American Academy of Pediatrics Committee on Environmental Health. Lead exposure in children: prevention, detection, and management. Pediatrics 2005; 116:1036.",
"     </a>",
"    </li>",
"    <li>",
"     National Center for Healthy Housing, University of Cincinnati, Department of Environmental Health. Evaluation of the HUD lead-based paint hazard control grant program: final report. National Center for Healthy Housing, Cincinnati, OH 2004. Available at: www.centerforhealthyhousing.org/HUD_National_Evaluation_Final_Report.pdf. Accessed January 2, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/42\">",
"      Farfel MR, Chisolm JJ Jr. Health and environmental outcomes of traditional and modified practices for abatement of residential lead-based paint. Am J Public Health 1990; 80:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/43\">",
"      Amitai Y, Graef JW, Brown MJ, et al. Hazards of 'deleading' homes of children with lead poisoning. Am J Dis Child 1987; 141:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/44\">",
"      Staes C, Matte T, Copley CG, et al. Retrospective study of the impact of lead-based paint hazard remediation on children's blood lead levels in St. Louis, Missouri. Am J Epidemiol 1994; 139:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/45\">",
"      Swindell SL, Charney E, Brown MJ, Delaney J. Home abatement and blood lead changes in children with class III lead poisoning. Clin Pediatr (Phila) 1994; 33:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/46\">",
"      Taha T, Kanarek MS, Schultz BD, Murphy A. Low-cost household paint abatement to reduce children's blood lead levels. Environ Res 1999; 81:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/47\">",
"      Aschengrau A, Beiser A, Bellinger D, et al. Residential lead-based-paint hazard remediation and soil lead abatement: their impact among children with mildly elevated blood lead levels. Am J Public Health 1997; 87:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/48\">",
"      Amitai Y, Brown MJ, Graef JW, Cosgrove E. Residential deleading: effects on the blood lead levels of lead-poisoned children. Pediatrics 1991; 88:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/49\">",
"      Weitzman M, Aschengrau A, Bellinger D, et al. Lead-contaminated soil abatement and urban children's blood lead levels. JAMA 1993; 269:1647.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Environmental Protection Agency. Urban Soil Lead Abatement Demonstration Progect, Volume III: Baltimore Report (2 Parts). EPA Report 600/ap-93/001c.",
"    </li>",
"    <li>",
"     U.S. Environmental Protection Agency. Lead-based paint abatement and repair and maintenance study in Baltimore: Preintervention findings. EPA Report 747-R-95-012.",
"    </li>",
"    <li>",
"     U.S. Environmental Protection Agency. Lead-based paint abatement and repair maintenance study in Baltimore: Findings based on the first year of follow-up. EPA Report 747-R-97-001.",
"    </li>",
"    <li>",
"     U.S. Environmental Protection Agency. Lead-based paint abatement and repair maintenance study in Baltimore: Findings based on two years of follow-up. EPA Report 747-R-97-005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/54\">",
"      Campbell C, Schwarz DF, Rich D, Dockery DW. Effect of a follow-up professional home cleaning on serial dust and blood lead levels of urban children. Arch Environ Health 2003; 58:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/55\">",
"      Farrell KP, Brophy MC, Chisolm JJ Jr, et al. Soil lead abatement and children's blood lead levels in an urban setting. Am J Public Health 1998; 88:1837.",
"     </a>",
"    </li>",
"    <li>",
"     United States Environmental Protection Agency. Basis for educational recommendations on reducing childhood lead exposure. www.epa.gov/oppt/lead/pubs/educationexesum.htm (Accessed on January 02, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/57\">",
"      Yeoh B, Woolfenden S, Lanphear B, et al. Household interventions for preventing domestic lead exposure in children. Cochrane Database Syst Rev 2012; 4:CD006047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/58\">",
"      Gulson BL, Sheehan A, Giblin AM, et al. The efficiency of removal of lead and other elements from domestic drinking waters using a bench-top water filter system. Sci Total Environ 1997; 196:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/59\">",
"      Gallicchio L, Scherer RW, Sexton M. Influence of nutrient intake on blood lead levels of young children at risk for lead poisoning. Environ Health Perspect 2002; 110:A767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/60\">",
"      Korioth, T. Lead found in dust from worn athletic turf. AAP News 2008; 29:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/61\">",
"      Recommendations for blood lead screening of young children enrolled in medicaid: targeting a group at high risk. MMWR Morb Mortal Wkly Rep 2000; 49 RR-14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/62\">",
"      State and local childhood lead poisoning prevention programs; notice of availability of funds. Centers for Disease Control and Prevention. Fed Regist 1999; 64:6093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/63\">",
"      Yiin LM, Weber J, Sannoh S, Rhoads G. Efficacy of the Community Reinvestment Act in promoting lead abatement. J Environ Health 2005; 67:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11001/abstract/64\">",
"      Kaiser J. Environmental health. Lead paint experts face a barrage of subpoenas. Science 2005; 309:362.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6493 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-DE283444F4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_11001=[""].join("\n");
var outline_f10_47_11001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1037656\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prenatal exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ingestion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Paint",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Soil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Water",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Food",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11089643\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10106941\">",
"      - Leaded objects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Inhalation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Leaded gasoline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Children's products and toys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Artificial athletic fields",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Paint and soil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Abatement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Education and dust control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Water",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Food",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Children's products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Artificial athletic fields",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Abatement funding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1037656\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6493\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6493|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/52/25422\" title=\"figure 1\">",
"      Leaded gasoline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6493|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/3/9277\" title=\"table 1\">",
"      Sources of lead exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/21/33116\" title=\"table 2\">",
"      Increase in infant blood lead concentration from breast milk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/30/1515\" title=\"table 3A\">",
"      Reducing pediatric lead exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/13/38107\" title=\"table 3B\">",
"      Reducing absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/46/16107\" title=\"table 4\">",
"      Preventing lead exposure from paint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/33/1563\" title=\"table 5\">",
"      Preventing lead exposure from soil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/36/43595\" title=\"table 6\">",
"      Household cleaning measures to decrease lead exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/24/21899\" title=\"table 7\">",
"      Preventing dietary lead exposure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=related_link\">",
"      Childhood lead poisoning: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=related_link\">",
"      Dietary recommendations for toddlers, preschool, and school-age children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_47_11002="Collection and storage of umbilical cord blood for hematopoietic cell transplantation";
var content_f10_47_11002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/47/11002/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/11002/contributors\">",
"     Bertram H Lubin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/11002/contributors\">",
"     Michael F Greene, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/47/11002/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/11002/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/11002/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/47/11002/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/47/11002/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/47/11002/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reconstitution of the bone marrow is an important and potentially curative treatment option for a wide variety of malignant and nonmalignant diseases, including acute and chronic leukemia, lymphoma, aplastic anemia, sickle cell anemia, thalassemia major, and a number of other genetic and acquired disorders. The pluripotent hematopoietic stem cells required for this procedure are usually obtained from the bone marrow or peripheral blood of an allogeneic (non-self) related or unrelated donor. In some situations where extensive myeloablative chemotherapy is required to treat a malignancy not involving the bone marrow, autologous (self) stem cells may be used.",
"   </p>",
"   <p>",
"    Engraftment and survival rates following hematopoietic cell transplantation (HCT) are optimized when the donor and recipient are genetically compatible. The risk of graft-versus-host disease (GVHD) correlates with the level of human leukocyte antigen (HLA) disparity. Unfortunately, finding an HLA-matched donor is not always possible, especially for minorities. While autologous hematopoietic stem cells provide perfectly compatible tissue, this type of transplantation is not appropriate in many cases, due to the presence of the disease to be treated in the collected autologous stem cells. Each full sibling potential donor has only a 25 percent chance of being fully HLA-matched with a sibling who requires a transplant. Therefore, many patients do not have an HLA-identical relative.",
"   </p>",
"   <p>",
"    When a suitable related donor is not available, a search is conducted to identify a potential unrelated HLA-matched donor. Finding an appropriate donor through a national registry is a lengthy process that is not always successful, especially for individuals who are not of Northern European descent. As a result, many patients who might benefit from HCT are not afforded this opportunity, or die during the extended process of securing a donor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H13#H13\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Matched unrelated donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the lack of matched related donors and the risk of severe GVHD that accompanies mismatched unrelated bone marrow or peripheral blood HCT, alternative sources of hematopoietic stem cells have been sought. Umbilical cord blood, the blood remaining in the umbilical cord and placenta following the birth of an infant, has emerged as a potential alternative source of hematopoietic stem cells in allogeneic HCT. Collection, storage, and ethical issues regarding the use of cord blood for HCT will be discussed here. Other issues related to umbilical cord blood transplantation are discussed separately, including the advantages and limitations to cord blood as a stem cell source and the administration of cord blood transplantation in adults using myeloablative and non-myeloablative preparative regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15865?source=see_link\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39145?source=see_link\">",
"     \"Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61609418\">",
"    <span class=\"h1\">",
"     CORD BLOOD AS A RESOURCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unrelated umbilical cord blood offers many practical advantages over unrelated donor bone marrow or mobilized peripheral blood progenitor cells as a source of hematopoietic stem cells including an expanded donor pool, ease of procurement and lack of donor attrition, lack of need for a complete HLA match, and decreased graft-versus-host disease for the degree of HLA disparity. Limitations to umbilical cord blood include an increased risk of graft failure, delayed immune reconstitution, limited stem cell number, and unavailability of the donor for additional donations (ie, donor lymphocyte infusions). This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15865?source=see_link&amp;anchor=H61604479#H61604479\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Advantages and limitations of cord blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cord blood units that are privately banked for potential autologous use have only a remote chance of being used for the intended purpose. An estimated 1 in 2700 umbilical cord blood units that are collected and stored privately are used for the child or a family member [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Estimating need for cord blood'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CORD BLOOD BANKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two main types of cord blood banks exist for the purpose of storing cord blood for potential future transplantation: public cord banks and private cord banks. It is estimated that several hundred thousand cord blood units are stored in such banks worldwide (",
"    <a class=\"external\" href=\"file://www.bmdw.org/\">",
"     www.bmdw.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In addition to these two main types of cord blood banks, some private and public cord blood banks provide a service called directed cord blood banking in which cord blood is reserved for a sibling or family member with a known potentially transplant-treatable disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Public cord blood banks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Public cord blood banks collect and store cord blood units for use by any individual who has a medical indication for hematopoietic stem cell transplantation and for whom a suitably matched unit is available. These banks perform collections at a limited number of hospitals throughout the world [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/2-6\">",
"     2-6",
"    </a>",
"    ], meaning that a mother can choose to donate her infant's cord blood to a public cord blood bank only if the infant is delivered at a hospital with access to such a bank. California, Connecticut, and a number of other states have developed more disseminated collection programs. More recently, programs have been developed that allow for the remote site collection of cord blood units with shipment to centralized banking facilities, thereby providing additional options for families to donate cord blood. Following collection, each cord blood unit is characterized, and the parameters (eg, HLA profile, total nucleated cell count) are placed in a public database accessible to health care providers. Public cord blood banks are usually non-profit, although a few for-profit cord blood banks bank both privately and publically. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Processing and preservation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Private cord blood banks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Private cord blood banks are for-profit enterprises that facilitate the collection of cord blood for families who are willing and able to pay for such a service [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/6\">",
"     6",
"    </a>",
"    ]. Typically, families decide to bank their infant's cord blood so that it might serve as a source of hematopoietic stem cells for the child or another member of the family should the need arise. Private cord blood banks supply the family with a collection kit, and then generally depend on the mother's obstetrician or midwife to collect the umbilical cord blood upon delivery and transport it to the company&rsquo;s stem cell processing laboratory. The cord blood unit is reserved for use by the family, which pays a fee for the initial collection and processing and then annually for the continued storage of their child's cord blood unit. However, given the lack of experience or interest on the part of those collecting the cord blood, the collection volume may be inadequate for transplantation purposes despite their subsequent storage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Directed cord blood banking",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to these two main types of cord blood banks, private as well as public cord blood banks provide a service called directed cord blood banking for families who currently have a child or other family member with a potentially transplant-treatable disease and who are expecting another child [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/7\">",
"     7",
"    </a>",
"    ]. A program providing such a service either facilitates or performs the cord blood collection, and then processes, characterizes, and cryopreserves the unit, which is reserved for exclusive use by the donor's family. These collection and banking services for medically indicated families, either private or public, are most often performed free of charge. (See",
"    <a class=\"local\" href=\"#H3967635\">",
"     'Additional information sources for parents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DONOR RECRUITMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategies for donor recruitment and consent depend on the type of program performing the banking. For public banks, it is vital that high standards of selection are employed in order to ensure the safety and quality of the cord blood supply. To this end, many banks utilize a maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family history questionnaire similar to that conducted for blood donation in the United States. This questionnaire serves to screen potential donors and their sexual partners for risk factors for infectious diseases, inherited immunologic and hematologic diseases, certain genetic diseases, cancer, and other conditions that could be transmissible by blood or hematopoietic stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, maternal blood testing is performed to screen for hepatitis B, hepatitis C, HIV-1 and -2, HIV p24, cytomegalovirus, syphilis, and in some programs human T-lymphotropic virus",
"    <span class=\"nowrap\">",
"     (HTLV)-I/II,",
"    </span>",
"    malaria, Chagas disease, and West Nile virus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Finally, upon delivery of the infant, the mother's and neonate&rsquo;s hospital charts are reviewed for signs or symptoms of congenitally acquired infection and for labor and delivery factors that could put the infant donor, and thus the collected stem cell product, at risk for infection.",
"   </p>",
"   <p>",
"    For private banks, and for those medically indicated directed donations, in which cord blood is reserved for use by the family alone, a unit may be banked regardless of the results of the maternal history, serologies, and infant evaluation. In this case, if the unit is requested for release, the transplant center makes a determination regarding the safety of the unit for transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Maternal (donor) consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;During their pregnancies, many expectant parents become aware of the possibility of banking their infant&rsquo;s cord blood for potential future use [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. They are encouraged to call upon their health care providers to help them decide whether or not to donate their infant&rsquo;s cord blood, or to pay to preserve it for private use. If the infant will be delivered at a hospital providing philanthropic donation to a public, non-profit cord blood bank at no cost to the family, such donation is encouraged. Donation is also encouraged for full siblings of a child with a potentially transplantable illness.",
"   </p>",
"   <p>",
"    The parents, however, may want to consider the following privacy issues associated with public banking:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How will infectious and genetic disease testing results be conveyed to the donor&rsquo;s family?",
"     </li>",
"     <li>",
"      What measures does the bank take to protect donor confidentiality?",
"     </li>",
"     <li>",
"      What is the quality of the collected cord blood?",
"     </li>",
"     <li>",
"      How is the unit collected and stored?",
"     </li>",
"     <li>",
"      How many units have been released for transplantation and what has been the outcome of the transplantation?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The process of obtaining informed consent from donors differs among banks. Private banks utilize a standard consent process that is completed during the prenatal period. Public banks, on the other hand, employ a variety of consent procedures in order to optimize expense and logistic variables. Some seek consent for cord blood donation during prenatal care; others utilize a phased consent process, in which mothers are preliminarily consented during labor, the cord blood is collected following delivery of the placenta, and complete signed consent is obtained after collection. In some hospitals, the placenta and umbilical cord are considered discarded material allowing for the collection of cord blood following delivery of the placenta with consent obtained only after successful collection is performed. Each of these consent protocols has financial and ethical ramifications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In all cases, the bank has the legal and ethical responsibility to provide adequate information to the mother so that she can make an informed, appropriate decision. Consent information should be provided in the mother&rsquo;s preferred language. At a minimum, the consent process for public banks should review the maternal testing required, the altruistic nature of the donation, and the potential laboratory or research use of samples that are not suitable for clinical use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43094?source=see_link\">",
"     \"Informed consent\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CORD BLOOD COLLECTION AND PROCESSING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61610752\">",
"    <span class=\"h2\">",
"     Cord blood collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protocols for umbilical cord blood collection are designed to avoid interfering with the delivery of the baby, while still preserving the sterility and maximizing the volume, and thus the number of hematopoietic stem cells collected in the cord blood unit. Importantly, cord blood collection should",
"    <strong>",
"     never",
"    </strong>",
"    compromise the safety of the mother or infant during childbirth. Standard obstetric procedures for determining the mode of delivery and timing of cord clamping should not be altered in an attempt to optimize cord blood collection.",
"   </p>",
"   <p>",
"    Collection may be performed either prior to (\"in utero\") or following (\"ex utero\") delivery of the placenta. An example of each type of collection procedure is described below. Ex utero collection is preferred because it is technically easier and safer for the clinician obtaining the sample, without compromising sample volume or sterility [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/13\">",
"     13",
"    </a>",
"    ]. Regardless of the technique employed, the earlier the blood is collected, the less likely it is that clotting will occur and the greater the chance of obtaining a maximal volume [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/14\">",
"     14",
"    </a>",
"    ]. Of importance, especially in the anemic or hypovolemic newborn, immediate cord clamping reduces the volume of placental blood transfused to the infant, which can have deleterious effects (eg, low blood volume and worsening anemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Importance of unit volume'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link&amp;anchor=H30#H30\">",
"     \"Management of normal labor and delivery\", section on 'Cord clamping'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       In utero collection",
"      </strong>",
"      &mdash; For &ldquo;in utero&rdquo; collection, the obstetrician or midwife receives the collection supplies in the form of a kit weeks before delivery. The kit is opened and the contents are surveyed in order to confirm that they are complete. Following delivery of the infant, the umbilical cord is clamped and cut in the usual manner. Prior to delivery of the placenta, a four- to eight-inch area of the cord is cleansed with an antiseptic solution provided in the kit. A 16 gauge needle, connected to a cord blood collection bag containing an anticoagulant solution, is inserted into the umbilical vein at the cleansed site, and the blood is allowed to drain into the bag by gravity. In utero collection can be performed by the obstetrician in the course of vaginal delivery or cesarean section.",
"     </li>",
"     <li>",
"      <strong>",
"       Ex utero collection",
"      </strong>",
"      &mdash; For &ldquo;ex utero&rdquo; collection, the collection supplies are kept in a room outside the delivery room. Following delivery of the placenta, it is immediately taken to the collection room, suspended from a collection stand, and the clamped umbilical cord is cleansed with antiseptic solution. A 16 gauge needle, connected to a cord blood collection bag containing an anticoagulant solution, is inserted into the umbilical vein at the cleansed site, and the blood is allowed to drain into the bag by gravity. Ex utero collection is usually performed by trained technicians.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some kits provided by for-profit companies utilize a syringe to collect the cord blood. If necessary, the needle may be repositioned, turned, or even removed and reinserted more proximal to the placenta in order to maximize the volume of blood collected. If the needle is reinserted, the new insertion site must be thoroughly cleansed prior to insertion.",
"   </p>",
"   <p>",
"    With either in utero or ex utero collection, when all the residual blood has been collected, the flow stops and the cord appears empty and mostly white. This usually occurs after a minimum of two to four minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/15\">",
"     15",
"    </a>",
"    ]. At this point, the tube between the needle and blood bag is clamped, the needle is removed from the umbilical cord and cut from the tubing and the bag is sealed and labeled. Ideally, at least 40 to 60 mL of blood (in addition to anticoagulant) will be collected. A volume below 40 mL is unlikely to contain sufficient numbers of cells to be used for transplantation. The cord blood is stored at room temperature in order to preserve cell viability until it is shipped or otherwise transported to the processing laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Follow-up studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A maternal blood sample is obtained within seven days of cord blood collection to screen for infections that might be transmitted to the infant and therefore might be found in the cord blood. This examination commonly includes testing for maternal HLA type, HIV (antibody and polymerase chain reaction), hepatitis C, hepatitis B (surface antigen, core antigen, and polymerase chain reaction), human T-lymphotropic virus",
"    <span class=\"nowrap\">",
"     (HTLV)-I/II,",
"    </span>",
"    treponema pallidum hemagglutination assay, West Nile virus, and cytomegalovirus IgG. Some cord banks also require testing for malaria and Chagas disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/10\">",
"     10",
"    </a>",
"    ]. This testing is restricted to publically banked cord blood units.",
"   </p>",
"   <p>",
"    Some public banks also require a saliva swab from the infant in order to screen for the presence of cytomegalovirus. Some also request a follow-up examination at six months to determine such relevant factors as seroconversion, the infant's postnatal history, or existence of potentially transmittable genetic disease. These conditions might lead to discarding of the stored cord blood unit or using it for research purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Importance of unit volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplantation outcome is significantly affected by the number of hematopoietic stem cells present in the cord blood unit as measured by the total number of nucleated cells (TNC) or the number of CD34+ stem cells. Importantly, the collection volume roughly correlates with both the TNC and the number of CD34+ stem cells present [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. It is not clear whether the collected cord blood volume, the TNC, or the number of CD34+ stem cells is significantly altered by the mode of delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15865?source=see_link&amp;anchor=H61604500#H61604500\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Cell dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Collection volumes and cell counts vary greatly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/21\">",
"     21",
"    </a>",
"    ]. A study of 542 umbilical cord blood collections at several hundred hospitals throughout the United States found that the mean collection volume was 103 mL, including 35 mL of anticoagulant solution, with a mean of 9 x 10",
"    <sup>",
"     8",
"    </sup>",
"    nucleated cells per collection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/7\">",
"     7",
"    </a>",
"    ]. Individual public cord blood banks use different TNC cutoffs to determine whether a particular unit will be stored for clinical use. Larger units with higher TNC numbers are preferred and a cutoff of 1 x 10",
"    <sup>",
"     9",
"    </sup>",
"    TNC per unit is commonly used [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various predictors of cord blood unit volume and cell count have been investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal and fetal characteristics &mdash; Heavier babies, larger placentas, and women with fewer previous live births had higher cell counts, while longer gestation correlated with greater TNC counts but lower CD34+ cell counts [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/21,22,27\">",
"       21,22,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fetal distress &mdash; One study has suggested that umbilical cord blood collected following cesarean delivery performed because of nonreassuring fetal heart rate tracing increases the number of mobilized stem cells [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/28\">",
"       28",
"      </a>",
"      ]. Similarly, umbilical cord blood from newborns with meconium-stained amniotic fluid also contains higher TNC counts and CD34+ cells [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mode of delivery &mdash; In one study, the average volume of cord blood obtained in 29 cesarean deliveries versus 126 vaginal deliveries was 104 and 84 mL, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/31\">",
"       31",
"      </a>",
"      ]. Since the percent of CD34+ cells was similar in the two groups, cord blood collected during cesarean deliveries had a higher absolute number of CD34+ cells per unit.",
"     </li>",
"     <li>",
"      Technical aspects of collection &mdash; In other studies, a shorter time between delivery of the infant and clamping of the umbilical cord resulted in larger collection volumes and greater cell counts [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Leaving a longer length of umbilical cord attached to the placenta may result in the collection of larger blood volumes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/32\">",
"       32",
"      </a>",
"      ]. It is unclear whether larger volumes are obtained when cord blood collection is performed prior to delivery of the placenta. Some studies report that in utero collection provided larger volumes and increased cell counts [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/14,33-35\">",
"       14,33-35",
"      </a>",
"      ], while others have shown no significant difference between in utero and ex utero collection [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/13,36\">",
"       13,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cord blood units collected from African-Americans have lower cell counts than those collected from Caucasians [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/37\">",
"       37",
"      </a>",
"      ]. The mechanism responsible for this is not known, but it is likely similar to that which explains the low neutrophil count in African-Americans compared with Caucasians.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cord blood collection should",
"    <strong>",
"     never",
"    </strong>",
"    compromise the safety of the mother or infant during childbirth. In general, ex utero collection is preferred, especially for public banking, because it is technically easier and safer for the clinician obtaining the sample, without compromising sample volume or sterility. In utero collection is often used for private collections. Standard obstetric procedures for determining the mode of delivery and timing of cord clamping should not be altered in an attempt to optimize cord blood collection. (See",
"    <a class=\"local\" href=\"#H61610752\">",
"     'Cord blood collection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Processing and preservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After collection, cord blood units should be tested, processed, and stored for future use, typically within 48 hours of collection. Because of the relatively unregulated nature of cord blood banking, cord blood unit characterization and processing procedures vary. In general, public cord blood banks must perform more extensive testing in order to maintain databases searchable by transplant centers. Procedures and quality standards for the safe collection, processing, testing, storage, selection, exchange, and clinical use of cord blood are provided by various organizations. New regulations developed by the US Food and Drug Administration will insure standardized procedures for cord blood safety. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Regulatory aspects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Complete characterization of a cord blood unit should include the following assays [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unit volume and weight, total nucleated cell count with differential, as well as an assessment of the unit's hematopoietic potential (eg, CD34+ cell count or colony forming unit count) after processing.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       ABO/Rh",
"      </span>",
"      blood type and human leukocyte antigen (HLA) class I (-A, -B) and class II (-DRB1) haplotypes.",
"     </li>",
"     <li>",
"      Testing for hepatitis B, hepatitis C, HIV-1 and -2, HIV p24, syphilis, cytomegalovirus, and bacterial culture.",
"     </li>",
"     <li>",
"      Hemoglobin electrophoresis to screen for the presence of a hemoglobinopathy in the donated specimen [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/9,39\">",
"       9,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At public banks, mononuclear cells, plasma, and DNA from the cord blood unit may be stored in an aliquot separate from the main unit for future infectious",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      genetic disease testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While some banks store cord blood units with little or no processing, others remove the majority of the plasma and red blood cells in order to store the units in a smaller volume [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/38,40-42\">",
"     38,40-42",
"    </a>",
"    ]. In general, processed units are preferred. This is principally because cord blood samples that have not had their red cells removed require washing prior to administration to remove red cell debris and free hemoglobin that may cause significant infusion reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/43\">",
"     43",
"    </a>",
"    ]. While the exact cause of the infusion reactions in such cases is not known, dilution in human serum albumin-dextran 40 may play a role in these infusion reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In addition, unprocessed cord blood units will typically contain more dimethyl sulphoxide (DMSO), which can result in hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/10\">",
"     10",
"    </a>",
"    ]. When possible, a split product should be collected. After testing and processing are completed, the viability of the hematopoietic stem cells is preserved by storing each unit in either liquid or vapor-phase nitrogen.",
"   </p>",
"   <p>",
"    Processing and storage can be successfully performed at remote sites. Accordingly, a network of community collection sites targeted at particular ethnic groups and serviced by a central processing and storage facility could maximize the genetic diversity of banked cord blood units in a cost-effective fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Shipping procedures are critical so that units are processed and stored within 48 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3967618\">",
"    <span class=\"h2\">",
"     Shelf-life of units",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known how long umbilical cord blood cells remain viable when stored in this manner; quality control procedures for testing viability are in their infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/49\">",
"     49",
"    </a>",
"    ]. However, other stem cell sources have been stored for many years and retained viability and engraftment potential.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, human cord blood cells stored for 21 to 23 years had an engraftment potential in mice similar to that of freshly-obtained cells [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, cord blood stored for up to 12 years showed minimal loss of hematopoietic progenitor cells by in vitro testing, with recoveries &gt;90 percent at 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of 93 children who received cord blood transplants varying in storage time from three months to 11 years, there was no correlation between storage time and time to engraftment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/52\">",
"       52",
"      </a>",
"      ]. For those children who failed to engraft, length of storage time did not appear to be a contributing factor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no accepted &ldquo;shelf life&rdquo; of cord blood units and the age of a stored unit does not usually affect unit selection. However, given otherwise equivalent cord blood units, a more recently collected unit may be preferred due to changes in standards for collection, processing, and storage over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Release of units for transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant centers search public databases to locate both donors and cord blood units that are appropriate for patients in need of HCT. If an appropriate cord blood unit is located and a decision is made to proceed with transplantation, the unit is shipped to the transplant center in its cryopreserved state and thawed and infused into the recipient according to the standardized protocols. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15865?source=see_link\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H2#H2\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'General considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate labeling and confirmation HLA typing of the unit are critical. In one report, 2 of 871 units (0.2 percent) sent to a single medical center for transplantation were mislabeled and potentially would have been transplanted incorrectly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Regulatory aspects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within the United States, private cord blood banking remains relatively unregulated. This is likely to change with new US Food and Drug Administration requirements. Establishments that are involvement in the collection, processing, testing, storage, and distribution of unrelated donor cord blood must register with the Food and Drug Administration (FDA) and are subject to FDA inspection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The AABB (formerly known as the American Association of Blood Banks), the Foundation for the Accreditation of Cellular Therapy (FACT), NETCORD (",
"    <a class=\"external\" href=\"file://www.factwebsite.org\">",
"     NetCord-FACT",
"    </a>",
"    ), and the National Marrow Donor Program have each developed standards for banking procedures and quality control that banks may elect to follow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More rigorous regulatory control could help ensure product quality and consistency, thereby facilitating the exchange of units between cord blood banks and transplant centers. However, any increase in regulatory scrutiny carries financial implications for cord blood banks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Costs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Private banking fees vary greatly. Typically, companies in the United States charge families approximately $2000 for processing the initial specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/57\">",
"     57",
"    </a>",
"    ]. In general, this fee does not include reimbursement for the collection procedure performed by the mother's obstetrician or midwife. Each company also charges a storage fee of approximately $125 per year per unit.",
"   </p>",
"   <p>",
"    It is difficult to assess the per-unit cost of public cord blood banking, as the financial model of these banks is quite different from that of private banks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/58\">",
"     58",
"    </a>",
"    ]. It is certain, however, that the high cost of public cord blood banking raises the question of financial viability. Public banks are sometimes able to obtain compensation from cord blood transplant recipients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their insurance companies upon release of a cord blood unit, but may rely on financial support from an external source (eg, an affiliated organization or a grant from the federal government). Unfortunately, less than 50 percent of cord blood units collected publically have cell counts that are sufficient for banking. Thus, costs associated with public banking place constraints on program sustainability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ETHICAL AND LEGAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because cord blood banking is relatively new, the legal aspects are actively evolving, while the ethical issues raised by both public and private banking have not yet been resolved. A thorough discussion of these topics can be found elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/59-66\">",
"     59-66",
"    </a>",
"    ]. However, a number of these issues are illustrated via the questions posed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Who owns a given cord blood unit, the child or the parents? Do the parents have the right to give the units away or sell them, or should they be held for the person from whom they came until he or she reaches adulthood?",
"     </li>",
"     <li>",
"      If the cells are to be used for someone other than the person from whom they came, must both parents agree or is consent from one adequate? What happens if the parents disagree?",
"     </li>",
"     <li>",
"      What happens to a unit stored by a for-profit company when there is a dispute within the family regarding its disposition? What should be done with a privately banked unit if the family stops paying the storage fees?",
"     </li>",
"     <li>",
"      When a cord blood unit is donated to a public bank, how can the privacy of the donor be protected without compromising the safety of the unit? Should a long-term link be maintained between units and donors, so that donors can alert the bank if they develop a disease that could be transmitted via the unit? Should the recipient be able to contact the donor in case additional blood cells may be needed (eg, hematopoietic stem cells, donor lymphocytes)? Alternatively, should all identifying links be destroyed, in order to preserve donor confidentiality?",
"     </li>",
"     <li>",
"      How shall the conflict of interest between donation for public banking purposes and banking for autologous use be resolved? What are the ethical implications of the fact that many families are economically unable to bank their children's cord blood through a for-profit company, but do not have access to a bank that stores blood for public use?",
"     </li>",
"     <li>",
"      When infectious disease (eg, HIV and other viral testing) and genetic testing is required for banking purposes, who should be informed of the results (eg, mother, father, child)? If nonpaternity is discovered in the course of testing, should that information be disclosed, and to whom (eg, mother, father, or child)?",
"     </li>",
"     <li>",
"      Are for-profit cord blood banking companies exploiting parents at a vulnerable time in their lives, or providing a valuable service [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/6,15,67\">",
"       6,15,67",
"      </a>",
"      ]? What sort of truth in advertising should be expected of these companies?",
"     </li>",
"     <li>",
"      What are the ethical ramifications of preimplantation genetic diagnosis and HLA typing for the purpose of producing a child who can supply a cord blood unit for an ill family member [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]?",
"     </li>",
"     <li>",
"      What liability for the quality of the cord blood unit is carried by a cord blood bank? What is the liability of the physician or midwife who performs the collection for private banking purposes?",
"     </li>",
"     <li>",
"      Should we as a society be concerned about the commodification or commercialization of cord blood, a substance of increasing value? Is cord blood banking more akin to blood banking or organ donation?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COUNSELING EXPECTANT PARENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During their pregnancies, many expectant parents become aware of the possibility of banking their infant&rsquo;s cord blood for potential future use [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. They may call upon their health care providers to help them decide whether or not to donate their infant&rsquo;s cord blood, or to pay to preserve it for private use. In particular, many parents confront the question of whether to bank their infant&rsquo;s cord blood through a private, for-profit company. Many pediatricians relate a general lack of knowledge with regards to counselling parents about cord blood banking. Given the current uncertainties of this technology, the American Academy of Pediatrics does not recommend that parents routinely store their infant&rsquo;s umbilical cord blood for future use unless there is an immediate medically indicated use for a sibling [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/15,70\">",
"     15,70",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists states that patients who request information on umbilical cord blood banking should be provided with &ldquo;balanced and accurate information regarding the advantages and disadvantages of public versus private banking&rdquo; and be informed of the approximately 1 in 2700 chance that an autologous unit of umbilical cord blood will be used for a child or family member [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/1\">",
"     1",
"    </a>",
"    ]. Parents should be warned that autologous cord blood will not be selected if the donor child develops leukemia as the cord blood will have genetic markers of leukemia. Private cord banking is not allowed in Italy and Spain, and other European committees (eg, European Commission's Group on Ethics in Science and New Technologies, Royal College of Obstetricians and Gynecologists, World Marrow Donor Association) have indicated their concern about the ethical status of private cord banks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/6,67\">",
"     6,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The emotional vulnerability of parents who want to do \"everything possible\" to ensure the future welfare of their children must be recognized while helping families make this decision. The promotional literature from private for-profit companies often does not accurately convey the potential benefits and limitations of cord blood banking and transplantation. Most of the reported cases of successful cord blood transplants utilizing cord bloods banked in private banks, as indicated on websites and not in peer reviewed publications, have been when a sibling is transplanted with the banked cord blood.",
"   </p>",
"   <p>",
"    Parents considering private cord blood banking should be informed of the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The indications for cord blood transplant are limited to certain genetic, hematologic, and malignant disorders. (A complete list is provided on the",
"      <a class=\"external\" href=\"file://marrow.org/Home.aspx\">",
"       NMDP website",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Routine storage of umbilical cord blood as \"biologic insurance\" against future disease is not recommended.",
"     </li>",
"     <li>",
"      Cord blood banked by families is much more likely to be used by the donors' siblings than by the donors.",
"     </li>",
"     <li>",
"      Private storage of umbilical cord blood should be considered if there is a family member with a current or probable future need for transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If, despite being given the above information, the parents decide to proceed with cord blood banking through a private agency, it is wise for them to thoroughly investigate available companies. There are various online resources available to guide parents in this process. At a minimum, parents should be advised to do the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Read all contracts thoroughly and know all costs associated with banking through a given company.",
"     </li>",
"     <li>",
"      Understand whether the stored cord blood will be available for autologous use only, or whether another member of the family, such as a sibling, could utilize the unit should the need arise (so-called \"family use\").",
"     </li>",
"     <li>",
"      Confirm that the company is financially and otherwise stable, since the cord blood may be stored for years to decades before being used.",
"     </li>",
"     <li>",
"      Inquire whether the company is accredited by a reputable regulatory agency (eg, AABB, FACT).",
"     </li>",
"     <li>",
"      Know how long the company has been involved in cord blood storage, how many samples they currently have in storage, whether any units banked through the company have been used for transplantation, and their outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Estimating need for cord blood",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Autologous donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to estimate a child's risk of requiring hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/71\">",
"     71",
"    </a>",
"    ]. Estimating the lifetime probability that an individual will need to undergo autologous",
"    <strong>",
"     or",
"    </strong>",
"    allogeneic HCT, given the current indications for HCT, is similarly difficult, and may be 2 to 10 per thousand [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the chance that a child (or family member) would ever benefit from HCT using his or her own cord blood has been estimated as one in 2700 individuals or less [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/1,38,71\">",
"     1,38,71",
"    </a>",
"    ]. One source estimated that 1 in 20,000 collections performed for families without any medical indication might be used for autologous transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, not all patients who develop a disease that can be treated with HCT will benefit from using their own cord blood cells. Autologous stem cells may be less effective than allogeneic stem cells in some medical situations. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the case of leukemia and other malignancies, the graft-versus-tumor effect that occurs with allogeneic transplants can be essential to the success of the transplant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link\">",
"       \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9400?source=see_link&amp;anchor=H9#H9\">",
"       \"General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults\", section on 'Graft-versus-leukemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The genetic abnormalities underlying many transplant-treatable diseases, including leukemia and the hemoglobinopathies, are either believed or known to be present in the genetic material of hematopoietic stem cells present at conception, rendering autologous cord blood transplantation either undesirable or completely inappropriate as a treatment option for these diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/73-75\">",
"       73-75",
"      </a>",
"      ]. In such cases, even if a family had stored their child's cord blood and the child was unfortunate enough to develop a transplant-treatable disease, the stored cord blood might not provide an appropriate source of mutation-free hematopoietic stem cells for transplantation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35354?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathogenesis of acute myeloid leukemia\", section on 'Two-hit hypothesis of leukemogenesis'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of effectively proven procedures to expand the number of stem cells in cord blood, use of cord blood as the sole source of stem cells is limited based upon the recipient&rsquo;s weight. There are several clinical trials evaluating use of cord blood stem cell infusions for conditions such as cerebral palsy and diabetes. However, at the present time, the data from these studies are extremely preliminary and do not support a recommendation for private cord blood banking. Indeed, while advances in ex vivo cell expansion, gene therapy, and regenerative medicine may someday provide therapeutic options for a wide variety of diseases, there is no scientific basis to advise families to bank a child's cord blood on the assumption that such technology will develop to the point of broad clinical utility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Allogeneic donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Families within which a transplant-treatable disease is known to exist (eg, thalassemia major, sickle cell disease, Diamond Blackfan anemia) have a potential need for cord blood. In these cases, cord blood storage should be encouraged and is available, even with private cord blood banks, at no cost [",
"    <a class=\"abstract\" href=\"UTD.htm?10/47/11002/abstract/1,76\">",
"     1,76",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Directed cord blood banking'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=see_link&amp;anchor=H7#H7\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\", section on 'Alternative donors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link&amp;anchor=H801617#H801617\">",
"     \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\", section on 'Alternative donors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Alternatives to cord blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the medical condition of the potential recipient, there are a number of alternatives to the use of autologous or allogeneic cord blood. The majority of individuals with transplant-treatable diseases are initially managed with other medical programs, such as chemotherapy and radiation therapy for malignant diseases, and supportive care for some congenital hemolytic anemias (eg, transfusion,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    for sickle cell disease).",
"   </p>",
"   <p>",
"    If the individual has obtained a reasonable clinical response and quality of life with these treatments, this may outweigh the potential morbidity and mortality associated with hematopoietic cell transplantation. However, in the hemoglobinopathies, the long term chronic illness-associated complications must be considered as these diseases have been cured by transplantation of mobilized peripheral blood progenitor cells, bone marrow",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cord blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of beta thalassemia\", section on 'Hematopoietic cell transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=see_link&amp;anchor=H2#H2\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\", section on 'Limitations and barriers to HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, if hematopoietic cell transplantation is contemplated, a number of other donor options are available, including HLA-matched related or unrelated donors, as well as HLA-mismatched or haploidentical related or unrelated donors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=see_link\">",
"       \"Patient information: Labor and delivery (childbirth) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3967635\">",
"    <span class=\"h2\">",
"     Additional information sources for parents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional noncommercial information concerning the potential benefits and limitations of cord blood donation and transplantation is available from the",
"    <a class=\"external\" href=\"file://marrow.org/Home.aspx\">",
"     National Marrow Donor Program website",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Umbilical cord blood, the blood remaining in the umbilical cord and placenta following the birth of an infant, has emerged as an alternative source of hematopoietic stem cells in allogeneic hematopoietic cell transplantation (HCT). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15865?source=see_link&amp;anchor=H61604472#H61604472\">",
"       \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Demand for cord blood'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Two main types of cord blood banks exist for the purpose of storing cord blood for potential future transplantation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Public cord blood banks collect and store cord blood units for use by any individual who has a medical indication for HCT and for whom a suitably matched unit is available. These banks perform collections at a limited number of hospitals throughout the world, meaning that a mother can choose to donate her infant's cord blood to a public cord blood bank if the infant is delivered at a hospital associated with such a bank. Several of these banks also have outreach programs supporting public cord blood donation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Public cord blood banks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Private cord blood banks are for-profit enterprises that facilitate the collection of cord blood for families who are willing and able to pay for such a service. Typically, families decide to bank their infant's cord blood so that it might serve as a source of hematopoietic stem cells for the child or another member of the family should the need arise. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Private cord blood banks'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of public and private cord blood banks provide a service, called directed cord blood banking, for families who presently have a child or other family member with a potentially transplant-treatable disease and who are expecting another child. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Directed cord blood banking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cord blood collection should",
"      <strong>",
"       never",
"      </strong>",
"      compromise the safety of the mother or infant during childbirth. Standard obstetric procedures for determining the mode of delivery and timing of cord clamping should",
"      <strong>",
"       not",
"      </strong>",
"      be altered in an attempt to optimize cord blood collection. While collection may be performed either prior to (\"in utero\") or following (\"ex utero\") delivery of the placenta, ex utero collection is generally preferred because it is technically easier and safer for the clinician obtaining the sample, without compromising sample volume or sterility. (See",
"      <a class=\"local\" href=\"#H61610752\">",
"       'Cord blood collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After collection, cord blood units should be tested, processed, and stored for future use within 48 hours of collection. Because regulations regarding cord blood banking are relatively new, cord blood unit characterization and processing procedures still vary. A maternal blood sample should be obtained within seven days of cord blood collection to screen for infections that might be transmitted to the infant and therefore might be found in the cord blood. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Follow-up studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Processing and preservation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parents considering private cord blood banking should be informed of the following issues (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Counseling expectant parents'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The indications for cord blood transplant are currently limited to certain genetic, hematologic, and malignant disorders.",
"     </li>",
"     <li>",
"      Routine storage of umbilical cord blood as \"biologic insurance\" against future disease is not recommended.",
"     </li>",
"     <li>",
"      Cord blood banked by families is much more likely to be used by the donors' siblings than by the donors.",
"     </li>",
"     <li>",
"      Private storage of umbilical cord blood should be considered if there is a family member with a current or probable future need for transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/1\">",
"      Committee on Obstetric Practice, Committee on Genetics. ACOG committee opinion number 399, February 2008: umbilical cord blood banking. Obstet Gynecol 2008; 111:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/2\">",
"      Barker JN, Wagner JE. Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer 2003; 3:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/3\">",
"      Rebulla P. Cord blood banking 2002: 112,010 of 7,914,773 chances. Transfusion 2002; 42:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/4\">",
"      Cord blood banks. Med Lett Drugs Ther 2001; 43:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/5\">",
"      Nishihira H, Kato K, Isoyama K, et al. The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis. Br J Haematol 2003; 120:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/6\">",
"      Moise KJ Jr. Umbilical cord stem cells. Obstet Gynecol 2005; 106:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/7\">",
"      Reed W, Smith R, Dekovic F, et al. Comprehensive banking of sibling donor cord blood for children with malignant and nonmalignant disease. Blood 2003; 101:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/8\">",
"      Askari S, Miller J, Clay M, et al. The role of the paternal health history in cord blood banking. Transfusion 2002; 42:1275.",
"     </a>",
"    </li>",
"    <li>",
"     Wall D. Umbilical cord blood transplantation. In: Pediatric Stem Cell Transplantation, Mehta P (Ed), Jones and Bartlett Publishers, Sudbury, MA 2004. p.337.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/10\">",
"      Navarrete C, Contreras M. Cord blood banking: a historical perspective. Br J Haematol 2009; 147:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/11\">",
"      Fernandez CV, Gordon K, Van den Hof M, et al. Knowledge and attitudes of pregnant women with regard to collection, testing and banking of cord blood stem cells. CMAJ 2003; 168:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/12\">",
"      Vawter DE, Rogers-Chrysler G, Clay M, et al. A phased consent policy for cord blood donation. Transfusion 2002; 42:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/13\">",
"      Lasky LC, Lane TA, Miller JP, et al. In utero or ex utero cord blood collection: which is better? Transfusion 2002; 42:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/14\">",
"      Wong A, Yuen PM, Li K, et al. Cord blood collection before and after placental delivery: levels of nucleated cells, haematopoietic progenitor cells, leukocyte subpopulations and macroscopic clots. Bone Marrow Transplant 2001; 27:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/15\">",
"      Cord blood banking for potential future transplantation: subject review. American Academy of Pediatrics. Work Group on Cord Blood Banking. Pediatrics 1999; 104:116.",
"     </a>",
"    </li>",
"    <li>",
"     Study, CBT. Chapter 3. Collection Procedures. In: Cord Blood Transplantation Study Cord Blood Bank Standard Operating Procedures. National Heart, Lung, and Blood Institute,1998.",
"    </li>",
"    <li>",
"     Program, SDCB. Collection Instructions for Obstetrician/Midwife. Oakland, CA 2003.",
"    </li>",
"    <li>",
"     Program, NYBCNCB. Collection of Placental/Umbilical Cord Blood Units. New York, NY 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/19\">",
"      Lecchi L, Rebulla P, Ratti I, et al. Outcomes of a program to evaluate mother and baby 6 months after umbilical cord blood donation. Transfusion 2001; 41:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/20\">",
"      Rogers I, Holt D, Macpate F, et al. Human UC-blood banking: impact of blood volume, cell separation and cryopreservation on leukocyte and CD34(+) cell recovery. Cytotherapy 2001; 3:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/21\">",
"      Nakagawa R, Watanabe T, Kawano Y, et al. Analysis of maternal and neonatal factors that influence the nucleated and CD34+ cell yield for cord blood banking. Transfusion 2004; 44:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/22\">",
"      Aufderhaar U, Holzgreve W, Danzer E, et al. The impact of intrapartum factors on umbilical cord blood stem cell banking. J Perinat Med 2003; 31:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/23\">",
"      Ballen KK, Wilson M, Wuu J, et al. Bigger is better: maternal and neonatal predictors of hematopoietic potential of umbilical cord blood units. Bone Marrow Transplant 2001; 27:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/24\">",
"      Donaldson C, Armitage WJ, Laundy V, et al. Impact of obstetric factors on cord blood donation for transplantation. Br J Haematol 1999; 106:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/25\">",
"      Askari S, Miller J, Chrysler G, McCullough J. Impact of donor- and collection-related variables on product quality in ex utero cord blood banking. Transfusion 2005; 45:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/26\">",
"      Aroviita P, Teramo K, Hiilesmaa V, Kekom&auml;ki R. Cord blood hematopoietic progenitor cell concentration and infant sex. Transfusion 2005; 45:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/27\">",
"      George TJ, Sugrue MW, George SN, Wingard JR. Factors associated with parameters of engraftment potential of umbilical cord blood. Transfusion 2006; 46:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/28\">",
"      Manegold G, Meyer-Monard S, Tichelli A, et al. Cesarean section due to fetal distress increases the number of stem cells in umbilical cord blood. Transfusion 2008; 48:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/29\">",
"      Solves P, Perales A, Mirabet V, Roig R. Stress factors and umbilical cord blood banking. Transfus Med 2007; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/30\">",
"      Solves P, Perales A, Fillol M, et al. Presence of meconium-stained amniotic fluid in cesarean deliveries increases the total nucleated cell content of umbilical cord blood units. Transfusion 2009; 49:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/31\">",
"      Yamada T, Okamoto Y, Kasamatsu H, et al. Factors affecting the volume of umbilical cord blood collections. Acta Obstet Gynecol Scand 2000; 79:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/32\">",
"      Jones J, Stevens CE, Rubinstein P, et al. Obstetric predictors of placental/umbilical cord blood volume for transplantation. Am J Obstet Gynecol 2003; 188:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/33\">",
"      Solves P, Moraga R, Saucedo E, et al. Comparison between two strategies for umbilical cord blood collection. Bone Marrow Transplant 2003; 31:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/34\">",
"      Solves P, Mirabet V, Larrea L, et al. Comparison between two cord blood collection strategies. Acta Obstet Gynecol Scand 2003; 82:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/35\">",
"      Surbek DV, Visca E, Steinmann C, et al. Umbilical cord blood collection before placental delivery during cesarean delivery increases cord blood volume and nucleated cell number available for transplantation. Am J Obstet Gynecol 2000; 183:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/36\">",
"      Sparrow RL, Cauchi JA, Ramadi LT, et al. Influence of mode of birth and collection on WBC yields of umbilical cord blood units. Transfusion 2002; 42:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/37\">",
"      Cairo MS, Wagner EL, Fraser J, et al. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. Transfusion 2005; 45:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/38\">",
"      Eichler H, Meckies J, Schmut N, et al. [Aspects of donation and processing of stem cell transplants from umbilical cord blood]. Z Geburtshilfe Neonatol 2001; 205:218.",
"     </a>",
"    </li>",
"    <li>",
"     Study, CBT. Chapter 6. Sample Testing and Characterization. Cord Blood Transplant Study Standard Operating Procedures, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/40\">",
"      Hubel A, Carlquist D, Clay M, McCullough J. Cryopreservation of cord blood after liquid storage. Cytotherapy 2003; 5:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/41\">",
"      Hahn T, Bunworasate U, George MC, et al. Use of nonvolume-reduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftment. Bone Marrow Transplant 2003; 32:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/42\">",
"      Petz L, Jaing TH, Rosenthal J, et al. Analysis of 120 pediatric patients with nonmalignant disorders transplanted using unrelated plasma-depleted or -reduced cord blood. Transfusion 2012; 52:1311.",
"     </a>",
"    </li>",
"    <li>",
"     June 28, 2010 Investigator letter from the National Marrow Donor Program, RE: BB-IND#7555: &ldquo;A Centralized Cord Blood Registry to Facilitate Allogeneic, Unrelated Umbilical Cord Blood Transplantation.&rdquo;",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/44\">",
"      Choi S, Hoffmann S, Cooling L. Another case of acute cardiopulmonary toxicity with cord blood infusion: is dextran the culprit? Transfusion 2012; 52:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/45\">",
"      Ma RW, Kwan JM, Ma DD, Fay KC. Acute life-threatening cardiovascular toxicity with umbilical cord blood infusion: the role of dextran. Am J Hematol 2010; 85:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/46\">",
"      Davey S, Armitage S, Rocha V, et al. The London Cord Blood Bank: analysis of banking and transplantation outcome. Br J Haematol 2004; 125:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/47\">",
"      Wada RK, Bradford A, Moogk M, et al. Cord blood units collected at a remote site: a collaborative endeavor to collect umbilical cord blood through the Hawaii Cord Blood Bank and store the units at the Puget Sound Blood Center. Transfusion 2004; 44:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/48\">",
"      Samuel GN, Kerridge IH, Vowels M, et al. Ethnicity, equity and public benefit: a critical evaluation of public umbilical cord blood banking in Australia. Bone Marrow Transplant 2007; 40:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/49\">",
"      Goodwin HS, Grunzinger LM, Regan DM, et al. Long term cryostorage of UC blood units: ability of the integral segment to confirm both identity and hematopoietic potential. Cytotherapy 2003; 5:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/50\">",
"      Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood 2011; 117:4773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/51\">",
"      Mugishima H, Harada K, Chin M, et al. Effects of long-term cryopreservation on hematopoietic progenitor cells in umbilical cord blood. Bone Marrow Transplant 1999; 23:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/52\">",
"      Jubert C, Wagner E, Bizier S, et al. Length of cord blood unit cryopreservation does not impact hematopoietic engraftment. Transfusion 2008; 48:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/53\">",
"      McCullough J, McKenna D, Kadidlo D, et al. Mislabeled units of umbilical cord blood detected by a quality assurance program at the transplantation center. Blood 2009; 114:1684.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/default.htm (Accessed on July 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/55\">",
"      Boo M, Ballen K, Maiers M. Cord blood unit access and selection: 2010 and beyond: best practices and emerging trends in cord blood unit selection. Biol Blood Marrow Transplant 2011; 17:S46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/56\">",
"      Warkentin PI, Foundation for the Accreditation of Cellular Therapy. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT). Cytotherapy 2003; 5:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/57\">",
"      Private cord blood banks. Med Lett Drugs Ther 2004; 46:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/58\">",
"      Querol S, Rubinstein P, Marsh SG, et al. Cord blood banking: 'providing cord blood banking for a nation'. Br J Haematol 2009; 147:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/59\">",
"      Gluckman E, Eurocord Netcord Organisation. Ethical and legal aspects of placental/cord blood banking and transplant. Hematol J 2000; 1:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/60\">",
"      Wadlow RC, Porter DL. Umbilical cord blood transplantation: where do we stand? Biol Blood Marrow Transplant 2002; 8:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/61\">",
"      Burgio GR, Gluckman E, Locatelli F. Ethical reappraisal of 15 years of cord-blood transplantation. Lancet 2003; 361:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/62\">",
"      Annas GJ. Waste and longing--the legal status of placental-blood banking. N Engl J Med 1999; 340:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/63\">",
"      Munzer SR, Smith FO. Limited property rights in umbilical cord blood for transplantation and research. J Pediatr Hematol Oncol 2001; 23:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/64\">",
"      Munzer SR. The special case of property rights in umbilical cord blood for transplantation. Rutgers Law Rev 1999; 51:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/65\">",
"      Danzer E, Holzgreve W, Troeger C, et al. Attitudes of Swiss mothers toward unrelated umbilical cord blood banking 6 months after donation. Transfusion 2003; 43:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/66\">",
"      Steinbrook R. The cord-blood-bank controversies. N Engl J Med 2004; 351:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/67\">",
"      Sullivan MJ. Banking on cord blood stem cells. Nat Rev Cancer 2008; 8:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/68\">",
"      Grewal SS, Kahn JP, MacMillan ML, et al. Successful hematopoietic stem cell transplantation for Fanconi anemia from an unaffected HLA-genotype-identical sibling selected using preimplantation genetic diagnosis. Blood 2004; 103:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/69\">",
"      Adams KE. Ethical considerations of applications of preimplantation genetic diagnosis in the United States. Med Law 2003; 22:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/70\">",
"      American Academy of Pediatrics Section on Hematology/Oncology, American Academy of Pediatrics Section on Allergy/Immunology, Lubin BH, Shearer WT. Cord blood banking for potential future transplantation. Pediatrics 2007; 119:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/71\">",
"      Johnson FL. Placental blood transplantation and autologous banking--caveat emptor. J Pediatr Hematol Oncol 1997; 19:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/72\">",
"      Nietfeld JJ, Pasquini MC, Logan BR, et al. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant 2008; 14:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/73\">",
"      Gale KB, Ford AM, Repp R, et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A 1997; 94:13950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/74\">",
"      Rowley JD. Backtracking leukemia to birth. Nat Med 1998; 4:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/75\">",
"      Tussiwand R, Maia A, Cazzaniga G, et al. Identification of pre-leukemic precursors of hyperdiploid ALL in cord blood (abstract). Blood 2003; 102:381a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/47/11002/abstract/76\">",
"      Reed W, Walters M, Trachtenberg E, et al. Sibling donor cord blood banking for children with sickle cell disease. Pediatr Pathol Mol Med 2001; 20:167.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3531 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-77.94.48.4-CE85A84A2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_11002=[""].join("\n");
var outline_f10_47_11002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61609418\">",
"      CORD BLOOD AS A RESOURCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CORD BLOOD BANKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Public cord blood banks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Private cord blood banks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Directed cord blood banking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DONOR RECRUITMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Maternal (donor) consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CORD BLOOD COLLECTION AND PROCESSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61610752\">",
"      Cord blood collection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Follow-up studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Importance of unit volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Processing and preservation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3967618\">",
"      Shelf-life of units",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Release of units for transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Regulatory aspects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Costs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ETHICAL AND LEGAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COUNSELING EXPECTANT PARENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Estimating need for cord blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Autologous donation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Allogeneic donation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Alternatives to cord blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3967635\">",
"      Additional information sources for parents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=related_link\">",
"      Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9400?source=related_link\">",
"      General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=related_link\">",
"      Hematopoietic cell transplantation in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43094?source=related_link\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35354?source=related_link\">",
"      Pathogenesis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15865?source=related_link\">",
"      Selection of an umbilical cord blood graft for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=related_link\">",
"      Treatment of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39145?source=related_link\">",
"      Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_47_11003="Compliance with medical consult";
var content_f10_47_11003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors that influence or improve compliance with consultant recommendations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Prompt response (within 24 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limit number of recommendations (&le;5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Identify crucial or critical recommendations (versus routine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focus on central issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make specific relevant recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use definitive language",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specify drug dosage, route, frequency, duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequent follow-up including progress notes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Direct verbal contact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Therapeutic (versus diagnostic) recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severity of illness",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_11003=[""].join("\n");
var outline_f10_47_11003=null;
var title_f10_47_11004="Farmers lung antigens in HP";
var content_f10_47_11004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypersensitivity pneumonitides associated with farming",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Environmental source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major causative antigen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Moldy hay, grain, silage",
"       </td>",
"       <td>",
"        Thermophilic actinomycetes, such as Faenirecti virgula (also known as Micropolyspora faeni or Saccharopolyspora rectivirgula)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungus, such as Aspergillus umbrosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moldy on pressed sugar cane (bagassosis, very rare cases)",
"       </td>",
"       <td>",
"        Thermoactinomyces sacchari, T. vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Tobacco plants (tobacco grower's lung; \"Blackfat\" tobacco)",
"       </td>",
"       <td>",
"        Aspergillus sp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scopulariopsis brevicaulis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Mushroom worker's lung",
"       </td>",
"       <td>",
"        Mushroom spores",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thermophilic actinomycetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Potato riddler's lung (moldy hay around potatoes)",
"       </td>",
"       <td>",
"        Thermophilic actinomycetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T. vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        F. rectivirgula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspergillus sp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paprika slicer's lung (moldy paprika pods)",
"       </td>",
"       <td>",
"        Mucor stolonifer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wine maker's lung (mold on grapes)",
"       </td>",
"       <td>",
"        Botrytis cincrea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Cheese washer's lung (moldy cheese)",
"       </td>",
"       <td>",
"        Penicillium casei",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspergillus clavatus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coffee worker's lung",
"       </td>",
"       <td>",
"        Coffee-bean dust",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tea grower's lung",
"       </td>",
"       <td>",
"        Tea plants",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_11004=[""].join("\n");
var outline_f10_47_11004=null;
var title_f10_47_11005="Common radioactive isotopes";
var content_f10_47_11005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common radioactive isotopes currently used",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Radionuclides",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Half life",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Radiation emitted",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Field of use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Lab",
"       </td>",
"       <td class=\"subtitle2\">",
"        Industry",
"       </td>",
"       <td class=\"subtitle2\">",
"        Medical",
"       </td>",
"       <td class=\"subtitle2\">",
"        Nuclear Power",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerium, 144Cs",
"       </td>",
"       <td>",
"        285 d",
"       </td>",
"       <td>",
"        beta",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cesium, 137Ce",
"       </td>",
"       <td>",
"        30 yr",
"       </td>",
"       <td>",
"        beta, gamma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cobalt, 60Co",
"       </td>",
"       <td>",
"        5 yr",
"       </td>",
"       <td>",
"        gamma",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodine, 131I, 125I",
"       </td>",
"       <td>",
"        8 d",
"       </td>",
"       <td>",
"        beta, gamma",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iridium, 192Ir",
"       </td>",
"       <td>",
"        74 d",
"       </td>",
"       <td>",
"        gamma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphorous, 32P",
"       </td>",
"       <td>",
"        14 d",
"       </td>",
"       <td>",
"        beta",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plutonium, 239Pu",
"       </td>",
"       <td>",
"        82x10(6) yr",
"       </td>",
"       <td>",
"        alpha",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radium, 226Ra",
"       </td>",
"       <td>",
"        1622 yr",
"       </td>",
"       <td>",
"        alpha, beta, gamma",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strontium, 90Sr",
"       </td>",
"       <td>",
"        28 yr",
"       </td>",
"       <td>",
"        beta",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Technetium, 99, 95Tc",
"       </td>",
"       <td>",
"        6 h to 60 d",
"       </td>",
"       <td>",
"        gamma",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tritium, 3H",
"       </td>",
"       <td>",
"        12 yr",
"       </td>",
"       <td>",
"        beta",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uranium, 234, 235, 238Ur",
"       </td>",
"       <td>",
"        2.5 x10(6) to 4.5x10(9) yr",
"       </td>",
"       <td>",
"        alpha, gamma",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shannon BE, Jenkins JL, Braen GR. Radiation Injury. In: Manual of Emergency Medicine. Lippincott Williams &amp; Wilkins, Philadelphia, 2000. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_11005=[""].join("\n");
var outline_f10_47_11005=null;
var title_f10_47_11006="Pathogenesis of OHSS";
var content_f10_47_11006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Pathogenesis of OHSS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 277px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_11006=[""].join("\n");
var outline_f10_47_11006=null;
var title_f10_47_11007="Diagnostic approach to weakness";
var content_f10_47_11007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Approach to the adult patient with the complaint of weakness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 368px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_47_11007=[""].join("\n");
var outline_f10_47_11007=null;
